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Malignant mesothelioma (MM) is a locally invasive and highly aggressive 
cancer arising on the mesothelial surface of organ cavities (mainly pleural) as a direct 
result of asbestos exposure. The latency period of MM is long (20-50yrs) after initial 
asbestos exposure, and the prognostic outcomes are dismal with median life expectancy 
of 6-12 months post-diagnosis. There are no useful biomarkers for early MM diagnosis, 
no successful therapeutic interventions. These vast voids of knowledge led to our 
hypotheses that secreted vesicles, termed exosomes, play an important role in MM 
development and tumorigenic properties. Exosomes are nano-sized particles secreted 
from all cell types and carry biologically active cargo in the form of proteins, RNA, and 
lipids that can potently act as intercellular messengers in both healthy settings and 
disease states. We are the first to have conducted studies implicating the roles of 
exosomes in MM pathogenesis. 
 
Firstly, we analyzed the proteomic signature of exosomes from asbestos 
exposure models, in vitro and in vivo. Our in vitro data demonstrated that asbestos 
exposed lung epithelial cells and macrophages secrete exosomes with differentially 
abundant proteins compared to non-exposed controls and some of these proteins are 
relevant to asbestos exposure toxicology and MM development. Additionally, the 
exosomes from asbestos exposed cells significantly modulated the gene expression of 
target mesothelial cells in a way that reflected epithelial to mesenchymal transition and 
other tumorigenic properties.  The in vivo mouse studies illustrated that mouse serum 
exosomes house differentially abundant proteins after asbestos exposure and this is 
measurable at an organism wide scale. 
 
Secondly, we assayed the miRNA composition of MM tumor exosomes 
compared to healthy mesothelial cell exosomes and found signature differences in 
miRNA abundances, particularly that MM tumor cells had significantly higher amounts 
of tumor suppressor miRNA, particularly miR-16-5p, in their exosomes. This led to the 
hypothesis that MM tumor cells preferentially secrete tumor suppressor miRNAs via 
exosomes to rid themselves of the anti-tumor effects. We employed exosomes secretion 
inhibitors and exosome force-feeding to demonstrate that MM cells do in fact secrete 
miR-16-5p (along with other tumor suppressor miRNAs) through exosomes and that 
this property can be targeted as a potentially novel therapeutic advance. Furthermore, 
we identified a mechanism of miR-16-5p loading into exosomes by the RNA binding 
protein HuR, and this mechanism is interestingly regulated by miR-16-5p itself in a 
negative feedback loop. 
 
Our studies thus far provide intriguing evidence on the role of exosomes in 
asbestos exposure and MM biology. We demonstrated the potential for exosomes as 
protein biomarkers in asbestos exposure and conduits of tumorigenic information to 
mesothelial cells. In addition, we incriminate exosomes as vehicles of tumor suppressor 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
1.1 Asbestos 
Any report worth its salt on asbestos induced disease including malignant mesothelioma 
(MM) must begin with a clear description of asbestos fibers themselves. Asbestos fibers 
are naturally occurring silicate particles named from the Greek “inextinguishable”, due 
their flame retardant properties and supreme insulator capacity. Asbestos has been 
documented as being used in over 3,000 manufacturing purposes; mainly in construction. 
The versatility of this fiber comes from its resistance to destruction, decomposition, and 
overall tensile strength (1). As will be discussed shortly, the wide-ranging use of asbestos 
was a major folly of man that has had broadly detrimental impacts on human health. 
There are two groups of the hydrated silicate fibers referred to as asbestos, serpentine and 
amphibole, both of which are delineated as having length to width ratios greater than 3:1. 
Chrysotile asbestos belongs to the serpentine group (referred to as such due to their curly 
fibers) and is the most widely used type of asbestos, accounting for nearly 95% of all mined 
and manufactured. The amphiboles are straight fibers, and among them are crocidolite and 
amosite. Although all types of asbestos are dangerous, crocidolite is accepted as being the 
most carcinogenic. Moreover, not only are there structural dissimilarities between the two 
classifications of asbestos, there are chemical differences too. Chrysotile (serpentine) 
asbestos’s chemical formula is Mg3Si2O5(OH)4 and crocidolite is Fe2H16Mg3Na2O24Si8+. 
By 1960, it was discovered that asbestos was toxic (2) and eventually was classified as a 
category 1 carcinogen by International Agency for Research on Cancer (IARC). The 
toxicity of asbestos fibers is directly associated to two main factors: the geometry and 
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chemical makeup. As the direct route of asbestos exposure is inhalation, fibers become 
deposited in the upper respiratory tract where they interact with epithelial cells and lung 
resident macrophages (3, 4). The fibers’ length and width aspect ratios determine how the 
cells interact with the fibers, whether by attempted phagocytosis or if the fiber causes 
inflammation through physical contact with the cell surface leading to ensuing 
inflammatory cascades (4, 5). It is understood that longer, thinner fibers migrate deeper 
into the lung, whereas shorter fibers remain lodged in the upper respiratory tract. 
Furthermore, the resultant toxicity of the fibers is greatly dependent on the production of 
reactive oxygen species in the lung, as caused by the redox potential of the fibers. Free 
radical production is a hallmark of asbestos exposure in the lung and, although all asbestos 
classification cause this, crocidolite is the most dangerous, perhaps due to the prevalence 
of iron, which based on Fenton reactivity will lead to significant radical production (6-8). 
Multiple diseases are the direct result of inhaled asbestos fibers. Pulmonary fibrosis, or 
asbestosis, begins with initiation at contact sites of alveolar epithelial cells, has a latency 
period of 20-30yrs, and presents itself most commonly at the sub pleural level in the 
bronchioles. A tenant of asbestos exposure, commonly observed in asbestosis patients’ 
thoracic lymph nodes, is the presence of golden-brown rode-shaped beads referred to as 
asbestos bodies. The development of asbestosis causes chest-tightness and pain as the lung 
tissue becomes fibrotic and hardened, and leads to restricted pulmonary function. 
Asbestosis cases in the USA are increasing although asbestos use is overall declining, and 




Other pleural diseases caused by asbestos include, pleural effusions and pleural 
plaques/lesions. A small number of asbestos exposed individuals develop pleural effusions, 
and this occurs up to 20 years after high concentrations of exposure. Pleural plaques are 
rather common developments of asbestos exposure and are composed of hyalinized fibrotic 
tissue. These plaques are common in the intercostal space of the thorax and diaphragm. 
These are a result of inflammation of the pleura and have a latency of about 10 years after 
exposure (10, 11).  
Additionally, lung cancer is associated with asbestos exposure. The cases of lung cancer 
associated with asbestos exposure appears to be directly correlated with smoking 
cigarettes. The combined effects of asbestos and smoking appear to be super-additive or 
even multiplicative, due to the 90-fold increase of predispositions of lung cancer in 
smokers and asbestos exposed individuals (12-14).  
The most aggressive disease caused by asbestos exposure, however, is the cancer referred 
to as malignant mesothelioma. 
 
1.2 Malignant mesothelioma 
Malignant mesothelioma (MM) is a highly aggressive tumor that originates on the 
mesothelial surface of organ cavities, and is the causative result of asbestos exposure in the 
majority of cases (15). MM predominantly arises in the thoracic cavity (85% of cases), or 
pleural surface, hence named malignant pleural mesothelioma (MPM). The other, less 
common tissue origins of MM are on the peritoneal cavity, pericardial surface, or tunica 
vaginalis (16). Due to its prevalence and the focus of the subsequent experiments 
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performed in the following thesis work, the focus will pertain primarily to MPM. An 
interesting note is that. MPM develops on the parietal surface of the pleural mesothelium, 
not the visceral surface. 
The latency period for MM development is between 20-50yrs after initial asbestos 
exposure, which correlates with the other asbestos related diseases as not immediately 
arising. The incidence of MM is on the increase worldwide, although reports by 
governmental agencies had initially predicted a plateau in 2015 followed by steady 
decreases. This lack of clairvoyance is likely due to the fact that asbestos is so prevalently 
common in nearly all geographic settings internationally, regardless of declining rates of 
asbestos mining of new manufacturing processes. Additionally, the unregulated asbestos 
use in industrial countries such as China, Russia, and India will add to the global upward 
trends in MM to a significant degree. 
Early diagnosis of MM is nearly impossible due to lack of biomarkers, and prognostic 
outcomes are grim with median survival post-diagnosis being around 12 months because 
of no successful therapeutic interventions. The large proportion of MM patients are male 
(75% or more) with median age of 73 (17). This statistic is due to the fact that asbestos 
exposure traditionally occurs in occupational settings such and factories, manufacturing 
plants, and in the military that are predominantly male dominated.  
MPM patients are commonly diagnosed after symptoms have developed such as 
breathlessness, painful breathing, chest-wall pain, and there is a typical presentation of 
pleural effusion or ascites (18). Unfortunately for patients, diagnosis after symptom onset 
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can take time prior to cytological analysis or is incidentally discovered via chest 
radiography.  
Along with asbestos exposure, there are implications that simian virus 40 (SV40) is 
involved in MM development via the blockage of tumor suppressor genes, making SV40 
a rather potent oncogenic virus linked to MM (19). In addition, there have been rare 
instances where radiation led to MM. 
It is estimated that there are 2 billion mesothelial cells in the human body, the origin sites 
for MM development. The function of healthy mesothelial cells is to allow friction free 
movement of organ tissues when moving against one another. Asbestos fibers, as 
mentioned, contact to lung epithelial cells and resident macrophages initially, so there are 
a few ideas as to how the assault of asbestos in the lung leads to tumorigenesis at a site on 
the surface of the lung. Once in the lung, it is suggested that they can be dragged outward 
towards the pleura via pulmonary lymph flow and become translocated near to or on the 
pleural surface (20). 
There are four main suggestions as to how asbestos damages the pleura, leading to 
tumorigenic changes (prior to the subsequent evidence defined within this thesis). First is 
that based on the geometry of asbestos fibers, they penetrate and damage/irritate the pleura. 
Second, by genotoxic effects and mitotic disruption by the fibers interacting with mitotic 
spindles, perhaps a result of partially phagocytosed fibers and direct piecing of the cell, 
causing chromosome damage. Third, ROS-based DNA damage from fibers that signals to 
and disrupts the redox state of mesothelial cells. And fourth, signaling via MAP kinases 
and extracellular signal–regulated kinases (ERK) (21-23) or other signaling molecule(s). 
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The uncontrolled growth of MM is attributed to multiple factors such as telomerase 
expression in majority of mesotheliomas, self-production of growth factors (platelet 
derived growth factors, epidermal growth factors, and Wnt pathway proteins) (24), and a 
very prevalent tenant of MM is the loss of tumor suppressor genes (25).  
The fact that only 5% of asbestos exposed individuals develop MM, insists that genetic 
predisposition also plays a role. One of the most well-delineated mutations indicating MM 
susceptibility is BRCA-associated protein 1 (BAP1). Families with BAP1 mutations have 
strong dispositions for MM development, among other cancers, meaning that BAP1 germ 
line mutations are also a form of hereditable multi-cancer syndromes. There are also other 
lower risk susceptibility genes for MM such as XRCC3, NAT2, and GSTM1. Additionally, 
tumor-suppressor gene mutations in LATS2, NF2, and CDKN2 are potent somatic 
mutations identified in patients who went on to develop MM (16, 25-27). 
Diagnosing MM is a challenging topic as it can be commonly mischaracterized as a 
carcinoma and because there are no useful means of early detection (i.e. biomarkers for 
early development or asbestos exposure). One of the first steps in diagnosis involves 
radiological imaging for localization and staging information. Cytological analysis is a 
crucial step, although not perfect, to assess the immunohistochemical makeup of a tumor 
ascitic fluid sample. The sample is assayed for the presence of mesothelial markers such 
as Wilms’ tumor antigen and further for markers of malignancy such as epithelial 
membrane antigen (EMA) (28). The inconclusive nature of such sampling typically 
necessitates biopsy and histopathological analysis. Staining of samples for cytokeratin aids 
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in ruling out sarcoma or melanoma, and further characterized by specific antibodies to MM 
such as EMA, calretinin, and mesothelin (a highly common MM marker) (29).  
The current state of biomarkers for MM is dismal, as none yet are definitively useful for 
early diagnosis or accurate prognostic indications. The cell adhesion glycoprotein, 
mesothelin, which is overexpressed in MM cells has a soluble form that can be elevated in 
the serum of MM patients. However, mesothelin is only seen to be of use in advanced 
stages of epithelioid MM, and not in other subtypes (30). Another potential biomarker in 
MM is osteopontin, which is involved in cell-matrix interactions and has been shown to be 
elevated in serum of MM patients, but is not a clear distinguisher between other pleural 
diseases (31). Fibulin-3, another possible biomarker, was also shown to be highly increased 
in MM patient plasma, but not as accurately as mesothelin (32, 33). Although these serum 
markers have showed some promise, they are not strong enough indicators of disease to be 
deemed bona fide biomarkers. The field of MM and asbestos exposure is in need of an 
accurate biomarker to make early diagnosis; any such evidence would be a crucial advance. 
The diagnostic and prognostic outcomes of patients is also related to the subtype of cancer 
and MM is capable of exhibiting three separately identifiable subtypes: epithelioid, 
sarcomatoid, and biphasic or mixed. Epithelioid MM cells are polygon, cuboidal, or oval 
and can appear similarly to non-cancerous mesothelial cells in some cases. The most 
common form of MM is epithelioid (80% or more of cases) and is the least aggressive with 
best prognostic outcomes. 
Sarcomatoid cells are more spindly in morphology and can appear to show elements of 
sarcoma cells. Sarcomatoid MMs are the least common and least responsive to 
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chemotherapeutic intervention and are more aggressive in that they grow faster and have a 
higher invasive capacity. Biphasic MM consists of a mix of both types within the same 
tumor, and patient life expectancy is higher when a larger portion of the tumor tissue is 
composed of epithelioid cells (29). 
There is currently no curative option in MM, and the standard of care is chemotherapy, 
radiotherapy, and surgery. Chemotherapy is the treatment option most commonly 
employed and has the most evidence of increasing MM patient survival. The common 
regimen of chemotherapy in MM utilizes cisplatin or pemetrexed, or a combination of the 
two. The combination of the chemotherapeutic drugs showed outcomes of up to month 
longer survival rates, and cisplatin alone showed a respective increase of about 9 months 
(34). Subsequent clinical trials with other drugs such as raltitrexed with cisplatin showed 
similar outcomes, but no change in chemotherapeutic standard of care has emerged from 
these trials (35). 
MM has been shown to be relatively resistant to most radiotherapy treatments, but locally 
directed radiation can be helpful as palliative care in some cases. As an adjuvant to 
chemotherapy or surgery, the results are mixed and there is a high risk of toxicity, so this 
mode of treatment is limited and unlikely to expand or continue (36). 
There exists disparate points of view on the usefulness of surgery in MM. In some cases, 
surgery is helpful for palliative care, and others state that surgery is only helpful in the 
setting of combined therapy such as with chemotherapeutics or immunotherapy. The two 
approaches to surgery in MM are removal of visible disease and debulking procedures to 
spare nonmalignant tissue, or a more extreme approach of extrapleural pneumonectomy 
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(EPP) to remove any and all traces of potentially malignant tissue. EPP has shown some 
promise for enhanced survival, but complication rates and mortality from surgery are high 
leading it be a rare option (37, 38). 
There is increasing ardor in the field of MM, as with all cancers, to treat the disease with 
immunotherapy. One of the most promising areas of such treatment lies in checkpoint 
blockade inhibitors, because tumor cells commonly upregulate surface receptor expression 
of inhibitory ligands that prevent immune cells from targeting them. This adaptive 
advantage of tumor cells is a popular site amongst researchers to target with antibodies that 
prevent the inhibitory signaling. Such checkpoint blockade inhibition would thusly prevent 
immune cell inhibition and allow the immune system to target the cancer. In the context of 
MM, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 
protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) have been investigated 
as possible therapeutics (39). 
Another approach of immunotherapy is to attack tumor cells with antibodies fused to potent 
toxins, termed immunotoxins. Because mesothelin is overexpressed in MM, mesothelin-
specific antibodies have been linked to toxin SS1P and has shown some anti-tumorigenic 
effects, especially in combination with chemotherapy (40, 41). Additionally, some 
oncolytic viral therapies have been suggested in MM, as have anti-cancer vaccines via the 
exposure of dendritic cells to tumor antigens to produce immune response (42).  
One of the most exciting advances in cancer immunotherapy involves adoptive cell 
therapies, where patients’ own immune cells are isolated and engineered ex vivo to expand 
into cells that can target tumor cells. These modified immune cells are reintroduced to the 
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patient as a means of treatment. Such immunotherapies harness T cells either by genetically 
modulating T-cell receptors (TCR) or chimeric antigen receptor (CAR) modified T cells 
(43). Currently there is one clinical trial for TCR targeting WT1 in MM; there are only 
limited antigens to target using TCR so the applicability is minimal. The limitations of 
TCR are non-existent in CAR T cell based approaches because T cells can theoretically be 
modified to target any antigen via this approach. There is a current trial testing CAR T cells 
against the antigen mesothelin which is overexpressed on the surface of many MM tumor 
cells. Mesothelin-targeted CAR T cell therapy in this sense harnesses the potential of T 
cells to attack tumors with this antigen, and the delivery method is an intrapleural single 
dose. Intrapleural delivery was shown to be more effective in mouse models studies leading 
up to the clinical phases as compared to systemic delivery; regional delivery eradicated 
tumors with 30-fold lower dose (44). 
Another important facet of this thesis work revolves around microRNA (miRNA), small 
non-coding RNA molecules about 20-25 nucleotides in length that are vital regulators of 
gene expression at the post-transcriptional level. The function of miRNAs is that they bind 
to mRNA molecules and either prevent their translation at the ribosome, or direct the 
mRNA to be degraded. The specificity of miRNAs is based on its complementary base 
pairing with mRNA, and because there does not need to be 100% fidelity of 
complementarity, each miRNA will have multiple targets, and every mRNA may be 
targeted by multiple miRNAs. In this gene regulatory sense, miRNAs can act as potent 
oncogenes or tumor suppressors depending in their targets. The levels of miRNA in tissues 
and cells, along with those that are secreted, can therefore be of important diagnostic and 
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prognostic value. The underlying biology of many tumors, including MM, is a result of 
dysregulated miRNA expression, and understanding fully the scope of miRNAs in these 
disease settings can be crucial for making therapeutic advances and identifying drug targets 
or biomarkers.  
Most commonly, tumor suppressor miRNAs are under-expressed in MM tumor cells and 
tissues. The targets of such miRNAs in MM are oncogenes involved in tumor progression 
and development, such as CCND1, BCL2, CDKN2A, NF2, JUN, HGF, and PDGFA, and 
these results have been shown across various studies in the previous decades (45). There 
are a number of well-defined miRNAs whose expression is nearly lost in MM including, 
miR-15, miR-16, miR-203, let-7, miR-31,, miR-126, miR-135b, miR-181a-2, miR-499, 
miR-517b, miR-519d, miR-615-5p, and miR-624. Within this listed set, and others not 
mentioned here, is a series of targeted pathways that are vital to tumor growth and 
progression. For examples, miR-126 targets VEGF mRNA and thereby prevents 
angiogenesis, but MM patients, who tend to show increased levels of VEGF in serum, have 
downregulated miR-126 in their tumors. This type of miRNA-based deregulation is 
important to MM biology, as it appears to be another type of genetic or mechanistic 
evolutionary growth advantage. By having low, or non-existent, levels of tumor suppressor 
miRNAs, MM tumor cells are more capable of uncontrolled growth and proliferation.  
miRNAs also play an important role in profiling MM tumors and in potential biomarker 
identification. It has been shown that certain miRNAs are useful for differentiating MM 
from carcinomas (miR-200, -141, and -429), and in identifying various MM subtypes (46). 
For this matter, MM miRNAs could be  helpful as diagnostic tools. Circulating miRNAs 
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are also becoming a more promising route for early detection, and in MM it has been seen 
that certain miRNAs (miR-103 and miR-625) are capable of distinguishing MM patients 
from asbestos exposed or healthy controls and differentiating MM from fibrosis (47). 
One well-defined miRNA aberration in MM is the loss of miR-16 expression. This miRNA 
is a potent tumor suppressor that functions by targeting the expression of genes such as 
CCND1 and BCL2. Multiple studies have shown that miR-16 is significantly under-
expressed in MM tumors and cells as compared to healthy controls. More intriguingly still, 
miR-16 is becoming a focus of potential miRNA based treatment strategies by 
reintroducing the miRNA back to tumors to induce the pro-apoptotic function (48). This is 
an exciting strategy that employs the fact that a targeting therapeutic strategy is possible 
by using the tumor suppressor miRNAs that MM has lost. 
The dysregulated landscape of miRNAs in MM is of much interest in the biomarker and 
treatment fields of MM and much is yet to be explored. The thesis work herein will shed 
some light on a subset of miRNAs in MM within the context of those that are secreted in 
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Exosomes are membrane-bound, intercellular communication shuttles that are 
defined by their endocytic origin and size range of 30-140nm. Secreted by 
nearly all mammalian cell types and present in myriad bodily fluids, exosomes 
confer messages between cells, proximal and distal, by transporting 
biofunctional cargo in the form of proteins, nucleic acids, and lipids, and play 
a vital role in cellular signaling in both normal physiology and disease states, 
particularly cancer. Exosomes are powerful progenitors in altering target cell 
phenotypes, particularly in tumorigenesis and cancer progression, with the 
ability to alter tumor microenvironments and to establish the pre-metastatic 
niche.  Many aspects of exosomes present them as novel means to identify 
cancer biomarkers for early detection and therapeutic targets, and using 
intrinsic and engineered characteristics of exosomes as therapeutic devices to 
ameliorate the progression of the disease.  This review outlines some of the 
recent and major findings with regards to exosomes in cancer, and their 
utilization as therapeutic opportunities. 
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The ability for cells to communicate is quintessential to the biology of multicellular 
organisms.  Intercellular signaling events are accomplished in many ways and depend on 
a complex array of networks and processes including direct contact, electrical and chemical 
components, soluble molecular messengers, or the secretion of membrane-bound vesicles.  
An emerging field in biological research focuses on exosomes as a seminal conduit for this 
cellular crosstalk.  Exosomes were first described in 1981 as “exfoliations” from neoplastic 
cell culture monolayers (49), and have since gained significant momentum for their 
biological and therapeutic relevance.  Nearly all mammalian cell types have been shown 
to produce exosomes and their presence has been confirmed in many bodily fluids, 
including urine, blood, saliva, and amniotic fluid (50).   
Exosomes are small, 30-140nm, membrane bound particles defined by their origin from 
the endosomal pathway (Figure 1), and are not to be confused with microvesicles which 
are larger (~1,000nm) and are shed directly from the plasma membrane (reviewed in (51)).  
The content of exosomes is another pivotal feature of their classification and ability to carry 
information and cargo, as they are enriched in RNA species (i.e. mRNA, miRNA), proteins, 
biofunctional lipids, and occasionally DNA (52).  With communication at the forefront of 
their function, exosomes can also participate in waste removal, antigen presentation, and 





Figure 1. Schematic representation of exosome biogenesis and release, with 
depictions of membrane proteins, cytosolic proteins, and nucleic acid.  (a) 
Endocytosis at the plasma membrane leads to the (b) immature endosome 
where invagination of the endosomal membrane occurs and molecular cargo is 
loaded into the newly forming particles.  (c) The mature endosome, or 
multivesicular body (MVB) contains the exosomes and (d) upon fusion of the 
endosomal membrane with the plasma membrane, (e) the exosomes are 
released to the extracellular environment, maintaining the producer cell 
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membrane topology and housing protein/nucleic acid cargo, which then can 
travel to recipient cells, locally or distally, communicate molecular information 
and/or induce phenotypic changes.  
Interestingly, exosomes are attributed to playing roles in both normal physiological 
conditions (immune surveillance, neural plasticity, tissue repair, stem cell maintenance, 
and blood coagulation pathways) as well as in the pathological processes of many disease 
states (54).  For this review, we will focus on the role of exosomes in cancer, although they 
are associated with the pathogenesis of viruses like HIV-1, the progression of Alzheimer’s 
and Parkinson’s disease, the spread of prion proteins, and inflammatory conditions (55).  
The roles of exosomes in disease demonstrate their prospective utilization as either 
therapeutic targets, or potentially as therapeutic agents. 
Production of exosomes occurs at the early endosome, resulting in the formation of a 
multivesicular endosome (MVE), however, the exact mechanisms of their biogenesis is not 
well understood.  The early endosome is the direct product of a primary endocytic event at 
the plasma membrane.  Invagination of the endosomal surface and subsequent pinching off 
of the membrane creates the exosomes, an endosomal-endosome, of sorts also referred to 
at this stage as intra-luminary vesicles.   
Two major pathways are suggested in the production of exosomes at the endosomal 
membrane: the Endosomal Sorting Complex Required for Transport (ESCRT)-dependent 
pathway and the ESCRT-independent pathway.  The ESCRT-dependent pathway requires 
an accessory protein ALIX and is comprised of four complexes: ESCRT-0 which identifies 
and loads ubiquinated proteins on the endosomal surface; ESCRT-I and ESCRT-II which 
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cause membrane budding; and ESCRT-III which is involved in membrane separation.  The 
ESCRT-independent pathway is proposed to involve lipids such as sphingosine-1-
phosphate and ceramide, microdomains enriched with tetraspanins, and the enzyme 
sphingomyelinase (56).  The study by Columbo et al. went on to illustrate that disrupting 
certain parts of the ESCRT machinery resulted in decreased production of exosomes from 
cells in culture.  Recent evidence reports an exosomal production pathway requiring the 
membrane protein syndecan and cytosolic protein syntenin, in which these two proteins 
interact with the ESCRT-accessory component ALIX, the GTPase ADP Ribosylation 
Factor 6 (ARF6), proteolipid protein D2, and the endoglycosidase heparinase (57).  In 
conjunction with these pathways, it should be noted that there are four major requirements 
for exosome biogenesis: cytoskeletal components such as actin and microtubules; 
molecular motors such as kinesin and myosin; molecular switches which are primarily 
small GTPases; fusion machinery and tethering factors such as SNAREs (58). 
The exosomal membrane reflects aspects of the endosomal membrane composition, 
membrane constituents of the parent cell, and maintains the same membrane topology as 
the plasma membrane.  The exosomal membrane, therefore, is enriched in MVE-related 
proteins such as flotillins, Annexins, GTPases, Rab, and SNAREs; proteins involved in 
MVE biogenesis such as ALIX, Tsg101; and membrane-microdomain associated proteins, 
particularly certain tetraspanins (CD9, CD63, CD81, and CD82) (51).   The lipid 
composition of exosomes is enriched in sphingomyelin, cholesterol, and ceramide.  
Moreover, the membrane of exosomes can also present Major Histocompatibility Complex 
(MHC I/II) molecules and/or antigens, depending on the cell type from which the exosome 
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was secreted. These specific proteins and lipid molecules are important tools in the 
classification of exosomes and are attractive targets for the identification of novel 
biomarkers (59).   
The internal cargo of exosomes is noticeably dissimilar to that of the producer cell’s 
cytoplasmic content, indicating that cargo loading into exosomes is not a simple, diffusive, 
or unregulated process. This selective packaging of certain proteins and RNA species into 
exosomes adds another layer of complexity to understanding their biogenesis and indicates 
a sophisticated sorting process.  Only some elucidations have been made as to the 
relationship between certain biogenesis/sorting molecules and their respective cargo such 
as ESCRT-0 loading ubiquinated proteins.  ESCRT-II has been shown to specifically bind 
mRNAs suggesting its role in the cargo sorting of mRNA into exosomes (60).   
Nevertheless, analysis of proteins and RNA identified in exosomes is readily available 
in an online database by ExoCarta.  The most commonly identified exosomal proteins are 
heat shock protein (HSP)-8 and CD63.  Cytoskeletal proteins are commonly identified (β-
actin, cofillin, moesin, and tubulins) in exosomes, as well as proteins involved in cellular 
signaling pathways (β-catenin, WNT5B, and Notch ligand Delta-like 4) (61).  Due to the 
fact that cargo recruitment is not well understood, it can only be postulated that specific 
chaperone proteins found in exosomes, like HSC, HSP90, 14—3-3, and PKM2, are 
regulators of the process (62) and that other proteins are incorporated based on their 




Notably, one of the more interesting components of exosome cargo is their enriched 
population of small non-coding RNAs, specifically microRNA (miRNA), but others are 
also incorporated (piRNA, snoRNA, scaRNA, Y RNA, siRNA, tRNA fragments, vault 
RNA) (64).  Nearly half of the genes in our cells are regulated by miRNA (65) further 
substantiating the signaling capacity and modulatory capabilities of exosomes on target 
cells. 
Exosomes are released to the extracellular space upon fusion of the MVE with the 
plasma membrane.  This process is mediated by a subset small, vesicular transport 
regulation GTPases known as Rab27A, Rab11, and Rab31 (66), and another reported 
mechanism for secretion, specifically for exosomes bearing WNT, involves the SNARE 
protein YKT6 (67).  Alternatively, some exosomes are not released, and are instead 
destined for lysosomal degradation, which has been attributed to MVE lipid composition 
where it appears that MVEs with cholesterol poor membranes, and/or have 
lysobisphosphatidic acid present are targeted for the lysosome (68). 
Target cell specificity is not yet fully understood but is likely determined by adhesion 
associated molecules present on the exosomal surface such as integrins and SNAREs, with 
the possible influence of tetraspanins complexes (69).  There are several fates of exosomes 
once bound to a recipient cell, prompting what signaling information is delivered: the 
exosome can bind and associate with a membrane receptor or dissociate; direct fusion with 





Exosomes and Cancer 
There is substantial and mounting evidence on the dynamic role of exosomes secreted 
by cancer cells in contributing to tumorigenesis, disease progression, metastasis, 
angiogenesis, extracellular matrix (ECM) remodeling, immune evasion, chemoresistance, 
and the establishment of the pre-metastatic niche (reviewed in (55)) (Figure 2).  Exosome 
secretion by tumor cells is markedly upregulated as is observed by increased exosome 
collection from cancer cell cultures or serum of cancer patients compared to non-cancerous 
conditions (70) (71).  Furthermore, the epigenetic cargo of tumor exosomes is remarkably 
different than the exosomes secreted by the same cell types before malignancy.  Tumor 
derived exosomes are capable of exchanging information between neighboring cancer cells 
and, more notably, can communicate with distant sites and various cell types.  The 
capability of tumor exosomes to house tumorigenic information and induce distal or local 
cellular responses that promote disease pathogenesis make tumor exosomes an attractive 
tool in identifying cancer biomarkers, uncovering molecular mechanisms to cancer 





Figure 2. Tumor derived exosomes are released constitutively from cancer 
cells, and are capable of relaying information which reprograms target cells 
and modifies physiological environments in miens beneficial to cancerous 
growth and metastasis. 
Communication with the tumor microenvironment is vital for tumor progression and 
metastasis. Cancer cells secrete exosomes to reprogram their environs and establish 
favorable conditions for tumor growth and invasion of healthy tissues.  This 
microenvironment is comprised of the ECM and stromal cells including fibroblasts, 
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endothelial and inflammatory immune cells, and tumor-associated vasculature (72). 
Evidence is also accruing that links adipose stromal cells, or adipocytes, to promoting the 
tumorigenic microenvironment, especially in obesity-related cancers (73). Fibroblasts 
synthesize ECM and are essential to repaving this extracellular network during aberrant 
cell growth.  Cancer exosomes can induce fibroblasts to become more activated in laying 
the framework for this favorable tumor microenvironment by eliciting the TGFβ/Smad 
pathway in target fibroblasts (74).  Fibroblast remodeling of the tumor microenvironment 
can also be promoted by the exosomal secretion of ECM metalloproteinases from tumor 
cells (75).   
Epithelial-to-mesenchymal transition, a hallmark of tumor microenvironments 
becoming more aggressive and metastatic, can only be accomplished through intercellular 
communication and evidence recently was reported that tumor exosomes are a contributing 
factor (76). This process of EMT is led by oncogenic transmission that is possibly mediated 
by exosomal cargo transfer which modulates certain aspects of differentiation associated 
with tumor-driving EMT (77). 
Brain tumor cells expressing an oncogenic epidermal growth factor receptor (EGFR) 
were shown to export and deliver this mutant EGFR to other cells, thus transferring 
oncogenic activity leading to activation of MAPK and Akt signaling pathways, 
morphological transformation, and anchorage-independent growth (78).  Such alterations 
can lead to consequent production of angiogenic factors such as vascular endothelial 
growth factor (VEGF) which can facilitate vascularization to the tumor mass.    
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Cancer exosomes are clearly powerful mediators with the aptitude for changing the 
behavior of neighboring cells.  This becomes even more evident with their ability to 
promote the formation of the pre-metastatic niche.  For metastasis to occur, not only do 
cancer cells need to migrate to a new environment, but that environment must be 
conditioned appropriately to allow colonization.   
An elegant in vitro and in vivo experiment demonstrated that exosome secretion was 
required for direction cell movement and persistent migration of cancer cells (79).  The 
experiments by Sung et. al utilized live-cell imaging to show that exosome secretion 
directly preceded and enabled adhesion assembly via an exosome induced autocrine 
signaling with fibronectin housed inside exosomes as the critical component.  Therefore, 
cancer exosomes are capable of secreting and delivering necessary ECM molecules to 
modulate integrin and adhesion formation to drive the migration and invasion of cancer 
cells. 
It has been illustrated that exosomes derived from metastatic melanomas promoted 
metastatic behavior of primary tumors through the horizontal transfer of MET oncoprotein 
to bone marrow progenitor cells, a process referred to as “educating” for metastatic 
colonization (80).   
Liver pre-metastatic niche formation was shown to be induced from pancreatic ductal 
adenocarcinomas (PDAC) derived exosomes that expressed high levels of macrophage 
migration inhibitory factor (MIF) and led to a fibrotic-microenvironment.  Via a MIF-
blockade, liver pre-metastatic niche formation was prevented, and upon measuring 
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exosomal MIF levels in patients with stage-1 PDAC, those with higher levels later 
developed liver metastasis compared to those with low MIF levels (81).   
Intra-vital imaging of cancer exosome uptake by non-cancer cells using the Cre-LoxP 
system, showed that mRNA cargo delivered to non-malignant cells induced enhanced 
migratory potential and metastatic capacity (82).   
In addition, miRNAs have an intriguing role in cancer and exosomes. MiRNAs are non-
randomly added to exosomes and carry functional information from cancer cells which can 
phenotypically change target cells in a fashion that shapes and alters microenvironments 
to allow favorability to cancer cell growth and invasion (83). Melo et. al. showed that 
miRNA maturation occurred in exosomes after their incorporation into vesicles.  When 
compared to miRNA content of exosomes derived from healthy cells, the cancer exosomes 
had a disproportionately higher concentration of mature miRNAs.  This suggests that 
cancer exosomes might not only act as simple postage boxes, but are rather active 
facilitators in the processing of their own cargo.  Breast cancer exosomes with functional 
miRNAs are capable of altering target cell transcriptomes and instigating non-cancer cells 
to become more tumorigenic (84).  The miRNA family, miR-200, regulates the process of 
EMT, mentioned above, and was seen to be increased in serum exosomes of cancer patients 
(85).  Transfer of miR-200 via cancer exosomes, therefore, increased the metastatic 
potential of target cells by altering gene expression to favor EMT. 
A recent study presented that a series of tumor cell lines all secreted exosomes 
containing the inhibitors of apoptosis (IAPs) Survivin, cIAP1, cIAP2, and XIAP.  The 
authors suggested that cancer exosomes contain these IAPs as a possible warning signal or 
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as an added layer of protection to the rogue proliferating cells from an ever-changing tumor 
microenvironment (86). 
The effects of cancer exosomes on the immune system is two-handed, as they can induce 
immunosuppressive functions that uphold tumorigenesis or can provide a boost to the 
immune response to tumors.  Apoptosis of CD8+ T cells can be induced by cancer 
exosomes through the death receptor pathway (87).  Cancer exosomes can lead to further 
T cell dysregulation by inducing the proliferation of regulatory T cells and inhibit effector 
T cell proliferation (88).  Additionally, cancer exosomes can negate the cytotoxic functions 
of natural killer cells (89). 
On the other hand, cancer exosomes can spread antigens, increasing dendritic cell 
presentation of those antigens.  Also, exosomes can interact with memory T cells leading 
to antigen-specific immune responses against the tumors (90). 
Cancer exosomes are also implicated in tumor resistance to chemotherapeutic drugs.  
The removal of cisplatin and trastuzamab from cancer cells by exosomes indicates a drug-
scavenging function (88).  It was also shown that certain chemoresistant cancer cells could 
horizontally transmit their drug-resistant phenotypes through their exosomal miRNAs (91), 
and an increasing number of studies are linking exosomal miRNAs to the ability of cancer 
cells to acquire drug resistance and conduct that resistance to other cancer cells (92).  
Mesenchymal stem cells (MSC) are known to be involved in chemotherapeutic drug 
resistance and MSC-exosomes have been implicated in promoting drug resistance in gastric 
cancer by activating the calcium/calmodulin-dependent protein kinase (CaM-Ks) and 
Raf/MEK/ERK kinase cascade (93). 
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A recent review by Braicu et. al outlines even further how secreted messages from 
cancer-derived exosomes use both membrane and cytosolic constituents, particularly 
miRNAs, to act as critical components of the tumorigenic circuit that disrupts the normal 
condition of healthy cells into the development of oncogenesis (92, 94).  
Exosomes in Therapy 
Unsurprisingly, due to their strong implications in cancer pathogenesis and biological 
compatibilities (i.e. their ability to cross physiological barriers like the blood brain barrier), 
exosomes are strong candidates for myriad therapeutic applications.  These possibilities 
include targeting exosomes that appear to be progenitors in cancer progression, engineering 
exosomes as therapeutic devices, and discovering novel biomarkers for early diagnosis and 
identifying molecular targets.  Aside from cancer, beneficial effects of therapeutic 
exosomes have already shown promise in myocardial ischemia reperfusion and kidney 
injury (95), myocardial infarctions (96), muscle or bone regeneration (97), arthritis (98), 
nerve regeneration (99), multiple sclerosis (100), and neurodegenerative diseases such as 
Alzeihmer’s or Parkinson’s (101). 
Due to their selective cargo loading and resemblance of their producer cells, exosomes 
are valuable for discovering cancer biomarkers (Figure 3).  With increasingly improving 
isolation techniques from cell culture and patient blood, and methodology for 
characterizing cancer exosome components, scientists are utilizing exosomes to identify 
molecules to target cancer more effectively and apply more personized techniques to 
detection, diagnosis, and prognosis.  Protein characterization by mass spectrometry (59), 
as well as immunocapture techniques for identifying and quantifying peptide and nucleic 
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acid (miRNA, mRNA, etc.) profiles (102) and commercially available products already 
provide useful approaches to biomarker discovery.  Some of the most recent cancer 
exosome biomarker studies include complete proteome analysis of melanoma exosomes 
(103) and circulating biomarkers (104), miRNA biomarker analysis of esophageal 
adenocarcinoma (105), prostate cancer (106), glioblastoma (107), serum miRNAs for acute 
myeloid leukemia (108), colorectal cancer (109, 110), gastric cancer (111), urinary 
exosomal miRNAs for ovarian cancer (112),(113), pancreatic cancer specific proteoglycan 
(114), proteomic biomarker profiling of cholangiocarcinoma (115), non-small cell lung 
cancer (116), glioma (117), and salivary exosomes for oral cancer (118). In addition, it has 
been discovered that circular RNAs (circRNA) are stably expressed in exosomes and these 
circRNAs are suggested to be a promising candidate for biomarkers in cancer(119). These 
examples provide insight that exosomes can be used as a more sensitive and less invasive 





Figure 3. (a) Exosomes can be isolated from cell culture supernatants or 
patients’ bio-fluids to assign diagnostic and prognostic signatures of cancer by 
profiling exosomal proteins or RNAs, therefore exosomes potentiate a non-
invasive, or liquid biopsy, technique for assessing tumorigenesis and cancer 
progression. (b) Inhibiting exosome function is one particular therapeutic 
strategy for pacifying the cancer promoting effects of tumor-derived exosomes 
either by blocking the formation and release of the exosomes from the producer 
cell, preventing uptake of the exosomes in the target cell. 
Very recently, the cell surface proteoglycan, glypican-1, was identified as being 
specifically enriched on cancer exosomes.  Monitoring glypican-1 on circulating exosomes 
demonstrated specificity and sensitivity in distinguishing between healthy subjects and 
patients with benign pancreatic cancer from early/late stage pancreatic cancer patients 
(114).  Glypican-1 on circulating exosomes may be an efficient non-invasive screening tool 
for pancreatic cancer, and exemplifies the possibilities of exosomes for cancer diagnostics. 
Attenuating the production and release of exosomes from tumor cells is one important 
therapeutic paradigm given that circulating exosomes nearly double in cancer patients and 
their cargo promote tumor progression and spread (Figure 3). 
One such method would be to inhibit certain molecules that are required for exosome 
formation within the cell (i.e. the endosomal pathway) such as ceramide synthesis via the 
sphingomyelinase pathway. The use of amiloride to reduce exosome production and reduce 
tumor progression was observed in vivo via myeloid-derived suppressor cells which 
suppress T cell activation (120), but similar results were not seen with amiloride treatment 
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of prostate cancer cells (121) suggesting that this mode of inhibition is cell-type dependent.  
Other factors that are involved in exosome biogenesis such as the ESCRT pathway and the 
syndecan proteoglycan and adaptor syntenin are possible targets also.   
The application of RNAi to inhibit certain gene regulation is of particular interest as 
their mechanistics are becoming better understood, the design of functional small 
interfering RNAs (siRNA) is improving to the point of preclinical and clinical trials (122). 
RNAi and small molecule inhibition of targeted exosome biogenesis molecules can 
effectively knockdown certain production characteristics of exosomes and be utilized for 
preventing for preventing exosome dissemination from diseased cells which might in turn 
lead to spread of disease phenotypes to target cells. The mechanisms for this action are 
either by gene knockdown by RNAi, such as engineered shRNAs that bind to, and prevent 
translation of exosome-production machinery including ESCRT proteins and/or GTPases 
involved in producing exosomes (Vader et. al) (123). For example, targeting the GTPase 
RAB27a which is required for the release of some tumor exosomes.  Peinado et. al 
demonstrated in their experiments mentioned above that RNAi of Rab27A GTPase in 
melanoma cells greatly abrogated exosome production and bone marrow education, 
consequently reducing the metastatic potential of the cancer (80).  Another study in 
mammary carcinoma cells led to decreased primary tumor growth and lung dissemination 
upon a blockade of RAB27a (124).  In addition, other GTPases that serve as factors in the 
docking/fusion of the MVB to the plasma membrane can serve as potential targets for 
deregulating exosome secretion from tumor cells.   
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Sung et. al illustrated in their experiments that knockdown of Rab27a and Syt7 reduced 
cancer exosome secretion between 2.2 and 3 fold fewer compared to normal cells and also 
dysregulated cell polarization and migratory persistence (79). 
Another possible target for inhibiting the tumorigenic function of cancer exosomes is to 
prevent the fusion or uptake of exosomes by target cells.  One experiment prevented tumor-
derived exosome uptake by cells through blocking phosphatidylserine with diannexin 
(125). 
It should be noted, however, that this mode of repealing exosome function poses 
potential complications in that many normal physiological processes might be 
inadvertently afflicted. 
An evolving approach in therapeutic exosomes is using them as drug delivery devices.  
Exosomes are ideal vehicles for molecule delivery (proteins, RNAs, small molecule 
drugs/drug oligonucleotides, etc.), due to their biocompatibility, stability in circulation, and 
ability to target them to certain cell types.  Small interfering RNAs (siRNA) have enormous 
potential as therapy with their gene-knockdown effects, but are difficult to employ due to 
their high instability.  Exosomes provide an innovative and newly popular device for 
carrying siRNAs, as well as shRNAs, miRNAs, and mRNAs.  The expression profile of 
tumor exosome miRNAs becomes dysregulated in many cancers and can be used for tumor 
characterization and diagnostics, as well as therapeutic payload (126).  One study 
exemplified this aspect by loading MSC-exosomes with miR-146b and managed to reduce 
primary brain tumor growth in rat glioma by intra-tumoral injection (127).  Elucidating the 
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natural mechanisms of miRNA loading into exosomes is imperative to progressing the use 
of miRNA as therapeutic cargo. 
Drug loading can be accomplished either endogenously or exogenously (Figure 4).  
Endogenous, or passive, loading is carried out by overexpressing the RNA species or 
molecule of interest in producer cells.  This passive loading is enabled by the cell’s native 
exosomal loading mechanisms and results in exosomes that contain the drug prior to 
isolation.  Exogenous, or active, loading begins with exosome collection and requires either 
co-incubation or electroporation of the exosomes with the drug/molecule of interest (55).  
Theoretically, it is possible that one could use exogenous drug loading on previously 






Figure 4. Loading exosomes with therapeutic cargo, such as RNA species for 
gene knockdown in targeted cancer cells or small molecule drugs of interest, 
can be achieved in two ways: (a) endogenously, by collecting exosomes from 
cells overexpressing the molecule of interest, or (b) exogenously, by collecting 
exosomes from an appropriate cell culture that produces exosomes suitable for 
specific targeting and then incubating or electroporating the exosomes with the 
molecule of interest.  Once the exosomes are successfully loaded, they can be 
used for downstream therapeutic applications. (c) Additionally, it is 
theoretically possible to combine the two methodologies as a more 
comprehensive approach to loading with molecules into pre-engineered 
exosomes. 
 
Additionally, it may be possible to use viral packaging strategies to load exosomes with 
molecules (128, 129) and marketed kits have become available to load exosomes in culture 
with proteins of interest, for example the XPack technology from System BioSciences 
(https://www.systembio.com/xpack).. 
Exosomes targeted to specific cell and tissue types can enhance specific uptake and 
reduce off-target deliveries.  Cell or tissue targeting can be achieved by engineering 
exosomes to express plasmid fusion constructs with targeting ligands fused to extracellular 
membrane proteins.  For example, exosomes were collected from mouse immature 
dendritic cells engineered to express Lamp2b fused to a tumor targeting integrin and loaded 
with doxorubicin by electroporation.  Intravenous injection of the engineered exosomes 
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delivered doxorubicin specifically to the specific integrin-positive breast cancer cells 
leading to inhibition of tumor growth whereas untargeted exosomes localized to the liver 
and spleen (130).  Different investigations showed that brain endothelial cell derived 
exosomes are successful at crossing the blood brain barrier to deliver anti-cancer drugs in 
a brain cancer zebrafish model (131) and that intra-tumoral injection of exosomes 
engineered to express an anti-tumor miRNA reduced glioma growth in rat models(127). 
Choosing the correct cell line for therapeutic exosome production is important for a few 
reasons.  The exosome must be lacking in immune-stimulating activity to prevent unwanted 
immune effects in target tissues.  For this immunogenic reason, immature dendritic cells 
have been favorable choices (132). Cell choice can also dictate the native population of 
exosomal surface proteins that might have a desirable ligand-receptor interaction with the 
proposed target cell.  Finding this optimal producer-target cell combination is vital to 
producing exosomes for therapy.  There is also the opportunity to create entirely artificial 
exosomes with therapeutic cargo and ideal surface moieties for target cell specificity. 
Strategic advances are being made in producing exosomes with targeted peptides via 
glycosylation sites for enhanced targeted delivery of exosomes for therapeutics (133). 
Tracking exosomes in vivo after injection is becoming more apparent in the literature 
and methodologies better established using fluorescent labels or membrane dyes (80, 128, 
134, 135).  These technologies allows researchers to resolve the biodistribution and local 
enrichment of injected exosomes. Tracing the transfer of functional exosomal cargo, such 
as RNAs, within the tumor microenvironment in vivo can provide researchers with the 
identities of possible targeting sites for anti-cancer drugs and engineered exosomes (136). 
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Human MSC-exosomes, which have intrinsic therapeutic activity, appear to be 
promising producers of exosomes for therapeutic applications and drug delivery as they 
are known to have successful therapeutic benefits in diseased animal models and display 
immunosuppressive activity (137).  MSC-exosomes delivered to mouse breast cancer cells 
delivered molecules which led to the downregulation of VEGF and therefore decreasing 
tumor growth by suppressing angiogenesis (138). 
The role of MSC-exosomes in promoting drug resistance in gastric cancer, as mentioned 
in the previous section, can be inhibited by blocking the CaM-Ks/Raf/MEK/ERK kinase 
cascade (93). 
Exosomes have potential applications as cancer vaccinations as well.  Exosomes loaded 
with α-galactosylcerimide and tumor specific antigen can activate cancer-specific adaptive 
immune responses decreasing tumor growth (139), and separately, isolated tumor-derived 
exosomes carrying tumor antigen were shown to effectively induce anti-tumor immune 
responses in primary and metastatic mouse melanoma models (140). 
 
Conclusions 
The idea of improving healthcare through personalized medicine is a growing field.  
Personalized medicine designates that tumor treatment be molded to the individual’s 
characteristics, biological signatures, and response to specific treatment. Hence, exosomes 
hold a spot in the development of efficacious personalized therapeutic techniques given 
their use for biomarker discovery and personalized diagnostic capacities.  In the future, it 
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might also be possible to isolate circulating exosomes from an individual, or from 
specifically harvested cell types, load them with specific molecules, in vitro with 
techniques mentioned above, tailored to a specific therapeutic strategy, and redeliver the 
modified exosomes back to a patient to induce a relevant response (i.e. reduce tumor 
growth). 
Disease intervention with exosomes is an exciting new avenue in therapeutics with 
novel strategies for cancer treatment.  There is promising evidence supporting the use of 
exosomes as diagnostic tools for discovering biomarkers, targeting exosomes to inhibit 
their disease related functions, exploiting them as drug delivery devices, and utilizing their 
inherent therapeutic potentials.   Further investigation is required to drive exosome based 
therapeutics to the next level of research and eventual clinical trials that will clarify the 
complex aspects of exosomes that both promote and mollify malignant environments.  
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Abstract 
Cancer research has found a novel foothold in studying exosomes, the 40-140nm 
membrane bound vesicles secreted by cells as molecular messengers. These secreted 
vesicles of endocytic origin act as signaling conveyors between cells by shuttling molecular 
cargo in the form of proteins, mRNA, miRNA, and lipids. The many roles of exosomes in 
normal physiology and disease are becoming clearer as they are increasingly studied. Their 
role in cancer is being found to range from sending pro-tumorigenic messages between 
cancer cells and to non-cancer cells to aid in the growth and spread of the tumor. Tumor 
exosomes are implicated in angiogenesis, metastasis, drug resistance, immune evasion, and 
even more processes involved in the pathophysiology of cancer. As we begin to uncover 
these roles, researchers are discovering the importance of understanding exosomes, as they 
pertain to cancer, as a means of discovering much needed biomarkers, elucidating the 
mechanisms of cancer biology, identifying therapeutic targets, and using exosomes 
themselves as a mode of therapy against cancer. 
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A Brief History 
One of the most exciting and cutting edge topics in modern day science orbits the now 
dominant theme of extracellular vesicle research. Of particular interest, is in regards to the 
subset of extracellular vesicles (EVs) referred to as exosomes, which can be seen by the 
rapid increase of publications over the past 30 years (Figure 5). Cell-derived vesicles first 
arrived on the scientific radar in the 1940’s when cell-free plasma was discovered to 
contain a clot-inducing subcellular element (141). Decades later the term ‘platelet dust’ 
was used to describe 20-50nm vesicles, followed the usage of the term microvesicles in 
1975 (142, 143). By 1981, the coinage, “exosome,” was used by Trams et. al regarding 
exfoliated vesicles with 5'-nucleotidase activity composed of increased amounts of 
sphingomyelin and polyunsaturated fatty acids (49). Subsequent discoveries over the last 
decades provided a more comprehensive understanding of the characterization, origin, 
biogenesis, and functions, which will be briefly summarized in this chapter before linking 
the ongoing trajectory of exosomes in regards to cancer research. 
 Currently, the term exosome refers to small (40-140nm) membrane bound vesicles 
of endocytic origin and are not to be confused with the larger (200-1,000nm) microvesicles 
produced by direct shedding from the plasma membrane. Traditionally, exosomes were 
deemed as nothing more than a waste mechanism for cells to dispose of unwanted material. 
However, it has become evidently clear that exosomes serve a much more biologically 
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sophisticated purpose in relaying messages between cells and tissues. Such molecular 
messages are profoundly adept at altering target cell phenotypes, as scientists have come 
to discover. Exosomes are known to be present in nearly every body fluid sampled from 
blood, cerebral spinal fluid, urine, lymph, amniotic fluid etc., and all mammalian cell types 
appear to be capable of producing these vesicles. Once released into the extracellular space, 
exosomes can travel to sites near, or distant from their dissemination, thereby providing 
potential for endocrine, paracrine, and even autocrine signaling. The molecular content of 
exosomes is of notable intrigue, ranging from biofunctional proteins, RNA species (mRNA 






Figure 5. Number of publications listed on PubMed using the keywords “exosome,” 
“exosome cancer,”, or “extracellular vesicles.”  
Biogenesis   
The biogenesis of exosomes, as mentioned above, is of endocytic origin and involves a 
more complicated pathway than that of microvesicles. After the primary invagination of 
the cell membrane through endocytosis, exosomes begin their creation on the surface of 
the endosome. A secondary invagination occurs here leading to the deposition of smaller 
vesicles inside the endosome. These smaller vesicles, at this stage, are referred to as 
intraluminary vesicles (ILVs), and the endosome containing them is now referred to as 
either a mature endosome or a multivesicular body (MVB). There are two fates for the 
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ILVs at this stage, one is to be targeted for degradation by the lysosome, which appears to 
be regulated by lipid composition, cholesterol poor membranes, and/or the presence of 
lysobisphosphatidic acid (68). The other fate for the MVB, and its content ILVs, is to 
proceed to fusion with the producer cell’s internal surface of the plasma membrane, thereby 
releasing the contents to the extracellular space. The now released vesicles are exosomes.  
 The mechanisms by which ILVs/exosome are produced during the secondary 
invagination on the endosomal membrane is yet to be fully understood, but certain 
components have been identified. One mode of exosome biogenesis requires the 
endosomal sorting complex required for transport (ESCRT) and is known as the ESCRT-
dependent pathway, whereas there is also an ESCRT-independent pathway. The ESCRT-
dependent pathway utilizes the accessory protein ALIX for sorting of syndecans through 
syntenin-mediated interactions and is comprised of four separate complexes: ESCRT-0 for 
loading ubiquinated proteins onto the endosomal surface; ESCRT-I and ESCRT-II for 
budding of the endosomal membrane; and ESCRT-III for separating the membrane. The 
ESCRT-independent pathway is reported as involving and requiring the lipids sphingosine-
1 phosphate and ceramide, the enzyme sphingomyelinase, and tetraspanin enriched 
microdomains (56, 144) . Both of these pathways are targets for inhibition of exosome 
secretion. 
 During the process of exosome genesis, lipids are sorted at the site of invagination 
and molecular cargo is packaged. The exact mechanisms of this process are also unclear, 
but it is known that there are four underlying requirements for this to occur: cytoskeletal 
components (actin, microtubules etc.), molecular motors (kinesin, myosin), molecular 
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switches (predominantly GTPases), and fusion machinery/tethering factors such as 
SNAREs (57). Interestingly, exosomes apparently have a diverse range of functions 
depending on the mode by which they are generated (58, 145).  
Once generated within the MVB, exosome release is mediated by small vesicular transport 
regulation GTPases (Rab27A, Rab11, and Rab31), which can work with SNAREs to fuse 
the MVB membrane to the internal surface of the plasma membrane, and these components 
are another area of interest for inhibiting exosome secretion (66). 
Isolation and Characterization 
 In order to adequately study populations of exosomes, researchers are working 
toward standardizing isolation techniques. However, more and more techniques are being 
introduced that make a standard approach increasingly unlikely. Nevertheless, the 
traditional gold-standard for exosome purification is differential ultracentrifugation and 
most commonly, exosomes are isolated from conditioned cell culture supernatant 
supplemented with exosome-free fetal bovine serum, but exosomes are also commonly 
collected from bodily fluids like plasma or urine. This technique is widely used because it 
is less likely to have contaminate protein aggregates, however it is highly time intensive 
and requires high volumes of media, as well as yielding low amounts of pelleted exosomes 
(146). Before ultracentrifugation, samples are cleared of cell and cell debris by shorter, 
lower speed spins followed by 100,000 to 150,000 × g spins for about 1 hour to clean the 
sample prior to another high speed spin. Another common technique applauded for clean 
sample prep is density gradient centrifugation which utilizes sucrose cushion to separate 
out vesicles based on size, mass, and density (147, 148).  
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 In addition, exosomes can be captured using various ultrafiltration techniques or 
size-exclusion chromatography which have become commercialized to separate preps 
based on size and molecular weight (149, 150). Immuno-affinity capture techniques are 
being employed to separate out exosomes based on their surface protein markers such as 
CD63, CD81, and CD9. Another popular method is by exosome precipitation, where 
samples are cleared of cells/debris and typically a solution of polyethylene glycols is added 
to insolubilize small exosome-sized vesicles and after an overnight incubation can be spun 
out at low speed (151, 152). 
 There are multiple means, after isolation, by which to characterize exosome 
preparations. The most agreed upon standards for defining an exosome now are membrane 
bound vesicles with a diameter of 40-140nm coming from endocytic origin. Because of 
this, size characterization and Western blot analysis for exosome markers such as certain 
tetraspanins (CD9, CD63, and CD81), MVB proteins (ALIX and TSG101), and heat shock 
proteins ((Hsc70, Hsp 90) are most commonly employed (153). Size characterization 
includes multiple avenues, most useful of which is nanoparticle tracking analysis, which 
not only provides size characterization, but also particle concentration and, in many 
circumstances, zeta potential. Dynamic light scattering can be used to determine exosome 
size populations, but to less effectiveness as nanoparticle tracking analysis. Additionally, 
transmission electron microscopy (TEM) can allow size characterization along with 
morphological characterization that is useful for defining pure exosome isolation, and 
recently scanning electron microscopy has been employed (154). TEM allows visualization 
of the double membrane structure of exosomes, along with a notable cup-shaped 
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morphology that is indicative of exosomes in TEM. Additional techniques are also being 
developed and used, such as high-resolution flow cytometry (155), and microfluidic-based 
systems (156). 
Content 
 Exosomes have been reported to be released from nearly every cell type and bodily 
fluid studied, and can interact with myriad target cell/tissue types. The molecular cargo of 
these exosomes dictate the diverse range of effects they may have on target cells, either 
near or far from their production. Such content ranges from proteins (surface or 
cytoplasmic), RNA species, functional lipids, and occasionally reported genomic DNA 
(157, 158). The surface protein content of exosomes resembles the surface composition 
and topology of its producer cell, and these surface molecules are determinates for potential 
target cell interaction, and such interactions are pertinent to normal physiology as well as 
disease processes (159). It should be noted here that there are multiple ways in which an 
exosomes may interact with a target cell: docking to cell surface protein and conducting a 
signaling cascade within the cell; the exosome may be endocytosed; or there may be direct 
fusion of the exosome to the target cell membrane. 
Beyond proteins, RNA species enriched in exosomes are of robust functional importance 
to the capacity of exosomes to elicit a biological effect. There have been many RNAs 
identified in exosomes to date (mRNA, piRNA, snoRNA, scaRNA, Y RNA, siRNA, tRNA 
fragments, vault RNA), but having gained the most attention is undoubtedly miRNAs (64).  
 The focus on miRNAs is because these small (around 22 nucleotides in length) non-
coding RNA strands are now known to regulate up to half of the genes within the human 
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body (91), and are highly enriched in exosomes. These miRNAs are transferred to target 
cells via exosomes, maintaining functionality to post-transcriptionally regulate gene 
expression, and are therefore of great interest when studying exosome components and 
signaling.  
Biological Function in Cancer 
The many roles of exosomes in normal physiology is vast: immune function and 
surveillance; neural plasticity and brain function; tissue repair; stem cell maintenance and 
function; blood coagulation; heart function and cardio protection; and the list could go on 
(54, 160). Conversely, exosomes also play an outsize role in many disease states including: 
pathogenesis of viruses like HIV-1and parasites like malaria (161, 162); heart diseases 
(163); kidney diseases, diabetes, and metabolic disorders (164, 165); disorders of 
pregnancy (166); central nervous system diseases such as Parkinson’s, Alzheimer’s, and 
multiple sclerosis (167, 168); and, as this book will focus on, exosomes are enormously 
important in the biology of cancer (70). 
 Because these small vesicles are such big players in human physiology and cancer, 
it is fundamental that researchers use them to uncover the mechanisms of healthy and 
abnormal physiologies, while also utilizing the molecular cargo as quarries of biomarkers. 
The dynamic role of exosomes secreted by cancer cells is substantial and are becoming 
understood to be involved in tumorigenesis, tumor growth/progression, metastasis, 
angiogenesis, extracellular matrix (ECM) remodeling, immune evasion, chemoresistance, 
and the establishment of the premetastatic niche (55, 80). On the front of biomarkers, it is 
important to note that neoplastic cells secrete exosomes with content that is markedly 
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dissimilar to that of their non-cancerous counterparts, and in many cases it has been 
reported that cancer cells secrete a larger volume of exosomes altogether when compared 
to non-cancerous cells. The unique signature associated with cancer exosomes is an 
exciting front in excavating for biomarkers to diagnose cancer, provide better prognostics, 
and identify therapeutic targets.  
 Proteomic identification and analysis of miRNAs as exosomal biomarkers of cancer 
is of great interest and importance to the field. Protein profiling from exosomes has led to 
very intriguing finds that may lead to clinical use, such as the discovery that Glypican-1 in 
exosomes can identify pancreatic cancer (114). Differential expression of miRNAs in 
exosomes, not only provides insight for biomarkers (169), but the array of functionality 
imparted by transferred exosomal miRNAs to tumor cells function phenotypically change 
target cells (170). Interestingly, along with sending pro-tumor miRNAs to targets, it is 
being uncovered that some tumors even shuttle tumor suppressor miRNAs away from 
themselves via exosomes to prevent their antitumorigenic effects (171, 172). Identifying 
such biomarkers and their mechanistic effects is of utmost importance in the realm of 
understanding cancer and the field of exosomes has significant potential. 
 Tumor derived exosomes carry their epigenetic cargo to other tumor cells to aid in 
their progression and also to non-tumor cells for the purpose of phenotypically altering 
them in order to aid in tumor growth and spread. The alterations caused by tumor exosomes 
to non-tumor cells can be that they dampen the immune response against the malignancy, 
reprogram surrounding cells in the tumor microenvironment to aid the tumor, or even 
convert non-malignant cells to become cancerous. The established communicatory link 
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between tumor cells and host cells via exosomes turns out to be dynamic system that 
promotes tumor survival. Tumor exosomes are capable to directly target immune cells to 
aid in the tumor’s evasion from the immune system by carrying immuno-inhibitory signals 
to immune cells (173). In addition, tumor exosomes are adept in establishing cells in the 
tumor microenvironment to make the location more favorable for the tumor. The cells that 
can be targeted in this setting include fibroblasts, stromal cells, endothelial and other 
inflammatory immune cells, and the vasculature surrounding the tumor. Altering and 
repaving the framework of the ECM by this route is accomplished by exosome signals to 
these cells and also by exosomal secretion of ECM metalloproteinases (72, 74, 75). Further, 
tumor exosomes are reportedly capable of leading to the well-characterized herald of 
tumorigenesis known as epithelial to mesenchymal transition, suggesting an extra layer of 
exosomes’ role in coordinating the spread of cancer (76). Exosomes promote angiogenesis 
and also are capable of conferring chemotherapeutic drug resistance to cancers by allowing 
the transfer of genetic cargo that more quickly allow the tumor cells to adapt and become 
resistant, but the exosomes are also used by the cancer cells to spit out the 
chemotherapeutics that are internalized (174, 175). 
 The therapeutic approaches using exosomes and what is newly being discovered is 
expanding greatly. Not only are the molecules present in tumor exosomes useful as 
therapeutic targets, but exosomes themselves can be engineered as therapeutic delivery 
agents and other treatment approaches include the inhibition of exosome secretion from 
tumor cells. The therapeutic potentials for exosomes in cancer include the direct targeting 
of exosomes that tumor cells produce and may be the progenitors of its progression, using 
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them as drug delivery devices, and by using them to as diagnostic and prognostic indicators 
of tumorigenesis based on biomarker discovery (176-180). 
 As the field of cancer exosomes expands, we are likely to uncover fascinating 
insight into the biology of cancer and the sophisticated mechanisms by which cancer 
develops, grows, and spreads. In these efforts, it is becoming clear that exosomes have 
enormous potential to biomarker discovery and therapeutic options that will shift the 
paradigm by which we understand, diagnose, and treat cancer. 
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Malignant mesothelioma (MM) is a devastating cancer of mesothelial cells, caused by 
asbestos exposure. Limited knowledge regarding the detection of asbestos exposure and 
early diagnosis of MM, as well as lack of successful treatment options for this deadly 
cancer, project an immediate need to understand the mechanism(s) of MM development. 
With the recent discovery of nano-vesicles, exosomes, with enormous potential to contain 
signature molecules representative of different diseases as well as to communicate with 
distant targets, we were encouraged to explore their role(s) in MM biology. In this review 
we summarize what we know so far about exosomes and MM based on our own studies 
and published literature from other groups in the field. 





Few areas of research have grown as quickly and with as much enthusiasm as that of 
extracellular vesicle research related to exosomes. Exosomes are small, 40-140nm 
membrane bound vesicles secreted from cells and originating from the endosomal pathway. 
These vesicles are enriched in biologically functional molecules (proteins, mRNA, 
miRNA, DNA and lipids) and are vital to intercellular communication (51). The 
communication conduit established by exosome transport from producer cells to target 
cells is important to normal physiology as well as disease states, such as cancer (181).  
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The stampede of studies in the field of exosomes has flooded valuable information about 
basic biology and disease into the scientific sphere. We now know that exosomes are more 
than simple waste receptacles used by cells to rid themselves of unwanted material, but are 
sophisticated molecular messaging systems that can act locally or distal from where the 
vesicles are secreted. Exosomal communication is implicated in a myriad biological 
systems from immune function and tissue repair (182), nervous system signaling (183), 
cardiac health (95, 184), to more sinister roles in viral pathogeneses like HIV-1 (185),  
Due to the pivotal roles exosomes play in disease, they provide much needed insight into 
progressing research into avenues such as biomarker identification for diagnostic and 
prognostic means (186), as well as identifying disease mechanisms as therapeutic targets 
(178, 179). 
The term asbestos refers to a group of hydrated silica fibers that occur naturally throughout 
the world. Classified as a category 1 carcinogen (187), asbestos is one of the more 
notoriously well-known cancer causing agents. Derived from the Greek word for 
inextinguishable, asbestos is widely used in the manufacturing process for a multitude of 
products and therefore is prevalent in a significant portion of the world’s communities, 
particularly in developing nations (188) making it a relevant human health hazard of the 
present and future (189).  
Exposure to asbestos occurs overwhelmingly through inhalation and leads to a litany of 
diseases including lung fibrosis (asbestosis), lung carcinoma and malignant mesothelioma 
(MM) (190).  Intriguingly there is an additive risk of lung cancer when cigarette smoking 
is combined with asbestos exposure (191). Asbestos fibers are known to first interact with 
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the upper-respiratory tract and exhibit more lasting effects on lung epithelial cells and 
resident macrophages, with the fiber geometry dictating how deep into the lungs the 
asbestos travels (longer, thinner fibers are capable of traveling further) (189, 192). 
MM is defined as a highly locally-invasive cancer which develops from mesothelial cells 
that line the body’s cavities. Once exposed to asbestos, there is a remarkably long latency 
period before MM develops, typically around 10-50 years. Furthermore, once MM is 
diagnosed, it is fatal within 6-12 months (193).  As noted the main determinate cause of 
MM is exposure to asbestos, and unfortunately there are currently no conclusive 
biomarkers for identifying exposure to asbestos or for early diagnosis of MM. Moreover, 
therapeutic strategies for MM are lacking as there are no successful regimens for fighting 
this disease after onset, with chemotherapeutic administration of pemetrexed and cisplatin 
being the only licensed approach (194). The mechanism by which this cancer develops in 
the first place, after asbestos exposure, is also less understood and by delineating the 
molecular pathways involved, we can gain a foothold of understanding that would no doubt 
lead to improvements in diagnosis and therapy. 
As there are clearly large gaps in the knowledge surrounding MM disease development, 
onset, treatment, and the minimal presence of potential biomarkers for asbestos exposure 
and early diagnosis, there exists potential to forward our understanding by delving into the 
realm of exosome research. This review will provide a brief summary of the current 
literature and experimental knowledge on MM and asbestos exposure as it pertains to 
advances in exosome-centered investigations.  
Malignant mesothelioma and exosomes 
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The first inquiry into exosomes and MM was a focused effort to identifying exosomes and 
their protein cargo from human caner pleural effusions. Exosomes were isolated by 
sucrose-gradient ultracentrifugation from the pleural fluid of patients suffering from MM, 
lung cancer, breast cancer and ovarian cancer. Matrix-assisted laser desorption ionization 
time-of-flight (MALDI-TOF) mass spectrometric analysis indicated large amounts of 
peptides originating from immunoglobulins and various complement factors, as well as 
previously undescribed exosomal proteins such as sorting nexing (SNX25) protein, B-cell 
translocation gene 1 (BTG1) and pigment epithelium-derived factor (PEDF) (195). Both 
BTG1 and PEDF were in increased abundance in exosomes from malignant processes 
which may designate as being involved in tumor exosome biogenesis, according to Bard et 
al. (2004). Moreover, Western blot analysis verified the presence of MHC class II 
molecule, HSP90, and immunoglobulin G and M. 
As indicated in the publication, before their results can be generalized, the risk of 
contaminating proteins that elute with exosomal proteins in these effusions needs to be 
taken into account. Although pleural effusions contain exosomes from many cellular 
origins not limited to tumor cells themselves, this report was an important first step in 
relating exosomes to MM, cancer and isolation of possible biomarkers from pleural 
effusions. 
As a follow-up to their first study to entrench upon the paradigm of exosome research in 
MM, the Lambrecht group (196) conducted a descriptive effort on the protein composition 
of exosomes that are secreted from MM tumor cells. They chose to study MM due to the 
limited knowledge of tumor antigens in the disease, and employed MALDI-TOF mass 
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spectrometry to outline the proteomic cargo of MM exosomes. MM tumor cell-lines were 
created from 10 patients diagnosed with MM, and exosomes were isolated from 7 of these 
tumor cell lines using ultra-centrifugation and characterized by TEM for their cup-shaped 
morphology and size range. Exosomal proteins were subjected to MALDI-TOF analysis 
and of the 38 identified proteins, four were confirmed by Western blot analysis: fascin, β-
tubulin, HSC70 and HSP90 (196).  
In addition, as reported in in vivo systems (197), these tumor exosomes were also enriched 
with MHC class I molecules, and the authors also indicated high levels of annexins which 
may be involved in membrane-cytoskeleton dynamics. This report by Hegmans et al. 
(2004) revealed several proteins that had not yet been indicated on tumor exosomes or in 
MM cell lines, therefore providing novel information on MM and tumor exosomes as a 
whole that could advance our understanding of the disease. 
In 2005, Clayton et al. published their work on the immunological functions of exosomes 
secreted by tumor cells (breast cancer and mesothelioma), and how these tumor exosomes 
altered the expression of the NKG2D receptor on target blood leukocytes. The exosomes 
secreted from these MM cancer cells turned out to be positive in expression of NKG2D 
ligands, and this was directly related the capacity of MM exosomes to decrease the capacity 
of effector T cells to kill target cells (198). 
In the study, it was demonstrated that the two MM cell lines used had high expression of 
NKG2D ligands (as well as positive staining for MICA, MICB and ULBP-3), and appeared 
to correlate with the MM exosomes’ aptitude in more effectively suppressing NKG2D 
expression on target cells. Overall, this report indicates a role of MM exosomes in 
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phenotypically altering immune cells in a way that can aid tumor cells in immune evasion 
by the presence of exosome ligands to NKG2D. 
A promising field of therapeutic cancer research of late is focused on the use of tumor-
associated antigens (TAA) present on tumor exosomes as a mode of dendritic cell based 
immunotherapy. The concept being that tumor exosomes bearing TAAs, mostly secreted 
from immunogenic cancers, are adept at inducing anti-tumor responses in mouse cancer 
models by activation of dendritic cells. An intriguing display of this potential was reported 
by Mahaweni et al.(199), except that by using MM cells, they incorporated a rather 
unprecedented step forward in this field because MM is regarded as a non-immunogenic 
cancer with very few TAAs known. Their investigation assessed if MM exosomes were 
potential antigen sources for dendritic cell based immunotherapy (199). 
Initially, a lethal dose of MM tumor cells were injected into BALB/c mice. After seven 
days of tumor formation in the mice, a single bolus dose of dendritic cells were injected 
into the tumor-bearing mice for immunotherapy. These dendritic cells, however, had been 
loaded with either MM exosomes or MM cell lysate (or PBS control) to quarry if the 
exosomes had an immunogenically priming capacity on the dendritic cells. The overall 
median survival of tumor bearing mice was significantly increased in the dendritic cell 
immunotherapy loaded with MM tumor exosomes compared to cell lysate indicating that 
there may be some promise in using MM exosomes as immunotherapy, as well as in other 
non-immunogenic tumors. 
The subsequent research regarding exosomes in MM had an intriguing focus on the 
formation of tunneling nanotubes (TnTs), the actin–based cellular extensions involved in 
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intercellular cargo transport. The relationship between TnT formation and their 
communicatory effects with MM tumorigenesis is unknown, and for their study, 
Thayanithy et al.(200) centered in on exosomes as possible mediators for TnT formation 
in MM. MM exosomes were purified and added to dishes of independently cultured MM 
cells, and it was found that in these conditions, MM tumor cells produced significantly 
more TnTs than cells cultured without exogenous exosome addition (200).  
The researchers indicated that the added tumor exosomes enriched at the base of, and inside 
the TnTs, which correlates interestingly to a 2016 report (201) on the mode of exosomal 
interaction with target cells. In the study by Heusermann et al., exosomes were 
demonstrated to localize and “surf” on filipodia (similar actin filamentous cellular 
projections) before internalization (201, 202). The uptake of MM exosomes by MM cells 
apparently facilitated more TnT connections between tumor cells, and connected cells had 
nearly twice the number of lipid-raft enriched regions. Taken together, it can be seen that 
MM exosomes may act as an induction agent of TnT formation between MM tumor cells, 
and perhaps this connection is an important conduit of cellular information vital to MM 
progression. 
Progressing on the understanding of the MM secretome, Greening et al. (203) released a 
comprehensive study on MM derived exosomal proteomic cargo. By use of quantitative 
proteomics, they delineated the protein make up of exosomes from 4 human MM cell lines 
and identified a total 2,178 proteins from all cells, with 631 common exosomal proteins 
between all groups (203). As this report came after the aforementioned exosomal inquiries 
in MM, there were several common proteins identified in the previous report (195), 
58 
 
however, 2,073 proteins were unique to this investigation. Of their MM exosome proteins, 
the investigators demarcated candidate biomarkers based on clinical relevance, amongst 
them: tubulin isotypes TUBB4A, Q8IWP6, B3KPS3; galectin-3-binding protein and 
LGB3P; alpha enolase, annexin 1 and G6PD. Furthermore, it was identified that MM 
exosomes contained mesothelin, calreticulin, vimentin, and superoxide dismutase, all 
known to be expressed highly in MM. Additionally, the results of this research uncovered 
the presence of 26 immunoregulatory components in MM exosomes (such as oncostatin-
M receptor (OSMR), multidrug resistance-associated protein 1 (ABCC1), and the SUMO-
1 activating receptor, SAE1), as well as 16 tumor-derived antigens, including glypican-1, 
which has been identified in many tumor derived exosomes and is recorded as potentially 
valuable biomarker for pancreatic cancer (204). Importantly, this study also provided 
valuable insight that showed that MM exosomes regulate the cells of the tumor 
microenvironment by increasing the migratory capacity of fibroblasts and endothelial cells 
in vitro. Together, their findings implicate MM exosomes as containing many proteins 
relevant to cancer, angiogenesis, metastasis, migration and immune regulation. 
The Robinson group provided another iteration on their quests for elucidating the 
complexities of the MM secretome suing iTRAQ proteomic analysis. Using 6 MM cell 
lines in comparison to 3 primary mesothelial cell cultures, it was seen that MM cell 
secretomes contained higher abundances of exosomal proteins (205). This study is 
primarily focused on the whole secretome with only some references to exosomes. 
The literature review presented above is 100% focused on exosomal content/signature from 
MM cells and how exosomes can help in communication between MM cells. However, the 
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role exosomes can play in development of MM or help in early diagnosis of MM is missing. 
For more than a decade our lab has been interested in uncovering mechanisms of MM 
development in response to asbestos exposure. Based on the fact that asbestos is inhaled 
into the lung, yet MM develops in remotely present pleural and peritoneal mesothelial cells, 
we were encouraged to focus on exosomes as a carrier of information from lung cells to 
mesothelial cells. As a first of its kind study our lab investigated the proteomic cargo and 
gene modulatory effects of exosomes from asbestos-exposed cells. Our investigation began 
by culturing lung epithelial cells (BEAS2B) or macrophages (THP1) (the first known cells 
to encounter asbestos upon inhalation) with asbestos and isolating their exosomes. These 
asbestos-exosomes were subjected to tandem-mass spectrometry for protein identification. 
It was shown that 145 proteins were identified in epithelial cell exosomes and 55 were 
significantly different in abundance in the asbestos exposed group including plasminogen 
activator inhibitor 1, vimentin, thrombospondin and glypican-1 (206). We next assessed 
that the exosomes from asbestos exposed epithelial cells led to genetic changes in target 
primary pleural human mesothelial cells (HPM3) that were reminiscent of epithelial to 
mesenchymal transition (EMT): down-regulation of E-cadherin, desmoplakin and IL1 
receptor antagonist (206).  
Upon proteomic analysis of macrophage exosomes, we (Munson et al. 2018) identified 785 
proteins. Of these proteins, 32 had significantly different abundances between exosomes 
from the asbestos exposed group and the control. Fifteen of these exosomal proteins were 
in greater abundance in the asbestos group compared to control and interestingly, vimentin 
and SOD were amongst those that increase in exosomes from macrophages after asbestos 
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exposure.  In response to exposure of asbestos exosomes from macrophages to target 
primary mesothelial cells, it was shown that significant genetic alterations occur in 
mesothelial cells: 498 gene changes total (with 1.5 fold cutoff with an ANOVA transcript 
level p-value less than 0.05), 241 up and 257 down-regulated. As a positive control, the 
group used asbestos fibers on mesothelial cells, and uncovered that 206 genes were 
mutually altered in the asbestos-exosomes exposed, or asbestos exposed group of 
mesothelial cells. Three up- (hCCNB2, hEGR1 and hFANCD2) and down-regulated 
(hCRELD2, hERO1B and hJAG1) genes were then validated by qPCR (206). Of note is 
that CCNB2 overexpression is attributed with MM and FANCD2 is up-regulated in MM 
and asbestos exposure (207, 208). This exciting discovery, is novel in that it implicates 
exosomes from asbestos exposed cells as being capable of changing mesothelial cell 
genetics in ways similar to how asbestos fibers would on their own. As a next step, this 
information will be verified in in vivo systems for future studies. 
As an initial step in the direction of in vivo study we committed our efforts to defining the 
proteomic signature of mouse serum exosomes in an asbestos exposure model. C57/Bl6 
mice were exposed to asbestos via oropharyngeal aspiration, and 56 days later, serum 
exosomes were isolated for proteomic analysis. Again using tandem-mass spectrometry for 
protein identification, we showed that there were 376 quantifiable proteins in the mouse 
serum exosomes, with the majority of protein being more abundant in the asbestos exposed 
group (209). Of these more abundant proteins in the asbestos exposed group, three were 
validated by Western blot analysis, all of which are acute-phase proteins: haptoglobin; 
ceruloplasmin, the copper carrying glycoprotein previously seen to be increased in MM 
61 
 
patients’ blood and asbestos exposed individuals (210); and fibulin-1, a member of the 
fibulin family, of which, fibulin-3 has been suggested as being implicative of asbestos 
exposure and MM (211). We did not see common exosomal proteins between our 2 
published studies as these are very different systems, in vitro vs in vivo and human vs 
mouse. 
In addition to the above mentioned published studies, we have also performed numerous 
studies with human mesothelioma cells, plasma from asbestos exposed and mesothelioma 
patient samples. We do find some common signatures between our study and others, 
including SOD, vimentin, and glypican-1 (203, 205). Studies were also performed with 
plasma exosomes isolated from healthy volunteers, asbestos exposed non-tumor group and 
asbestos exposed mesothelioma groups. Although the number of exosomes per ml of 
plasma were not different in various groups, the exosomal protein quantity was more in 
different disease groups as compared to controls. Proteomic analysis performed on these 
samples showed the presence of coagulation-related proteins in exosomes from the disease 
group (mesothelioma and asbestos-exposed) as compared to control. Control group plasma 
exosomes presented a signature including immunoglobulins, lipoproteins and platelet-
related proteins. These data indicate altered immune surveillance in MM samples 
concomitant with the increase of coagulation factors (unpublished data). We plan to 







Asbestos exposure is a serious health concern for thousands of people worldwide, and MM 
is the cancer resulting primarily from asbestos exposure. To date, there are no successful 
therapeutic regimens for treating MM, and with the dismal survival time after diagnosis 
and lack of biomarkers for early detection make it an important area for propagating 
research. The field of exosomes in cancer has exploded recently due to the fact that these 
extracellular vesicles are emerging players in the dynamics of cancer biology, contributing 
to cellular crosstalk involved in cancerous processes and housing cancer biomarker 
signatures. Many advances have been made to date using exosomes for biomarker 
identification, detecting novel therapeutic targets, and basic understanding of tumor 
biology (212, 213). In this regard, using exosomes to gain needed insight into MM 
development, detecting potential biomarkers, pinpointing therapeutic targets and 
harnessing exosomes as drug delivery devices and immunoregulators against cancer are 
the next big steps researchers must take. 
The studies reviewed above provide the initial framework for understanding possible 
biomarkers and the underlying biology of MM and asbestos exposure. From their findings, 
research can commit to further identifying means of early detection of asbestos exposure 
or asbestos-related disease development, as well as uncovering much needed therapeutic 
targets. Moreover, the ability to understand the mechanistics of MM development and 
progression in regards to exosomes is an important realm that may be utilized in treating 
MM cancer patients. Ultimately, we hope that exosome research in MM continues on this 
forward trajectory and more significant findings are made into the figuring out how 
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asbestos causes cancer and finding ways to identify dangerous exposure to asbestos and 
early cancer detection before a fatal diagnosis is made. 
Acknowledgements 
Financial support from the Department of Defense grant (W81XWH-13-PRCRP-IA) and 
NIEHS RO1 (ES021110) to AS is acknowledged. PM is supported by the Department of 








Figure 6. Schematic overview of themes discussed in this dissertation outlining the 
chronological reasoning of experiments and broad concepts. The following chapters 
delve into the experiments and characterizations that led to the reasoning that asbestos 
exposure of lung epithelial cell and macrophages leads to exosomes with unique protein 
cargo that travels to target mesothelial cells and alters them genetically. This alteration 
leads to potential development of malignant mesothelioma (MM) and MM tumor cells 
secrete exosomes with unique miRNA cargo. These MM exosomes turned out to be a 
65 
 
route of removing tumor suppressor miRNAs, namely, miR-16-5p. We went to exploit 
this process by inhibiting exosome secretion and force-feeding MM tumor exosomes 
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Asbestos-induced diseases like fibrosis and mesothelioma are very aggressive, without any 
treatment options. These diseases are diagnosed only at the terminal stages due to lack of 
early stage biomarkers. The recent discovery of exosomes as circulating biomarkers led us 
to look for exosomal biomarkers of asbestos exposure in mouse blood. In our model, mice 
were exposed to asbestos as a single bolus dose by oropharyngeal aspiration. Fifty six days 
later blood was collected, exosomes were isolated from plasma and characterized and 
subjected to proteomic analysis using Tandem Mass Tag labelling. We identified many 
proteins, some of which were more abundant in asbestos exposed mouse serum exosomes, 
and three selected proteins were validated by immunoblotting. Our study is the first to show 
that serum exosomal proteomic signatures can reveal some important proteins relevant to 
asbestos exposure that have the potential to be validated as candidate biomarkers. We hope 




The causative factor leading to the development of malignant mesothelioma (MM) is 
exposure to asbestos fibers 1. Mesothelioma is a fatal cancer arising on the mesothelial cell 
lining of the pleura, most commonly, but can also present itself on the peritoneal lining, 
pericardium, and rarely the testicular tunica vaginalis. A recent CDC report states that there 
are a substantial number of MM cases, which are increasing in numbers 2. The median 
lifespan, once diagnosed with MM, is 6-10 months and there are currently no successful 
treatment options. Further, there are no standard biomarkers for early diagnosis of the 
disease, neither are there any biomarkers to indicate harmful levels of asbestos exposure. 
It is therefore a highly valuable public health endeavor to identify signatures of asbestos 
exposure in order to more adequately detect harmful levels exposure before an individual 
develops MM. 
The field of biomarker discovery has found its trajectory leading to the field of extracellular 
vesicle investigations, particularly exosomes. Exosomes are 30-140 nm membrane bound 
vesicles derived from endocytic origin, which are now known to be major players in 
transmitting biological content between cells and tissues 3-4. Their content is remarkable in 
that it can be utilized for discovering unique biomarkers of disease states, such as cancer. 
Beyond biomarker discovery, exosome research has furthered the understanding of myriad 
biological mechanisms. Therefore, this avenue of discovery is fitting to make the necessary 
strides in being able to one day diagnose dangerous exposure to asbestos and pre-empt the 
development of MM. 
To date there is no study of exosomes proteomic signature in relationship to asbestos 
exposure, making our paper the first of its kind. There is mounting evidence, however, of 
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the relevance and toxicology of exosomes released after exposure to chemicals and 
environmental toxins 5. Asbestos itself is one of the most well-known environmental toxins 
and is currently classified as a Class I Carcinogen. Furthermore, the use of exosomes as 
cancer and disease biomarkers is now very common place, with serum exosomal proteomic 
signature being a particular focus for many studies on elucidating unique signatures 6-7. 
One of the most exciting uses of serum exosomes for biomarker discovery was by Melo et 
al. in 2015 indicating that exosomal Glipican-1 was a discriminate factor for pinpointing 
pancreatic cancer 8. 
The current study presented focuses on describing the exosomal proteomic analysis of an 
asbestos exposure mouse model. Our preliminary goal was to quarry for differential 
abundances of proteins in exosomes derived from asbestos exposed animals, particularly 
proteins in increased abundance, or unique, as those would more likely lead to future 
biomarker identification studies. The mouse model used here, exposes animals to asbestos 
via oropharyngeal aspiration (OA) in a bolus dose. OA is a well-established mode of 
exposing mice to asbestos fibers by deposition in the airway and lungs 9 and is closest to 
an inhalation model. Serum was collected and exosomes were isolated for proteomic 
profiling.  
Although the full nature of exosome cargo packaging is not fully understood, it is known 
that exosomes become specifically enriched in certain proteins and molecules from the 
producer cell cytoplasm in ratios not directly parallel to the cytosolic fraction or freely 
secreted portion of those same molecules (given that all of them are freely secreted from 
the cell in the first place). Hence, isolating exosomes provides a specific vantage point that 
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avoids much of the other potentially unimportant molecules that are secreted into the 
circulation or into cavity spaces.  
Materials and Methods 
Oropharyngeal Aspiration of asbestos 
C57/Bl6 mice (5/group) were exposed to crocidolite asbestos (NIEHS reference sample) 
or saline (50 μL) as a single bolus dose by oropharyngeal aspiration (OA) as described 9. 
After 56 days of exposure, whole blood was collected via cardiac puncture and serum was 
collected using Microtainer Serum Separating Tubes (BD, Franklin Lakes, NJ) following 
the manufacturer’s protocol. Serum was frozen at -80°C until exosome collection. All 
experiments using mice were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Vermont, Larner College of Medicine 
(Burlington, VT).  
Exosome Isolation 
Exosomes were collected from serum using ExoQuick (System BioSciences, Palo Alto, 
CA) according to the manufacturer’s protocol 10-11. Precipitation method was used for 
serum exosome isolation, because of very low volume (200 μL) of the serum sample 
availability. 
Transmission Electron Microscopy (TEM) 
The membranous structure and size of exosomes was assessed by TEM. Formvar/carbon 
coated nickel 200 mesh grids were glow discharged for 60 seconds, and 5µL of sample was 
placed on grid and incubated for 1 minute.  Excess sample was wicked and the grids were 
touched to 30µL water drops with wicking performed between each rinse. Grids were 
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touched to 2 sequential 30µL drops of 2% aqueous uranyl acetate, excess was wicked, and 
grids were air dried. Grids were imaged under transmission electron microscope for 
exosomes using a JEOL 1400 TEM (JEOL, Peabody, MA). 
NanoParticle Tracking Analysis 
Number and size of exosomes were further assessed by nanoparticle tracking analysis 
(NTA) using the ZetaView PMX 110 (Particle Metrix, Meerbusch, Germany) and Software 
ZetaView 8.02.31. 
Exosome marker characterization 
Exosome purity was characterized by assessment of exosome specific markers, CD9  and 
CD81 by using specific antibodies (Sigma Aldrich, St. Louis MO) in immunoblot analysis 
as described below 12. 
Sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and trypsin digestion   
The extracted exosomal proteins (maximum amounts less than 100 µg) were loaded onto 
SDS-PAGE.  Equal amounts (100 ng) of gylceraldehyde-3-phosphate dehydrogenase 
(Sigma Aldrich) were added to each sample to control for digestion and labeling 
efficiencies.  The proteins were allowed to migrate 3 to 5-mm into the separating gel, and 
then the gels were stained with Coomassie Brilliant Blue. The gel lanes were excised into 
3 slices according to their molecular weights (I- upper, II-mid, III-lower). (Figure 2A) The 
slices were destained with 50% acetonitrile (ACN)/50 mM NH4HCO3 and subjected to 
trypsin digestion protocols, as described previously 13.   
After our initial pilot experiments, we have optimized this gel based separation strategy to 
allow the high abundant proteins to be confined to gel slice II-mid, whereas the relatively 
85 
 
low abundant proteins were localized in gel slices I-upper and III-lower.  Gel slices I, II, II 
were analyzed separately in three mass spectrometry runs to increase the proteome 
coverage.   
Peptide labeling by Tandem Mass Tags   
The labeling procedures were performed according to the manufacturers’ protocols 
(Thermo Fisher Scientific, Waltham, MA, USA) with the following modifications.  Briefly, 
dried peptides in gel slice II, and gel slices I and III from each sample were resuspended in 
50 and 25 µL of triethyl ammonium bicarbonate, respectively.  Twenty and ten µL of TMT 
reagents (0.8 mg dissolved in 41 µL of acetonitrile (CH3CN)) was added to gel slice II, and 
gel slices I and III, respectively, followed by briefly vortexing and an incubation for 1.5 h 
at room temperature.  After incubation, 5% hydroxylamine was added to quench the 
reactions. One-third the reactions were combined, dried down and kept at -80o C until mass 
spectrometry analysis.   
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
The purified labeled peptides were resuspended in 5 µL of 2.5% acetonitrile CH3CN and 
2.5% formic acid (FA) in water for subsequent LC-MS/MS based peptide identification 
and quantification.   Analyses were performed on the Q-Exactive mass spectrometer 
coupled to an EASY-nLC (Thermo Fisher Scientific, Waltham, MA, USA).  Samples were 
loaded onto a 100 μm x 120 mm capillary column packed with Halo C18 (2.7 μm particle 
size, 90 nm pore size, Michrom Bioresources, CA, USA) at a flow rate of 300 nl min-1.  
Peptides were separated using a gradient of 2.5-35% CH3CN/0.1% FA over 150 min, 35-
100% CH3CN/0.1% FA in 1 min and then 100% CH3CN /0.1% FA for 8 min, followed by 
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an immediate return to 2.5% CH3CN/0.1% FA and a hold at 2.5% CH3CN/0.1% FA.  
Peptides were introduced into the mass spectrometer via a nanospray ionization source and 
a laser pulled ~3 μm orifice with a spray voltage of 2.0 kV.  Mass spectrometry data was 
acquired in a data-dependent “Top 10” acquisition mode with lock mass function activated 
(m/z 371.1012; use lock masses: best; lock mass injection: full MS), in which a survey scan 
from m/z 350-1600 at 70, 000 resolution (AGC target 1e6; max IT 100 ms; profile mode) 
was followed by 10 higher-energy collisional dissociation (HCD) tandem mass 
spectrometry (MS/MS) scans on the most abundant ions at 35,000 resolution (AGC target 
1e5; max IT 100 ms; profile mode).  MS/MS scans were acquired with an isolation width 
of 1.2 m/z and a normalized collisional energy of 35%.  Dynamic exclusion was enabled 
(peptide match: preferred; exclude isotopes: on; underfill ratio: 1%; exclusion duration: 30 
sec). Product ion spectra were searched using the SEQUEST and Mascot search engines 
on Proteome Discoverer 1.4 (Thermo Fisher Scientific, Waltham, MA, USA) against a 
curated Mouse Uniprot (Mus protein database; 3AUP000000589; downloaded Feb. 21, 
2017) with sequences in forward and reverse orientations.  Search Parameters were as 
follows: (1) full trypsin enzymatic activity; (2) maximum missed cleavages = 2; (3) 
minimum peptide length = 6, (4) mass tolerance at 20 ppm for precursor ions and 0.02 Da 
for fragment ions; (5) dynamic modifications on methionines (+15.9949 Da: oxidation), 
Dynamic TMT6plex modification (The TMT6plex and TMT10plex have the same isobaric 
mass) on N-termini and lysines (229.163 Da); (6) 4 maximum dynamic modifications 
allowed per peptide; and (7) static carbamidomethylation modification on cysteines 
(+57.021 Da).  Percolator node was included in the workflow to limit the false positive 
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(FP) rates to less than 1% in the data set. The TMT ratios were generated with a common 
denominator using the four controls. All the protein identification and quantification 
information (<1% FP; with protein grouping enabled) was exported from the msf result 
files to Excel spreadsheets for further statistical analyses. Identification of keratins were 
removed from the list. Average means and p-values were calculated in Excel 
(Supplementary Table. S 1, Excel spreadsheet).   
Western blot analysis for validation of proteins: 
Few selected high abundance proteins were validated by immunoblot analysis in exosomes 
isolated from serum of saline and asbestos exposed mice. Western blot analysis was 
performed on exosome samples from serum suspended in 4X lysis buffer and boiled for 5 
min at 95 °C. Thereafter 10–15 μL of each sample was resolved on a 10% SDS PAGE for 
subsequent immunoblotting for selected proteins, ceruloplasmin (Abcam, Cambridge, 
MA), haptoglobin (Abcam) and fibulin-1 (Thermo Fisher Scientific) using specific 
antibodies as described before 12. 
 
Results 
Characterization of exosomes 
Mouse serum exosomes were purified by ExoQuick precipitation following the 
manufacturer’s protocol and characterized before proteomics analysis. Isolated exosomes 
from mouse serum was initially characterized by nanoparticle tracking analysis (NTA) and 
transmission electron microscopy (TEM) to assess the particle concentration, size 
distribution, and membrane bound nature, as exosomes under TEM have a characteristic 
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cup-shaped morphology 14 (Figure 1A). NTA indicates particles directly the in size range 
of exosomes with a median size of 68.1nm (Figure 1B). Exosome preparation from serum 
also showed exosome specific markers, CD9 and CD81 (Figure 1C).  
Proteomic analysis of exosomes 
The exosomes isolated from serum and analyzed by Tandem-Mass-Tag profiling yielded 
results of 376 quantifiable proteins (with less than 1% FP). The proteins were compared 
between the control, non-asbestos exposed mice (n=4), and mice exposed to asbestos via 
pharyngeal aspiration (n=5) and sorted by fold change (asbestos/control) and statistical 
significance (Supplementary Table S1). Although there were only a few proteins that had 
differentially abundance in the asbestos group with statistical significance (p < 0.05) due 
to biological variations among individual animals, proteins were clearly more abundant 
after asbestos exposure (Figure 2B). The proteins identified to be more abundant in the 
asbestos group were sorted through for biological significance, as well as if there was 
statistical significance, and the top 15 which met either or both criteria were compiled 
(Table 1).  
Validation of selected proteins by immunoblot analysis:  
Three of these exosomal proteins in greater abundance from the asbestos exposed animals, 
and of particular biological interest (excluding any contaminating serum proteins), were 
validated by Western blot analysis to confirm proteomics results (Figure 3A), and ponceau 
staining was used to ensure equal protein loading (Figure 3B) as no reliable standard exists 
for secreted proteins. Four of five asbestos exposed animals showed increased exosomal 
fibulin-1, all five animals showed increased exosomal ceruloplasmin, and three of five 
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mice showed increased exosomal haptoglobin (Figure 3). Our protein validation was 
performed on the same group of mice and shows the same trends of abundance as indicated 
by our proteomics heatmap. The fact that the ratios determined by Western blot are in 
agreement with the TMT ratios for individual animals, demonstrates that our proteomics 
approach was robust and is applicable for these types of serum exosome proteomic 
profiling. 
STRING Pathway Analysis 
Pathway analysis was completed for the top 200 most abundant exosomal proteins in each 
group, based on fold change, using STRING functional protein-protein association network 
(https://string-db.org/) and the resulting top 10 Gene Ontology biological processes derived 
from the networking were compiled (Table 2). 
 
Discussion 
This short study is the first of its kind to present data on the relevance of exosome-protein 
signature in regard to in vivo exposure to asbestos fibers. Asbestos exposure is the main 
causal factor of MM, the fatal cancer of the mesothelial lining of the pleura, peritoneum, 
and pericardium. There is no means of early diagnosis of MM, or capability to diagnose 
harmful exposure to asbestos fibers due to a lack of useful biomarkers. We conducted these 
studies to begin in an unexplored area of asbestos and exosome biomarker discovery. We 
chose to use a well-defined mouse model of asbestos exposure, OA. Studies from NIOSH 
and others have compared OA with inhalation exposure to asbestos and found these two 
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very comparable ways to expose mice to asbestos 15-16. OA is notably capable of eliciting 
the systemic effects of asbestos exposure from which we isolated serum exosomes.  
Use of mouse models to understand the systemic and/or local effect of asbestos exposure 
on exosomal protein candidates is the first step towards identifying biomarkers of asbestos 
exposure. Our mouse model allowed us an in vivo approach to describing the exosomal 
protein content of mouse serum, and any associated differences upon asbestos exposure. 
Currently, the 2 most common methods available to isolate exosomes from various samples 
are ultracentrifugation and ExoQuick precipitation. Comparative exosome isolation studies 
done using these two methods showed either comparable results 11 or better 10 results with 
ExoQuick. Due to very small volume (~200 μL) of serum availability from mouse, we used 
the ExoQuick precipitation method to isolate exosomes. Characterization of our exosome 
preparation showed a membranous structure in correct size range expressing specific 
markers. Proteomic analysis of our preparation identified a total of 376 proteins. Amongst 
these proteins, we observed an increased abundance of multiple proteins of biological 
interest in the asbestos group. The heterogeneous effects observed in the asbestos group is 
not uncommon due to several reasons, 1) it is an insoluble (fibrous) agent and is not 
available to all cells (or all surfaces of tissues) uniformly, and 2) it is well known that only 
a small percentage of asbestos-exposed individuals develop mesothelioma suggesting a 
susceptibility issue 17-18. 
Moreover, as this study was intended to yield insight on potential exosomal protein 
biomarkers for asbestos exposure we believe the proteins with most increased abundance 
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for asbestos exposed animals are of most interest. Within this subset of identified exosomal 
proteins there are some potential implications in the biology of asbestos exposure.  
Increased proteins in the asbestos group that were validated by Western blot analysis were, 
ceruloplasmin, haptoglobin, and fibulin-1. These are acute phase proteins and shown 
previously to be upregulated in response to asbestos exposure 19-22.  Ceruloplasmin is a 
copper-carrying glycoprotein and plays an important role in iron metabolism 23-24. The 
toxicity of asbestos is in part due to iron metabolism dysregulation after exposure in the 
lung 25. Ceruplasmin has been shown in a 2014 study to be increased in the serum of 
asbestos exposed individuals and even higher in those with mesothelioma 26. Use of 
postoperative tetrathiomolybdate to deplete copper and ceruloplasmin in mesothelioma 
patients has been shown to be beneficial 27, suggesting a strong role of ceruloplsmin in MM 
tumorigenesis.  
The fibulin family of proteins (fibulin-1, -2, -3, -4, -5) are known to share extensive 
molecular functional similarities and sequence homology 28-29, and recent publications 
have indicated that fibulin-3 levels may be indicative markers of asbestos exposure and 
mesothelioma 30-32. Our experiments have identified that fibulin-1 is increased in exosomes 
from asbestos exposed animals, which may indicate a role of fibulin family member in 
extracellular matrix remodeling after asbestos exposure. What is unique about fibulin-1 in 
this study is that it appears to be specifically enriched in exosomes of asbestos exposed 
animals, whereas the other studies indicate freely secreted fibulin-3.  
Another protein of interest that was detected in increased abundance in the asbestos groups 
was ficolin-1, a protein involved in cell morphogenesis and known to target fibrinogen. 
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Additionally, exosomal 14-3-3 protein sigma was increased in serum of asbestos exposed 
mice and it has been shown that this protein has extracellular functionality as an adaptor 
protein. The only known extracellular 14-3-3 proteins are secreted via exosomes, and have 
been shown to target the Wnt signaling pathway in target cells via the association of 
discheveled-2 33. Interestingly, 14-3-3 protein sigma also plays roles in matrix 
metalloproteinase activity, activating fibroblast migration, and even reducing fibrosis and 
inflammation, both of which are hallmark effects of asbestos exposure 34. Interestingly, 14-
3-3-theta levels were found to be upregulated in conditioned medium from MM cells as 
compared to mesothelial cells 35, suggesting important role(s) of this group of proteins in 
mesothelioma tumorigenesis. 
The potential consequences of exosomal proteins listed above is speculative based on 
previous research and requires further study to elucidate mechanistic roles. However, our 
data is novel by being the first to indicate unique protein signatures of exosomes in 
response to asbestos exposure. Those exosomal proteins in greater abundance after 
asbestos exposure may lead to the identification of more useful biomarkers to diagnose and 
prevent asbestos related disease, as exosomal strategies are becoming convenient and 
commonplace. 
The development of useful biomarker-based diagnostic, and potentially therapeutic 
enterprises is of great public health concern for asbestos-related diseases and beyond. We 
intend to continue our expedition to mine for exosomal biomarkers of asbestos exposure in 
future and ongoing experiments. Those include in vitro models of asbestos exposure and 
isolation of exosomes from the blood of individuals with known exposure to asbestos and 
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mesothelioma patients. Our intentions are to provide new and useful exosome based 
strategies to identify asbestos exposure, and this study is the first of its kind in taking that 
initial step forward. 
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Figure 1. Characterization of exosomes derived from mouse serum by transmission 





Figure 2. Depiction of gel cuts into three bands prior to in-gel trypsin digestion (A) and 
heatmap showing differential abundance of mouse serum exosomal proteins in response to 
asbestos exposure. Mice were exposed to saline (n=4) or asbestos (n=5) by oropharyngeal 
aspiration. Eight weeks later serum was collected, exosomes were isolated and proteomic 




Figure 3. Proteomic results were validated by immunoblot assay. Three selected proteins, 
ceruloplasmin, haptoglobin, and fibulin, found in high abundance in asbestos group were 
validated by immunoblot analysis as described in materials and methods (A). As these are 
secreted proteins, loading controls are not available. Equal loading was achieved by 
keeping the starting and final volume same across the samples and was assessed by 





Table 1: Top 15 most biologically significant serum proteins from the most abundant 
exosomal proteins identified by proteomics analysis on asbestos-exposed mice compared to 
non-exposed mice 
Accession # Description Fold 
Change 
p-value 
Q61646 Haptoglobin OS=Mus musculus GN=Hp 
PE=1 SV=1 - [HPT_MOUSE] 
3.559 0.232 
O70456 14-3-3 protein sigma OS=Mus musculus 
GN=Sfn PE=1 SV=2 - [1433S_MOUSE] 
3.401 0.415 
Q5FW60 Major urinary protein 20 OS=Mus musculus 
GN=Mup20 PE=1 SV=1 - 
[MUP20_MOUSE] 
3.075 0.188 
Q8K0E8 Fibrinogen beta chain OS=Mus musculus 
GN=Fgb PE=1 SV=1 - [FIBB_MOUSE] 
3.058 0.172 
Q91X70 Complement component 6 OS=Mus 
musculus GN=C6 PE=1 SV=1 - 
[Q91X70_MOUSE] 
3.014 0.151 
Q91X72 Hemopexin OS=Mus musculus GN=Hpx 
PE=1 SV=2 - [HEMO_MOUSE] 
2.592 0.235 
Q91V57-3 Isoform 3 of N-chimaerin OS=Mus musculus 




Q08879-2 Isoform C of Fibulin-1 OS=Mus musculus 
GN=Fbln1 - [FBLN1_MOUSE] 
2.248 0.160 
Q61147 Ceruloplasmin OS=Mus musculus GN=Cp 
PE=1 SV=2 - [CERU_MOUSE] 
2.169 0.199 
G3X9T8 Ceruloplasmin OS=Mus musculus GN=Cp 
PE=1 SV=1 - [G3X9T8_MOUSE] 
2.166 0.198 
Q3V3K3 Putative uncharacterized protein OS=Mus 
musculus GN=Taok3 PE=1 SV=1 - 
[Q3V3K3_MOUSE] 
1.942 0.044 
Q08879 Fibulin-1 OS=Mus musculus GN=Fbln1 
PE=1 SV=2 - [FBLN1_MOUSE] 
1.801 0.227 
P19091 Androgen receptor OS=Mus musculus 
GN=Ar PE=1 SV=1 - [ANDR_MOUSE] 
1.642 0.047 
E9Q5F6 Polyubiquitin-C (Fragment) OS=Mus 
musculus GN=Ubc PE=4 SV=1 - 
[E9Q5F6_MOUSE] 
1.549 0.030 
Q5U405 Transmembrane protease serine 13 OS=Mus 







Table 2: Top 10 most significant gene ontology biological components in serum based on 
pathway analysis from the top 200 proteins of highest expression (highest fold change) in 
exosomes from asbestos exposed mice. 
Pathway ID Biological Process Observed 
Gene Count 
FDR 
A    
GO.0006952 defense response 22 4.45E-13 
GO.0006956 complement activation 9 1.55E-12 
GO.0006959 humoral immune response 10 7.91E-11 
GO.0006953 acute-phase response 8 1.85E-10 
GO.0045087 innate immune response 14 7.56E-10 
GO.0052547 regulation of peptidase activity 13 1.06E-08 
GO.0006950 response to stress 27 1.33E-08 
GO.0002253 activation of immune response 10 1.54E-08 
GO.0030162 regulation of proteolysis 15 4.33E-08 
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Asbestos exposure is a determinate cause of many diseases such as mesothelioma, fibrosis 
and lung cancer posing it as an important human health hazard. At this time, there are no 
identified biomarkers to demarcate asbestos exposure prior to the presentation of disease 
and symptoms, and there is only limited understanding of the underlying biology that 
governs asbestos induced disease. Our study uses exosomes, 30-140 nm extracellular 
vesicles, to gain insight into these knowledge gaps. As inhaled asbestos is first encountered 
by lung epithelial cells and macrophages, we hypothesize that asbestos exposed cells 
secrete exosomes with signature proteomic cargo that can alter the gene expression of 
mesothelial cells, contributing to disease outcomes like mesothelioma. In the present study 
using lung epithelial cells (BEAS2B) and macrophages (THP-1), we first show that 
asbestos exposure causes changes in abundance of some proteins in the exosomes secreted 
from these cells. Furthermore, exposure of human mesothelial cells (HPM3) to these 
exosomes resulted in gene expression changes related to epithelial to mesenchymal 
transition and other cancer related genes. This is the first report to indicate that asbestos 
exposed cells secrete exosomes with differentially abundant proteins and that those 
exosomes have a genetically altering effect on mesothelial cells.  





Exposure to asbestos is a main causal factor of several human diseases, including malignant 
mesothelioma (MM), lung fibrosis (asbestosis) and bronchial carcinoma (1). Notably, lung 
cancer risk is supra-additively increased when an individual both smokes tobacco and is 
exposed to asbestos (2). The term asbestos (stemming from the Greek term for 
inextinguishable) refers to a group of hydrated silicate fibers with a length-to-width ratio 
greater than 3 and is classified as a category 1 carcinogen (3). The wide use of asbestos for 
industrial purposes across the world, demonstrates its relevance as a human health hazard, 
now and for years to come (4). Exposure to asbestos occurs primarily through inhalation 
with fibers first making contact with the upper respiratory tract. Depending on fiber 
geometry, some asbestos fibers (such as those that are longer and thinner) will penetrate 
deeper into the lung, and tend to have more deleterious biological effects (5). The initial, 
and lasting, assault of asbestos occurs on airway epithelial cells and resident macrophages 
(6, 7), and because the mechanisms of asbestos related disease remains unclear, we 
hypothesize that these epithelial cells and macrophages exposed to asbestos secrete 
signature factors that contribute to disease development. 
To date, there are no studies implicating the role of exosomes in MM pathogenesis and 
diagnosis. The latency period after initial exposure to developing malignant disease is 15-
60 years, and once diagnosed, MM is fatal within 6-12 months (8). We believe that 
identifying a unique protein secretome from asbestos exposed cells will contribute to the 
advancement in knowledge needed to diagnose asbestos exposure and possibly aid in future 
clinical settings. Due to this need for biomarker identification, the aim of this current study 
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is to evaluate secreted protein signatures from in vitro asbestos exposure models by 
focusing on proteins found within the subset of extracellular vesicles known as exosomes. 
Exosomes are membrane bound vesicles in the size range of 30-140 nm, and are derived 
from endocytic origin  (9). These secreted particles have emerged as attractive tools in 
biomarker identification and as tools for evaluating biological phenomena. Importantly, 
exosomes are now known to be more than simple waste disposal, but have vital roles in 
normal physiology and disease states (10). Identification of protein biomarkers using 
exosomes is gaining significant traction in the field of disease research, and has potential 
for uncovering new modes of diagnoses (11), similar to the discovery of glypican-1 
containing exosomes in the identification of pancreatic cancer (12). Additionally, 
exosomes from MM cells and tumors have been previously quarried for their proteomic 
signature (13, 14), but this study will be the very first of its kind in identifying exosomal 
proteins from asbestos exposed human cells. This is an essential effort, because in order to 
have a more thorough understanding of this disease, we must delve into all aspects of 
asbestos exposure leading to disease development. 
The purpose of this research study is to descriptively outline the protein subsets determined 
from exosome isolates of asbestos exposed cells, particularly those unique or upregulated 
as compared to non-asbestos exposed controls.  
Furthermore, we are very interested in understanding the mechanism by which MM 
develops. As it is not clear whether mesothelial cells transform via direct interaction with 
asbestos fibers, or by secreted factors from other cells interacting with the fibers. Perhaps 
it is both, but we envisioned that exosomes may also be progenitors of disease by sending 
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molecular cargo to mesothelial cells, from asbestos exposed epithelial cells or 
macrophages, that may transform non-tumorigenic mesothelial cells to becoming more 
tumorigenic. This is a novel idea developed by our lab, that exosomes from asbestos 
exposed cells might lead to or prime disease in an unexposed region (i.e. the pleura or 
peritoneum). 
We hypothesize that asbestos exposed cells secrete exosomes containing unique protein 
cargo that might be informative in the biology of asbestos related disease states, and that 
these exosomes are capable of biologically altering target mesothelial cells to becoming 
more tumorigenic. 
Materials and Methods 
Cell culture and treatment 
Human bronchial epithelial cells (BEAS2B) and macrophage cell line (THP-1) were 
purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and 
were grown as reported before (6, 15) in exosome-free fetal bovine serum (FBS) (Thermo 
Fisher Scientific, Waltham, MA, USA).   
Cells were down-shifted to reducing medium (0.5% exosome free medium) for overnight 
and NIEHS reference sample crocidolite asbestos was added to the cells (5 μg/cm2, 72 hr) 
as described previously (16). For THP-1 cells, we performed experiments with and without 
priming cells with the tumor promoting agent (TPA) phorbol myristate acetate (PMA) 
before adding asbestos. Cells were pre-treated with  0.5μM PMA for 3 hours as described 
previously(6). In present experiments, we used exosomes from untreated cells as control. 
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Inert particles were not used as we have shown in our previous publications that they don’t 
have significant effect on gene expression or other biological processes (17-19).  
After 72 hr incubation with asbestos or controls with no asbestos (and other treatments), 
conditioned cell culture supernatant was removed for exosome isolation. 
Exosome Isolation from cell culture medium 
Exosomes were isolated using ExoQuick-TC precipitation reagent (System BioSciences, 
Palo Alto, CA, USA), according to the manufacturer’s protocol (20, 21), incorporating a 
0.22μm filtration step after the first centrifugation to ensure a more pure yield of exosomes.  
Transmission Electron Microscopy (TEM) 
Formvar/carbon coated nickel 200 mesh grids were glow discharged for 60 seconds, and 
5µl of sample was placed on grid and incubated for 1 minute.  Excess sample was wicked 
and grid was touched to 30µl water drops with wicking performed between each rinse. Grid 
was touched to 2 sequential 30µl drops of 2% aqueous uranyl acetate, excess was wicked, 
and grids were air dried. Grids were imaged under transmission electron microscope (JEOL 
1400 TEM) for exosomes. 
Dynamic Light Scattering 
Dynamic light scattering (DLS) measurements were made on exosome preparations 
suspended in PBS using the Zetasizer Nano ZSP system Model ZEN5600 (Malvern 
Instruments, Malvern, United Kingdom) using a 633 nm He-Ne laser as the light source 
and the Malvern application software. 
Nanoparticle Tracking Analysis 
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Exosomes number and size were further assessed by nanoparticle tracking analysis (NTA) 
using the ZetaView PMX 110 (Particle Metrix, Meerbusch, Germany) and Software 
ZetaView 8.02.31. 
Scanning electron microscopy for detection of asbestos fibers in exosomes 
Exosomes from control or asbestos exposed cells were imaged using a JEOL 6060 scanning 
electron microscope to check for presence of asbestos fibers within exosomes. 
Characterization of exosomes by antibodies: Few isolated exosome samples from 
experiment were characterized by anti-CD81  
Two aliquots of isolated exosomes from representative groups were characterized by 
immunoblot analysis for presence of exosomal marker CD81 (Sigma Aldrich) and also for 
absence of calnexin (Novus Biologicals, Littleton, CO, USA) to rule out contaminating ER 
vesicles. 
Exosome uptake by mesothelial cells 
Exosomes from epithelial cells and macrophages were labeled using PKH67 dye (Sigma 
Aldrich) according to the manufacturer’s protocol. Labeled exosomes were suspended in 
PBS and added to target mesothelial cells and imaged on an Olympus IX70 inverted light 
microscope. 
Proteomic analysis on exosome samples 
Proteins extracted from equal volume of medium (maximum amounts less than 100µg) 
were run by SDS-PAGE.  Equal amounts (100ng) of gylceraldehyde-3-phosphate 
dehydrogenase (GAPDH, Sigma: G5537-100UN) were added to each sample to control for 
digestion and labeling efficiencies.  The proteins were allowed to migrate 3 to 5mm into 
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the separating gel, which were stained with Coomassie Brilliant Blue.  Single wide bands 
in which the proteins still had not been separated were excised, destained with 50% 
acetonitrile (CH3CN)/50 mM NH4HCO3, and subjected to trypsin digestion protocols, as 
described previously (22).   
Peptide labeling by Tandem Mass Tags   
The labeling procedures were performed according to the manufacturers’ protocols 
(Thermo Fisher Scientific, Waltham, MA, USA).  Briefly, the dried peptides from each 
sample were resuspended in 102.5µL of triethyl ammonium bicarbonate, and 0.8 mg of 
TMT reagents dissolved in 41µL of CH3CN was added, followed by briefly vortexing and 
an incubation for 1.5 hr at room temperature.  After incubation, 8µL of 5% hydroxylamine 
was added to quench the reactions.  Twenty-five µL from each of the reactions (control, 
PMA, asbestos, PMA and asbestos for THP-1 experiment, or control and asbestos for 
BEAS2B experiment) were combined and dried down. The THP-1 samples were further 
purified by ZipTip (Millipore, MA, USA).  All samples were kept at -80oC until mass 
spectrometry analysis.   
Protein identification by liquid chromatography-tandem mass spectrometry (LC-
MS/MS)  
The purified labeled peptides were resuspended in 5µL of 2.5% CH3CN and 2.5% formic 
acid (FA) in water for subsequent LC-MS/MS based peptide identification and 
quantification.   Analyses were performed on the Q-Exactive mass spectrometer coupled 
to an EASYnLC (Thermo Fisher Scientific, Waltham, MA, USA).  Samples were loaded 
onto a 100μm x 120mm capillary column packed with Halo C18 (2.7 μm particle size, 90 
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nm pore size, Michrom Bioresources, CA, USA) at a flow rate of 300nl min-1.  Peptides 
were separated using a gradient of 2.5-35% CH3CN/0.1% FA over 150 min, 35-100% 
CH3CN/0.1% FA in 1 min and then 100% CH3CN/0.1% FA for 8 min, followed by an 
immediate return to 2.5% CH3CN/0.1% FA and a hold at 2.5% CH3CN/0.1% FA.  Peptides 
were introduced into the mass spectrometer via a nanospray ionization source and a laser 
pulled ~3 μm orifice with a spray voltage of 2.0 kV.  Mass spectrometry data was acquired 
in a data-dependent “Top 10” acquisition mode with lock mass function activated (m/z 
371.1012; use lock masses: best; lock mass injection: full MS), in which a survey scan 
from m/z 350-1600 at 70,000 resolution (AGC target 1e6; max IT 100 ms; profile mode) 
was followed by 10 higher-energy collisional dissociation (HCD) tandem mass 
spectrometry (MS/MS) scans on the most abundant ions at 35,000 resolution (AGC target 
1e5; max IT 100 ms; profile mode).  MS/MS scans were acquired with an isolation width 
of 1.2 m/z and a normalized collisional energy of 35%.  Dynamic exclusion was enabled 
(peptide match: preferred; exclude isotopes: on; underfill ratio: 1%; exclusion duration: 30 
sec). Product ion spectra were searched using the SEQUEST and Mascot search engines 
on Proteome Discoverer 2.2 (Thermo Fisher Scientific, Waltham, MA, USA) against a 
curated Human Uniprot (Homo sapiens protein database; 3AUP000005640; downloaded 
September 22, 2017). Common processing and consensus workflows for Reporter based 
Quantification were used with minor modifications.  In the processing workflow,  the 
following parameters were set as follows: (1) full trypsin enzymatic activity; (2) maximum 
missed cleavages = 2; (3) minimum peptide length = 6, (4) mass tolerance at 10 ppm for 
precursor ions and 0.02 Da for fragment ions; (5) dynamic modifications on methionines 
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(+15.9949 Da: oxidation), dynamic TMT6plex modification (The TMT6plex and 
TMT10plex have the same isobaric mass) on N-termini and lysines (229.163 Da); and (6) 
static carbamidomethylation modification on cysteines (+57.021 Da).  Percolator node was 
included in the workflow to limit the false positive (FP) rates to less than 1% in the data 
set.   
Statistical analysis 
In the consensus workflow, parameters were set as follows: (1) both unique and razor 
peptides were used for quantification; (2) Reject Quan Results with Missing Channels: 
False; (3) Apply Quan Value Corrections:  False; (4) Co-Isolation Threshold: 50; (5) 
Average Reporter S/N Threshold = 10; (6) “Total Peptide Amount” was used for 
normalization and (7) Scaling Mode was set “on All Average”.  Ratio calculation was 
Summed Abundance Based.  For Hypothesis testing, “background based” ANOVA was 
used for analyzing the two independent experiments of THP-1 cells (two separate 4plex 
TMT runs (two SDS-PAGE), control, treated with asbestos, treated with PMA, treated both 
with PMA and asbestos) and the “individual proteins” ANOVA was used for the 
experiment of BEAS2B cells (two technical replicates were run for the 6plex TMT with 3 
biological replicates, (control C1 -3, asbestos treated A1-3) incorporated).   p-values and 
adjusted p-values (Benjamini-Hochberg method) were calculated accordingly. Only 
proteins identified in all replicates were kept.  For THP1 data, fold changes 
(asbestos/control; PMA/control; PMA+asbestos /control) from the two biological 
replicates with CV% > 20% were eliminated. 
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All the protein identification and quantification information (<1% FP; with protein 
grouping enabled) was exported from the Proteome Discoverer result files to Excel 
spreadsheets for further statistical analyses. The normalized and scaled (to total peptide 
amount) values were then imported into the JMP Pro 13 (SAS Institute, Cary, North 
Carolina, USA) to construct the heat maps.    
Validation of proteins by immunoblot analysis 
Exosomal proteins were validated by immunoblot analysis using antibodies specific to 
vimentin (Cell Signaling, Danvers, MA, USA), thrombospondin, superoxide dismutase, 
and glypican-1 (Abcam Cambridge, MA, USA) as previously published (23). Proteins 
selected for validation were of biological relevance to asbestos exposure and/or cancer. 
 
Exposure of human mesothelial cells to isolated exosomes 
Primary human pleural mesothelial cells (HPM3) were purchased from Brigham and 
Women’s Hospital, Boston and cultured as previously published (18). Exosomes isolated 
from asbestos exposed, or unexposed control cells (above) (either BEAS2B or THP-1) 
were suspended in PBS. For the BEAS2B exosome experiment, either 10µg or 20µg of 
exosome protein were added to target mesothelial cells every day for 4 days. For the 
macrophage experiment, equal volumes of exosome preparation rather than protein content 
from different groups (to take in consideration of different number of exosomes released 
per different conditions), were added to mesothelial cells. After 96 hr of treatment, 
mesothelial cells were harvested and total RNA was isolated using the RNeasy Plus Mini 
Kit (Qiagen, Hiden, Germany).  
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PCR Array to assess the effect of BEAS2B exosomes on EMT related genes in 
mesothelial cells:  
Effect of BEAS2B exosomes on mesothelial cells was analyzed by PCR Array using EMT 
template (Qiagen) to assess the gene expression patterns of epithelial-to-mesenchymal 
transition (EMT) genes as previously described (23).  
Microarray analysis to assess the effects of THP-1 exosomes on mesothelial cells:  
RNA quality from THP-1 exosome exposed mesothelial cells was assessed prior to 
microarray analysis using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), 
and subsequently the RNA was analyzed using the Clariom S assay (Thermo Fisher 
Scientific, Waltham, MA, USA) microarray for human samples. This was chosen for a 
wider breadth of potential gene expression changes outside of the more narrowed view of 
one pathway. Microarray data analysis was performed using the Transcriptome Analysis 
Console 4.0 (Thermo Fisher). Our parameters were set to any gene that was expressed 
differently by both 2 fold and 1.5 fold up or down with a p-value less than 0.05. 
NIH DAVID was used to classify functional annotation and pathway analysis for genes 
that were expressed differently in our experimental groups. 
QRT-PCR to validate gene expression changes:  
Validation of expression changes in selected genes of interest (related to asbestos exposure 
and/or cancer) was conducted by qRTPCR after cDNA synthesis from 1µg RNA using 
Reverse Transcription Using AMV Reverse Transcriptase (Promega, Madison, WI, USA) 
following the manufacturer’s protocol as previously published (23). We used Assays on 
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Demand primers and probes for E-cadherin, IL-1ra, desmoplakin, CCNB2, EGR1, 
FANCD2, ERO1B, CRELD2 and JAG1 (Thermo Fisher). 
Results 
Exosome isolation and characterization from BEAS2B cells  
Successful isolation of exosomes was characterized by TEM, DLS, and Western blot 
analysis for exosomal marker CD81 (Figure 1). TEM indicates membrane bound vesicles 
in the size range indicative of exosomes along with the characteristic depressed spherical 
shape (or “cup-shaped” as some describe) of exosomes imaged by TEM. DLS show vesicle 
size populations in the size range of exosomes. SEM analysis showed no presence of 
asbestos fibers inside exosomes. No samples showed any significant signal for calnexin 
suggesting no contamination of ER. 
Proteomic analysis of exosomes from asbestos exposed and control BEAS2B cells 
showed different signature 
Proteomics profiling was conducted on exosomes from BEAS2B cells, asbestos exposed 
or control, using isobaric TMT tags. We identified a total of 145 proteins and compiled a 
list of proteins with significant differential abundances (55 proteins with p-value ≤ 0.05, 
and 34 proteins with adjusted p-value ≤ 0.05) in asbestos exposed group when compared 
to the control group (Table 1, Figure 2A, B).A few of such proteins increased in abundance 
in the asbestos group are: plasminogen activator inhibitor 1, vimentin, 14-3-3 protein 
sigma, thrombospondin, transitional endoplasmic reticulum ATPase, and glypican-1 
(Table 1). 
Two proteins identified by proteomic analysis were validated by immunoblot analysis 
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Western blot analysis of glypican-1 and thrombospondin validated that these exosomal 
proteins are increased from epithelial cells exposed to asbestos (Figure 2C). Due to 
secretory nature of exosome no normalization control could be included and equal loading 
of proteins was verified by Ponceau staining (data not shown). 
Exosomes from asbestos exposed epithelial cells are taken up by mesothelial cells 
A set of isolated exosomes were PKH67 labelled and added to mesothelial cells to verify 
that epithelial cell exosomes interact and are taken up by mesothelial cells. As shown in 
Figure 3A, green fluorescent labelled exosomes were identified inside mesothelial cells 
suggesting their uptake by mesothelial cells. Monitoring different areas of dish showed a 
consistent 50-60% cells positive for labelled exosomes. 
Exosomes from asbestos exposed epithelial cells caused altered gene expression in 
mesothelial cells 
In order to assess if exosomes from asbestos exposed epithelial cells were capable of 
altering the gene expression pattern of mesothelial cells, isolated exosomes from exposed, 
or control epithelial cells were added repeatedly to mesothelial cells. After 96 hr, 
mesothelial cell RNA was isolated and analyzed by PCR Array for EMT. The data 
indicated multiple gene changes, the top 10 most up- or down-regulated in response to 
exosomes from asbestos exposed cells are listed in Table 2. From this list, 3 genes were 
validated by qRTPCR (Figure 3B), E-cadherin, desmoplakin, and IL1 Receptor Antagonist 
(IL1RN). We observed a downward trend in these three genes in response to exposure to 
exosomes from asbestos exposed cells as compared to control exosomes (Figure 3B). 
Exosomes isolated and characterized from THP-1 
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Exosomes from THP-1 cells were isolated and characterized for their purity, size and 
intactness using antibodies, NTA, DSL and TEM (Figure 1). DLS and NTA both show 
vesicle size populations in the size range of exosomes, with some discrepancies between 
samples analyzed on both machines. This anomaly could be explained by the differing 
nature of how each instrument analyzes particles and particles sizes, and perhaps the 
population of very small (~10 nm) vesicles may be an artifact of DLS, as this population 
is not observed with the more robust technique of NTA on the same sample. TEM data 
shows intact, membrane bound exosomes in size range of 40-140 nm (Figure 1). CD81 
presence and calnexin absence demonstrated the purity of the preparation (Figure 1D). 
Proteomic analysis showed increased abundance of proteins in asbestos exposed 
exosomes from THP-1 
Exosomes were isolated from 4 different groups of THP-1 cells; control- non-asbestos 
exposed; Asbestos exposed; PMA primed- asbestos exposed; PMA primed- no asbestos 
exposure.  
Proteomic analysis of TMT labeled macrophage exosomal proteins from all groups 
provided a total list of 785 identified exosomal proteins, many of which showing moderate 
alterations in abundance between groups (Figure 4A, Table 3). PMA priming had no added 
effect on exosomal protein signature as compared to asbestos alone (no priming) group, 
(data not shown) suggesting that unlike other stimuli, asbestos exposure to human 
macrophages do not require priming. 
Thirty-two proteins were identified with differential abundance in the asbestos treated 
group as compared with the control group (p < 0.05; Figure 4B, Table 3).  Fifteen proteins 
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were in greater abundance from asbestos exposed groups. Two of these proteins’ 
abundance were validated by Western blot analysis to be in fact increased in exosomes 
from asbestos exposed macrophages: superoxide dismutase and vimentin (Figure 4C). 
Exosomes from THP-1 cells are taken up by mesothelial cells 
A set of isolated exosomes were PKH67 labelled and added to mesothelial cells to verify 
that THP-1 cell exosomes interact and are taken up by mesothelial cells. As shown in 
Figure 5A, green fluorescent labelled exosomes were identified inside mesothelial cells 
suggesting their uptake by mesothelial cells. 
Exosomes from asbestos exposed THP-1 cells cause gene changes in mesothelial cells 
Exosomes isolated from asbestos exposed and control THP-1 cells were added to 
mesothelial cells (HPM3). In this experiment, we also included a positive control by 
exposing a group of mesothelial cells directly to asbestos fibers. After 96 hours of exposure 
total RNA was extracted and subjected to microarray analysis. Three groups were labeled 
as follows: control exosomes (0) (cells exposed to no-asbestos THP-1 exosomes), asbestos 
exosomes (cells exposed to asbestos exposed THP-1 exosomes) and asbestos fibers (cells 
directly exposed to asbestos fibers). Cutoff thresholds for analysis were set as anything 
with a 2 fold or a 1.5 fold transcript-level change with an ANOVA transcript-level p-value 
less than 0.05. 
Our main comparison of interest was the asbestos exosome group versus the control 
exosome group, whilst vying to draw parallels to the asbestos fiber group to the control 
exosome group. Our results of 1.5 fold cutoff for the asbestos exosome exposed mesothelial 
cells compared to control exosome exposed mesothelial cells were that a total of 498 genes 
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changed significantly, 241 up and 257 down (Figure 5B,C, Table 4). In addition, the 
comparison between control exosome exposed cells to mesothelial cells directly exposed 
to asbestos fibers yielded differential expressions of 3,788 genes, 1,803 up and 1,985 down 
(Figure 5C). Of these two separate comparisons, there were a total of 206 genes that were 
mutual in their differential expression profiles (Figure 5D). With a more stringent cutoff of 
2 fold or more up or down between asbestos exosomes versus control exosomes, we 
observed a total of 80 significant gene level changes, with 32 up and 48 down regulated. A 
comparison of gene expression profile in mesothelial cells in response to asbestos 
exosomes and asbestos fibers only is presented in Table 5. 
Six common genes of interest were selected from those genes that were shared in being 
differentially expressed upon exposure to either asbestos exosomes or asbestos fibers 
themselves for validation by qRTPCR, three of which were up and three down regulated 
by asbestos exosomes or asbestos fibers themselves upon addition to mesothelial cells, 
based on known and potential biological relevance in asbestos exposure. The three chosen 
which were upregulated were hCCNB2, hEGR1 and hFANCD2, and the three 
downregulated were hCRELD2, hERO1B and hJAG1. Validation by qRTPCR showed the 
same significant trends as in microarray results in all six genes (Figure 5E). CCNB2 was 
chosen because of its significance in regard to MM, although it was not in our list of top 
10 over expressed genes. 
Discussion 
Exposure to asbestos fibers is a major human health concern, as it is causally associated 
with MM, lung cancer and fibrosis. The scientific and medical communities, at this point, 
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have yet to delineate a useful set of diagnostic biomarkers for asbestos exposure that may 
be used to pre-empt the deadly illnesses that result from inhaling the fibers. Due to the fact 
that such inhalation of asbestos fibers is the primary source of one’s exposure, and the first 
cells to contact the fibers are therefore lung epithelial cells and resident macrophages, our 
study includes these cell types. 
Our study is aimed at exosomal protein abundances in response to asbestos exposure in 
epithelial cells and macrophages. Additionally, as mesothelial cells are specifically 
susceptible to asbestos, leading to MM, we wanted to gauge the subsequent effect these 
exosomes may have on mesothelial cells that could be the targets of such exosomes and 
thereby beget the development of MM. Our rationale is that it is currently unknown if MM, 
a tumor arising on the mesothelial cell lining of cavities (i.e. pleura or peritoneum), is the 
result of direct contact with asbestos fibers migrating from within the lung to the outer 
lining or from secreted factors (loaded in exosomes) from the original cells to contact the 
fibers being sent to the mesothelial cells leading to transformation, or perhaps both.  
The design herein was to isolate exosomes from asbestos exposed epithelial cells or 
macrophages, quarry them for proteomic signatures of asbestos exposure, and to also take 
these purified exosomes and add them to healthy mesothelial cells and analyze for gene 
expression changes that may be involved in MM tumorigenic process. 
The study described in this paper is new, in that we are the first to report on the signature, 
and potential role, of exosomes in the context of asbestos exposure.  
The results of our proteomics analyses of exosomes from asbestos exposed epithelial cells 
indicate that there is clearly a shift in protein abundances in epithelial exosomes upon 
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asbestos exposure. We observed increased abundance of thrombospondin-1 in both 
analyses (mass spectrometry experiment and immunoblot blot validation) of exosomal 
proteins from asbestos exposed epithelial cells. This is interesting as thrombospondin-1 has 
been identified as being significantly overexpressed in MM tumors (24). We were also 
intrigued to see that proteomics analysis indicated higher exosomal abundances of vimentin 
upon producer cell exposure to asbestos because vimentin is a key regulator in the response 
to asbestos exposure by regulating the NLRP3 inflammasome and is used as a 
mesenchymal marker in the transition of mesothelial cells to a more neoplastic state (23, 
25). Additionally, we validated the increased exosomal abundance of glypican-1 in 
exosomes from asbestos exposed cells, which piqued our interest because of its established 
role as being an exosomal indicator of cancer, most notably as a pancreatic cancer exosome 
biomarker (12, 26). 
Next we studied the effect of epithelial cell exosomes on mesothelial cells. To begin, we 
confirmed the uptake of said exosomes by using an established method of PKH67 labelling 
of exosomes and adding to mesothelial cells for visualization of uptake (27, 28). 
Subsequently, the effect of exosomes from producer epithelial cells (either asbestos 
exposed or control) was studied on mesothelial cell transformation genes (EMT pathway). 
Our rationale for this EMT array was because we have shown recently that asbestos 
exposure causes mesothelial to fibroblastic transition (MFT/EMT) in vitro and in vivo (23) 
. Furthermore, many of the known genetic alterations that occur in mesothelial cells that 
are hallmarks of tumorigenesis and MM are categorized as EMT genes, either the loss of 
epithelial-like gene expression or gain of more mesenchymal gene expression (29-31). 
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Our findings were modest changes in multiple EMT genes consistent with the expectation 
that exosomes from asbestos exposed epithelial cells can lead to changes in mesothelial 
cells similar to those that would occur if the mesothelial cell was in direct contact with 
asbestos fibers or undergoing transition to a more mesenchymal state. Our PCR array 
indicated a significant upregulation in STEAP1 when mesothelial cells were targeted with 
asbestos exosomes, and increased STEAP1 has been reported as a result of mesothelial cell 
contact with asbestos fibers (32). We also were encouraged to see that asbestos exosomes 
lead to marked reduction in IL-1RN, and significant reduction in the expression of known 
epithelial markers E-cadherin and desmoplakin. Reduction in E-cadherin and desmoplakin 
expression are well-described as markers for EMT (33, 34), and these alterations have been 
described in mesothelial cell exposure to asbestos (35, 36). Our conclusions from these 
epithelial cell experiments are that there is undoubtedly a signature abundance modification 
in exosomal proteins from epithelial cells exposed to asbestos fibers and that these 
exosomes are capable to interact with, and alter gene signature in mesothelial cells. Lack 
of significance in some results could be attributed to either shorter duration of exposure 
with exosomes or lower concentration of exosome being available to cells.  
Next, we studied the macrophages and their influence on mesothelial cells as these are the 
first cell type to interact with asbestos fibers in the lung along with epithelial cells. Due to 
previous reports in literature that THPs need priming before responding to stimulus, we 
performed experiments with and without priming of THPs with PMA before exposing to 
asbestos. Our proteomic data showed that priming was unnecessary for macrophage 
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exosomes to be affected by asbestos exposure, therefore, that data will not be enumerated 
upon. 
Our results indicated that exposure to asbestos does indeed alter the abundances of certain 
exosomal proteins in THP-1 cells. We were primarily interested in only those proteins that 
were increased upon exposure to asbestos, as our quest is to surmount data that may lead 
to biomarker discovery. Those proteins of interest increased in asbestos exosomes from 
macrophages included vimentin (also shown increased in the epithelial study), superoxide 
dismutase, annexin 5 and we also identified thrombospondin in macrophage exosomes. 
Vimentin was of interest due to its role in inflammasome initiation and asbestos exposure 
as listed above. Superoxide dismutase was particularly interesting because of its ability to 
scavenge oxidants and the fact that it is elevated in asbestos exposure models described 
elsewhere and in mesothelioma studies (37-40). Our results followed by subsequent 
validation indicate that exposure to asbestos does lead to protein abundance differences in 
exosomes from macrophages. 
Our next endeavor was to classify if asbestos exosomes from macrophages have an ability 
to elicit gene expression changes in mesothelial cells. First, we made sure that exosomes 
were taken up by mesothelial cells by adding PKH67 labeled exosomes to mesothelial cells 
and visualizing their uptake.  
Microarray data analysis showed that asbestos exosomes exposure to mesothelial cells 
significantly changed the expression of 498 genes compared to cells exposed to control 
exosomes. Furthermore, as expected and published before (18), direct exposure of 
mesothelial cells to asbestos fibers altered expression of 3,788 genes, and of these, 206 
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genes were commonly differentially expressed by both experimental groups compared to 
control. The fact that we see such gene expression similarities indicates that exosomes from 
asbestos exposed macrophages undoubtedly have the ability to elicit gene expression 
changes in mesothelial cells in parallel modes to direct asbestos exposure. Furthermore, 
finding the gene-changes that were not common with direct asbestos exposure is intriguing 
as it suggests the capability of exosome contents to affect mesothelial cell gene expression 
and requires further validation.  
To confirm the robustness of our data we validated six genes of interest EGR1, CCNB2, 
FANCD2, CRELD2, ERO1B, and JAG1. EGR1 is a transcriptional regulator of genes 
required for cellular differentiation and mitogenesis, and has been shown by our group to 
be increased in cells exposed to asbestos (15) and its involvement in mesothelial cell 
response signaling to asbestos (41). Additionally, we were interested in the up-regulated 
gene CCNB2, a key regulator in cell-cycle machinery, is involved in TGFβ meditated cell-
cycle control, and is involved in the instability of chromosomes with its overexpression 
modifying chromosome segregation and spindle checkpoint (42). Notably, overexpression 
of CCNB2 is an attribute of MM (43, 44). Also overexpressed in mesothelial cells exposed 
to asbestos exosomes from macrophages was the regulator of chromosomal stability, 
FANCD2, which is upregulated in MM, caused by asbestos exposure (45, 46).  
As for the observed down-regulated mesothelial cell genes, our interest was the 
endoplasmic reticulum (ER) stress inducible gene CRELD2 and the oxidoreductase ERO1B 
involved in ER stress, as asbestos is known to lead to ER stress (47, 48). Lastly, we drew 
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attention to JAG1 expression, the notch ligand, which is involved in transcriptional 
regulation in cancer (49). 
Taken together, our data on asbestos exosomes from macrophages provides robust 
indication for their ability to mirror many of the gene expression changes of mesothelial 
cells exposed directly to asbestos fibers. This is another addition to the building evidence 
of the biological importance of exosomes in disease, and supports our hypothesis that 
exosomes may be the carrier of information from asbestos exposed macrophages to 
mesothelial cells to cause oncogenic changes and MM. Our report is the first to provide 
insight on the role of exosomes in asbestos induced mesothelial cell diseases.  
This study provided clues to a proteomic signature of exosomes from asbestos exposed 
epithelial cells and macrophages, that is an initial motion to future exosomal biomarker 
studies in human subjects exposed to asbestos. We are excited to contribute this data to the 
field of exosomes and asbestos research as there is undeniable evidence that asbestos 
exosomes are information conduits that alter gene expression in target mesothelial cells. 
That exosome induced alteration is remarkably comparable to those changes prompted by 
direct asbestos fiber contact on mesothelial cells, strongly suggesting that exosomes may 
be a pivotal player in the human response to asbestos exposure that leads to disease 
development. Undoubtedly, there are limitations to this study, like the lack of in vivo data 
and the role of inflammasomes and reactive oxygen species on exosome packaging and 
secretion. We intend to further develop and validate upon this story in future in vivo 
experiments and human serum samples from asbestos exposed individuals. Our future 
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studies will confirm and finely delineate the role of exosomes in asbestos exposure biology 
and as mines for biomarker discovery. 
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Figure 1. Exosome isolation and characterization from human bronchial epithelial 
(BEAS2B) cells and THP-1 macrophages. A) TEM showing exosomes membrane bound 
structure and proper size range (scale bar = 100 nm), B) DLS indicating exosome size 
distribution, C) NTA indicating exosome size distribution and concentration of particles, 






Figure 2. Proteomic analysis of exosomes from asbestos exposed and control BEAS2B 
cells showed different protein signature. A) Heat map indicating the abundances of all 
proteins identified in both groups, B) expanded heat map section showing all differentially 
abundant proteins with p-value less than 0.05 (one TMT experiment: asbestos vs. control, 
3 biological replicates, 2 technical replicates), listed according to fold change, C) 




Figure 3. Exosomes from asbestos exposed epithelial cells are taken up by mesothelial 
cells and caused altered gene expression. A) PKH67 labeled exosomes from BEAS2B cells 
interact with and are taken up by target mesothelial cells, scale bar = 100 nm, B) qPCR 
validation of differentially expressed genes (CDH1, DSP, and IL1RN) from PCR Array of 
mesothelial cells after exposure of cells to exosomes from asbestos exposed BEAS2B cells. 






Figure 4. Proteomic analysis showed proteins with differential abundances in asbestos 
exposed exosomes from THP-1. A) Heat map indicating the abundances of all proteins 
identified in both groups, sorted according to p-value, (1, 2: two separate TMT 
experiments) B) expanded heat map region showing exosomal proteins with differential 
abundance between control group and asbestos exposed group with p-value less than 0.05 
(asbestos vs. control, two biological replicates), listed according to fold change, C) 






Figure 5. Exosomes from asbestos exposed THP-1 cells are taken up by mesothelial cells 
and caused gene expression changes. A) PKH67 labeled exosomes from THP-1 cells 
interact with and are taken up by target mesothelial cells, scale bar = 100 nm, B) Clariom 
S microarray heat map of gene expression between control mesothelial cells and 
mesothelial cells exposed to exosomes from asbestos exposed macrophages, C) Number of 
differentially expressed genes from microarray analysis in groups of asbestos exosomes vs. 
control, asbestos fibers vs control, and asbestos exosomes vs. asbestos fibers, D) Venn 
diagram showing genes differentially expressed between control mesothelial cells and 
asbestos exosome exposed cells (A), control and asbestos fiber exposed mesothelial cells 
(B), and the shared genes differentially expressed between both comparisons (AB),  E) 
qPCR validation of genes upregulated in asbestos exosome and asbestos fiber groups 
compared to control (CCNB2, EGR1, and FANCD2) and genes downregulated in asbestos 
exosome and asbestos fiber groups compared to control (CRELD2, ERO1B, and JAG1). * 




Table 1: Top upregulated proteins in exosomes collected from asbestos exposed BEAS2B 





P05121 Plasminogen activator inhibitor 1  1.706 0.000490422 
P08670 Vimentin  1.582 0.016013921 
P21333 Filamin-A  1.466 0.000388539 
Q15582 Transforming growth factor-beta-   
 
induced protein ig-h3  1.419 0.000522876 
P55072 Transitional endoplasmic reticulum   
 
ATPase  1.333 0.005639401 
P01579 Interferon gamma  1.315 0.033787902 
Q16270 Insulin-like growth factor-binding   
 
protein 7  1.308 0.000727588 
Q12805 EGF-containing fibulin-like extracellular   
 
matrix protein 1 1.306 0.002498946 
P07996 Thrombospondin-1  1.292 0.01433131 
P0C0L4 Complement C4-A  1.263 0.000724361 
P08758 Annexin A5  1.248 0.012712613 
Q15149 Plectin 1.215 1.41242E-05 
P06396 Gelsolin  1.188 0.059612729 
P02675 Fibrinogen beta chain  1.17 0.005784599 
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P35052 Glypican-1  1.163 0.004177749 
 
 
Table 2: PCR Array analysis showing top up and downregulated genes in HPM3 cells 
exposed to asbestos administered BEAS2B exosomes 
Gene Name Fold Change p-Value* 
Upregulated   
Six transmembrane epithelial antigen of the 
prostate 1 1.298 0.018268 
Zinc finger E-box binding homeobox 1 1.2646 0.725035 
Versican 1.198 0.153794 
Vacuolar protein sorting 13 homolog A (S. cerevisiae) 1.1452 0.139756 
Calcium/calmodulin-dependent protein kinase II 
inhibitor 1 1.1322 0.291454 
Notch 1 1.1207 0.604015 
Serpin peptidase inhibitor, clade E    
(nexin, plasminogen activator inhibitor type 1), member 
1 1.1198 0.316425 
Tetraspanin 13 1.1198 0.197028 
PTK2 protein tyrosine kinase 2 1.1171 0.150141 
Pleckstrin 2 1.1126 0.188704 
PPPDE peptidase domain containing 2 1.1097 0.113347 
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Protein tyrosine phosphatase type IVA, member 1 1.108 0.334835 
Cadherin 2, type 1, N-cadherin (neuronal) 1.1015 0.298931 
   
Downregulated 
  
Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 0.5824 0.305409 
Fibroblast growth factor binding protein 1 0.6299 0.067967 
Cadherin 1, type 1, E-cadherin (epithelial) 0.6597 0.048589 
Desmocollin 2 0.7248 0.103433 
Interleukin 1 receptor antagonist 0.7297 0.325295 
Matrix metallopeptidase 9    
(gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase) 0.746 0.074611 
Desmoplakin 0.7474 0.008235 
SRY (sex determining region Y)-box 10 0.7577 0.09832 
Bone morphogenetic protein 7 0.7594 0.102055 
Goosecoid homeobox 0.7594 0.102055 
Wingless-type MMTV integration site family, member 
11 0.7594 0.102055 
Human Genomic DNA Contamination 0.7594 0.102055 
Positive PCR Control 0.7644 0.128955 
Reverse Transcription Control 0.7786 0.048837 
Nodal homolog (mouse) 0.7859 0.12515 
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*Bold entries, p≤0.05.   
 
Table 3: Top upregulated proteins in exosomes collected from THP-1 cells exposed 
to asbestos with or without PMA* 
Protein Control PMA Asb PMA+Asb  
Vimentin  1 1.1637 2.8122 1.2380 
40S ribosomal protein S19  1 0.9677 2.1622 1.9157 
Superoxide dismutase [Mn],     
mitochondrial (Fragment)  1 0.7706 1.7601 1.3151 
Isoform 4 of Superoxide dismutase     
[Mn], mitochondrial  1 0.9338 1.6439 1.3213 
40S ribosomal protein S10 1 0.8829 1.6290 1.4406 
Myosin light polypeptide 6 
(Fragment)  1 1.0701 1.4684 1.2477 
Apolipoprotein B-100  1 1.0271 1.4000 0.9767 
Glutamine synthetase  1 1.1757 1.3199 1.1531 
Isoform 3 of Liver carboxylesterase 1  1 0.8012 1.2963 1.0236 
Phosphomevalonate kinase 1 1.3831 1.2602 1.1758 
Nuclear mitotic apparatus protein 1     
(Fragment)  1 1.5058 1.2517 1.0953 
10 kDa heat shock protein,     
mitochondrial 1 0.8768 1.2365 0.9184 
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Myosin regulatory light chain 12A 1 1.1347 1.2262 1.2004 
Importin-4  1 1.1950 1.2223 1.1424 
Actin-related protein 2/3 complex     
subunit 4  1 0.9399 1.2216 0.9938 
*Values are average fold changes relative to control. 
Table 4: Microarray analysis showing top up and downregulated genes in HPM3 cells 
exposed to asbestos administered THP-1 exosomes as compared to control exosomes 
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Gene Name Fold Change p-Value 
Upregulated 
  
Early growth response 1 3.43 0.0096 
Meiosis-specific nuclear structural 1 3.22 0.0031 
Histone cluster 1, H3g 2.82 0.00003 
Transcript Identified by AceView, 
Entrez Gene ID(s) 4731 2.81 0.001 
POTE ankyrin domain family, 
member C 2.69 0.0034 
Long intergenic non-protein coding 
RNA 663 2.54 0.0075 
PARP1 binding protein 2.53 0.009 
Fanconi anemia complementation 
group D2 2.47 0.024 
Transcript Identified by AceView, 
Entrez Gene ID(s) 79677 2.42 0.0148 
Chromosome 16 open reading frame 
52 2.34 0.0402 








Cysteine rich with EGF-like domains 
2 0.156 0.0013 
Glycoprotein Ib (platelet), beta 
polypeptide; septin 5 0.225 0.0178 
Stromal cell-derived factor 2-like 1 0.271 0.0073 
Endoplasmic reticulum 
oxidoreductase beta 0.285 0.0005 
Schlafen family member 11 0.314 0.005 
Jagged 1 0.321 0.0002 
Arginase 2 0.344 0.0325 
Cell division cycle 6 0.351 0.0091 
Transcript Identified by AceView, 
Entrez Gene ID(s) 153339 0.365 0.0188 
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Malignant mesothelioma (MM) is an aggressive cancer of the mesothelial surface of organ 
cavities, almost exclusively a direct result of asbestos exposure. The disease is essentially 
incurable with no means early diagnosis and the standard chemotherapeutic regimens do 
not extend the life of patients. Our group recently began a quest into surveying MM tumor 
biology with a focus on exosome-contained microRNAs (miRNAs). We discovered that 
the most abundant miRNAs in MM cancer exosomes were tumor suppressors, particularly 
the pro-apoptotic miR-16-5p. This observation lead us to hypothesize that MM cells 
preferentially secreted tumor-suppressor miRNAs via exosomes. Through separate 
avenues of potential therapeutic advance, we embarked on an innovative strategy to kill 
MM tumor cells. We inhibited exosome secretion using small molecule inhibitors, thereby 
down-regulating miR-16-5p in exosomes and rebuilding cellular miR-16-5p leading to loss 
of proliferation/cell death, decreased migration/invasion, and reduced of miR-16-5p target 
oncoproteins CCND1 and BCL2. In addition, we force-fed MM tumor exosomes back to 
the producer MM tumor cells, leading to increased levels of cell death, and a reduction in 
the same oncoproteins as seen in our exosome inhibition trials. We also recapitulated these 
results with direct transfection of miR-16-5p.We demonstrated this phenomenon in 
multiple MM cell lines and confirmed that this is a cancer-cell specific effect. Additionally, 
we uncovered a mechanism of miR-16-5p loading into exosomes by the RNA binding 
protein HuR. Our data provide novel evidence on a tumorigenic mechanism of MM tumor 





Malignant mesothelioma (MM) is a remarkably deadly cancer arising after exposure to 
asbestos fibers (1). Median life-span after diagnosis is 6-12 months, there is a latency 
period of 20-50 years after initial asbestos exposure, and MM is relatively un-diagnosable 
until the disease is in advanced stages (2). Due to limited knowledge of biomarkers for 
asbestos exposure and early detection of this cancer, coupled with no successful therapeutic 
regimens other than chemotherapeutic intervention with cisplatin and pemetrexed, this 
disease signifies large gaps in scientific knowledge that, when filled, would greatly benefit 
human health (3). 
An exciting realm of cancer research has developed over the past decade by focusing on 
nano-sized extracellular vesicles, known as exosomes, to answer pivotal problems such as 
those mentioned above. Exosomes refer to a class of vesicles produced via the endocytic 
pathway and ranging in size from 30-140nm in diameter. As a new piece to the puzzle of 
cancer, exosomes represent an important aspect of biological signaling between cells and 
as a means of novel biomarker identification strategies (4). This is directly linked to the 
biofunctional cargo enriched in exosomes such as proteins, miRNAs, and lipids (5,6). 
To date there are only a handful of publications focusing on exosomes in the disease setting 
of mesothelioma. The initial steps towards this area were to analyze the proteomic make 
up of exosomes isolated from pleural effusions (7) and separately by mesothelioma tumor 
cells (8). A decade after these reports, it was shown that tumor-derived exosomes could be 
used in dendritic-cell (DC) based immunotherapeutic strategies against mesothelioma by 
treating tumor-bearing mice with DCs loaded with MM exosomes, showing that the 
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exosomes imparted the mice with an immunological response against the MM thereby 
increasing survival rate (9).  There have been multiple of investigations into the miRNAs 
involved in mesothelioma, particularly by Glen Reid’s group who has summarized a large 
swath of such knowledge and reported miRNA levels in MM tumor cells and tissues. Of 
note, the study indicated very low expression levels of tumor suppressor miRNAs in MM 
such as miR-16-5p, miR-15, miR-31, and let-7a, to name a few (10). Notably, only one 
current research article looks at the miRNA signature associated with circulating 
extracellular vesicle (EV) miRNAs in MM patients, and found that miR-103a-3p and miR-
30e-3p were discriminatory for MM from asbestos-exposed patients with no cancer (11). 
Recently, our group has shown differential abundance of exosome proteomic signatures in 
mouse-serum after asbestos exposure (12), and suggested a novel mechanism by which 
MM may develop by exosomes traveling from asbestos exposed cells to mesothelial cells 
thereby modifying the mesothelial cells’ gene expression patterns (13). 
Our present study is the first to present a quarry into the exosomal miRNAs of MM along 
with findings implicating new avenues of potential biomarkers and therapeutic options. 
Here, we investigate the signature miRNAs in MM tumor cell exosomes, and formulated a 
hypothesis that MM tumor cells preferentially secrete the tumor suppressor miR-16-5p via 
exosomes. Furthermore, we demonstrated that by inhibiting exosome secretion or force-
feeding cancer exosomes back to MM cells can rebuild miR-16-5p levels in the cancer cells 
resulting in significant killing of cancer cells. In addition, we implicated the RNA binding 
protein, HuR, as being involved in the mechanism of miR-16-5p loading into exosomes. 
Our findings may lead to potential therapeutic strategies for MM in future.  
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Materials & Methods 
Cell Culture 
Human MM cell lines, H2373, H2595, and HP-1 were kindly contributed by Dr. Harvey 
Pass (New York University, New York, NY) (14) and Hmeso cells were isolated by Reale 
et al. (15). Human primary pleural mesothelial cells HPM3 and human immortalized 
peritoneal mesothelial LP9/TERT-1 (LP9) cells were purchased from Brigham and 
Women’s Hospital, Harvard University, Boston, MA.  
All cell lines were cultured as previously reported (16). Cell lines were validated by STR 
DNA fingerprinting using the Promega CELL ID System (Promega, Madison, WI) (16).  
Cisplatin was purchased from Alfa Aesar (Ward Hill, MA) and concentrations for the 
present study were selected based on previously published literature for MM cells (17). 
GW4869, Cl-amidine (chloramidine), and bisindolylmaleimide-I were purchased from 
Cayman Chemical (Ann Arbor, MI) and used at concentrations based on published reports 
indicating successful inhibition of exosome release from cells (18,19). DMSO in equal 
volume added to control wells as vehicle control. 
Immunostaining of MM cells for HuR 
Hmeso cells were fixed in 4% PFA, blocked, washed, and incubated overnight at 4°C with 
HuR antibody (Cell Signaling Technology, Danvers, MA) as previously described (16). 
For a negative control, one slide was stained as described, excluding primary antibody. 
After further washing, cells were incubated with a fluorescently conjugated secondary 
antibody, AlexaFluor® 647 (Thermo Fisher, Grand Island, NY). Following nuclear 
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staining with DAPI (Thermo Fisher), sections were imaged with a Nikon A1R-ER 
Confocal Microscope. 
Exosome Isolation and Characterization 
Exosome Isolation from cell culture medium 
Exosomes were isolated using ExoQuick-TC precipitation reagent (System BioSciences, 
Palo Alto, CA, USA), as previously described (13).  
Transmission Electron Microscopy (TEM) 
Double membrane structure of exosomes and size was confirmed using transmission 
electron microscope (JEOL 1400 TEM) as previously published (13). 
Nanoparticle Tracking Analysis 
Exosomes number and size were further assessed by nanoparticle tracking analysis (NTA) 
using the ZetaView PMX 110 (Particle Metrix, Meerbusch, Germany) and Software 
ZetaView 8.02.31(13). 
Characterization of exosomes by Western blot analysis  
Two aliquots of isolated exosomes from representative groups were characterized by 
immunoblot analysis for presence of exosomal marker CD81 (Sigma Aldrich) and also for 
absence of calnexin (Novus Biologicals, Littleton, CO, USA) to rule out contaminating ER 
vesicles (13). 
MicroRNA Isolation and Microarray 
Isolation of miRNA from exosome pellets was accomplished using Qiagen miRNeasy 
Micro Kit (Venlo, Netherlands) by adding QiaZol reagent directly to pellets and following 
the manufacturer’s protocol. 
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RNA quality from exosomes was assessed prior to microarray analysis using the Agilent 
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), and subsequently the RNA was 
analyzed using GeneChip™ miRNA 4.0 Array (Thermo Fisher Scientific, Waltham, MA, 
USA) performed on exosomal miRNA from HPM3, Hmeso and H2373 cells (n=2). Data 
was analyzed using Transcriptome Analysis Console 4.0 (Thermo Fisher).  Parameters 
were set to any gene that was expressed differently by both 2 fold and 1.5 fold up or down 
with an ANOVA p-value less than 0.05. 
Validation of expression changes in selected miRNAs of interest was conducted by 
qRTPCR after cDNA synthesis from exosomal miRNA (normalized to 2uL exosome 
miRNA or 2ng miRNA from cells) using TaqMan Advanced cDNA miRNA cDNA 
Synthesis Kit (Thermo Fisher, Waltham, MA) following the manufacturer’s protocol. We 
used TaqMan Assays on Demand primers and probes for human miRNAs miR-16-5p, miR-
30a-5p, miR-222-3p, and miR-31-5p, and for internal control miRNA cel-miR-39-3p 
(Thermo Fisher) was used. 
Exosome secretion inhibition from cells 
Exoxome secretion from cells was inhibited by using 2 different small molecule inhibitors 
described above. 
Immunoblot analysis 
Cellular proteins of interest (miR-16-5p targets and HuR) were assessed by immunoblot 
analysis using antibodies specific to CCND1 and BCL-2 (Abcam) or HuR (Cell Signalling) 
as previously published (16). Proteins selected for immunoblot analysis were of biological 




Cell viability was determined in various experiments by MTS Assay CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega) as per the manufacturer’s 
recommendations (20). 
In Vitro Tumorigenic Assays 
Mesothelioma cells were treated with cisplatin/exosome inhibitors/transfected with 
miRNA mimics, and were assessed for various tumorigenic assays as described below. 
3-D model to grow mesothelioma spheroids 
Mesothelioma cells were grown in a 3-D model using the Cultrex 3-D Spheroid 
Colorimetric Proliferation/Viability Assay from Trevigen, Inc. (Gaithersburg, MD). 
Mesothelioma cells were seeded at a density of 2,500/well following the manufacturer’s 
protocol. Six days later colorimetric analysis (MTT) was performed as stated in the 
manufacturer’s protocol (20). 
Migration Assay 
Migration of MM cells was assessed using 6-well Transwell polycarbonate filters (Corning 
Costar Corp., Corning, NY) with an 8-μm pore size as described previously  
Invasion Assay 
Invasiveness of MM cells was assessed using 24-well Transwell polycarbonate filters 
(Corning Costar Corp., Corning, NY) with an 8-μm pore size with 1mg/mL Matrigel 
coating gel on upper well as described previously (16). 
siRNA & miRNA Transfection 
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On-Target plus Non-Targeting small-interfering RNA (siRNA) (scrambled control) or On-
Target plus SMARTpool human ELAV1 (HuR) siRNA (100 nmol/L, Dharmacon, 
Lafayette, CO) were transfected into 95% confluent cells using Lipofectamine RNAiMAX 
(Invitrogen), following the manufacturer’s protocol. The efficiency of HuR protein 
knockdown was determined by Western blot analysis after 48hr. Two separate lots of 
siRNA were used in duplicate for each siHuR experiment. 
MISSION miRNA mimic miR-16-5p and MISSION miRNA negative control  were 
transfected into 95% confluent cells using Lipofectamine RNAiMAX (Invitrogen), 
following the manufacturers protocol. Two lots of miR-16 mimic were used in duplicate 
for each transfection experiment.  
Success of transfection was verified by protein or RNA levels of transfected RNA.  
Exosome Uptake by MM Cells 
Exosomes were labeled using PKH67 dye (Sigma Aldrich) according to the manufacturer’s 
protocol. Labeled exosomes were suspended in PBS and added to target cells and imaged 
on an Olympus IX70 inverted light microscope as described previously (13). 
Exosome Force Feeding to MM cells 
Exosomes were isolated from Hmeso MM cancer cells and equal volumes of exosome 
preparation rather than protein content from different groups were added to Hmeso cells. 
After 24 hr of exposure with exosomes, cells were imaged by phase contrast microscopy 
with 20× objective lens and subsequently analyzed by MTS assay or cell protein lysate was 




All experiments were performed in duplicate or triplicate and repeated at least twice. A 
one-way analysis of variance (ANOVA) followed by a Newman-Keuls procedure for 
adjustment of multiple pairwise comparisons or the student’s unpaired two-tailed t-test was 
applied to all data to establish the significance of observed differences between the various 
experimental groups. p ≤ 0.05 was considered significant. All statistical analyses were 
performed using the GraphPad Prism software program version 7.0 (GraphPad Software, 
La Jolla, CA). 
 
Results 
Exosome Isolation and Characterization from MM Cells 
The isolation of  exosome samples was characterized by transmission electron microscopy 
(TEM), Western blot analysis for exosomal marker CD81, and nanoparticle tracking 
analysis (NTA) (Supplementary Figure 1). The vesicle isolates are predominantly in the 
size range of 30-140nm in diameter as seen in TEM and NTA, and are enriched in CD81. 
TEM also indicates the well-described “cup-shape” morphology of the exosomes, and none 
of the exosomal samples showed a signal for calnexin, suggesting no presence of 
endoplasmic reticulum contaminants. 
Mesothelioma Cancer Cells Secrete High Levels of miR-16-5p in Exosomes 
miRNA microarray profiling was conducted on isolated exosomal RNA from MM cell 
lines and primary mesothelial cells to compare non-cancer versus cancer signature (Figure 
1A). There were a total of 20 exosomal miRNAs upregulated and 110 downregulated in 
expression from MM tumor cell exosomes as compared to exosomes from primary 
158 
 
mesothelial cells, with a >2-fold cut-off for both parameters. All 130 miRNAs with >2-
fold differential expression are significant with ANOVA p-value < 0.05 (Supplementary 
Table 1 supplementary data). 
We chose to validate the exosomal miRNA expression levels of 3 upregulated (miR-16-
5p, miR-222-3p, miR-30a-5p) and one down regulated (miR-31-5p) miRNA by qRTPCR 
(Figure 1B), all of which have been implicated in MM biology. Additionally, we validated 
exosomal miRNA by qRTPCR with 2 extra MM cell lines, H2595 (epithelioid subtype) 
and HP-1 (biphasic), along with the originally tested Hmeso and H2373, and show (Figure 
1B) that miR-16-5p, miR-222-3p, and miR-30a-5p are upregulated in exosomes from both 
epithelioid subtypes, Hmeso and H2595. The sarcomatoid H2373 showed upregulation 
only in miR-16-5p and miR-30a-5p, however, no upregulation was observed in the biphasic 
HP-1. miR-31a-5p was significantly decreased in all MM cancer exosomes.  
We also performed qRTPCR to indicate the intracellular levels of each miRNA analyzed 
to show appropriate comparisons of producer cell quantities versus the amount secreted in 
exosomes, and found that all were significantly under-expressed as compared to the 
primary mesothelial cells HPM3 (Figure 1C). 
Inhibited exosome secretion of MM cells attenuated tumorigenic properties 
Treatment of Hmeso MM cells with small molecule inhibitors GW4869 (GW, 40µM) or 
combination of Bisindolylmaleimide-I (10µM) with Chloramidine (50µM) (B&C), for 72 
hours, resulted in significant reductions in exosome secretion from both treatment groups 
(Figure 2A & B) as measured by NTA. Subsequent analysis of miR-16-5p provided with 
confirmation that inhibition of exosome secretion leads to concomitant reduction in 
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secreted miR-16-5p in addition to increased levels of intracellular miR-16-5p within MM 
cancer cells (Figure 2C). This result suggests that both inhibitors function differently in 
their capacity to effect exosome secretion and miR-16 secretion, and that neither inhibitor 
regulates levels of miR-16. If the inhibitors regulated miR-16 levels directly, we would 
expect to have seen intracellular levels of the miRNA altering in the same direction as 
observed in the exosomes; instead, they are increased in the cell and decreased in the 
exosomes. For further validation, we measured 4 other exosomally secreted miRNAs that 
were initially identified by microarray, and found that exosome inhibition also leads to 
reduced levels of exosomal miR-222-3p, miR-30a-5p, miR31-5p, and let-7e-5p (Figure 
2D), when measured from direct exosome preparations. 
We further measured the viability of MM tumor cells (Hmeso, H2595, and H2373) using 
the MTS colorimetric assay following 72hr treatment with exosome secretion inhibitors 
with and without cisplatin. As shown in Figure 3A-C, B&C mediated exosome inhibition 
caused significant cell death by itself whereas GW did not lead to significant reduction in 
cell viability (data not shown). Both exosome secretion inhibitors led to significant 
reductions in cell numbers when combined with a low dose of cisplatin (Figure 3A-C). 
Furthermore, Annexin-V expression, assayed by flow cytometry, was slightly elevated in 
all treatment groups compared to control and cisplatin alone, indicating that apoptosis alone 
does not explain the decrease in cell viability observed upon inhibition of exosome 
secretion (data not shown). 
To elucidate further both the mechanism of reduced number of cells and the effects of miR-
16-5p replenishment, we conducted Western blot analysis of miR-16-5p target proteins 
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CCND1 and BCL2 in exosome secretion inhibited MM cells. Protein levels of both 
CCND1 and BCL2 decreased in exosome secretion inhibited Hmeso cells (Figure 3D), and 
CCND1 was decreased in H2595 cells (Figure 3E). BCL2 could not be detected for H2595 
cells. At the mRNA level, we showed that exosome inhibition does not affect expression 
of CCND1 (Figure 3G), although cisplatin does, and that BCL2 levels are significantly 
reduced upon exosome inhibition and increased with cisplatin (Figure 3G).  
The effect of exosome secretion inhibition with and without cisplatin also led to significant 
reductions in MM cell growth in 3-D spheroid models in both Hmeso (Supplementary 
Figure 2 A-C) and H2373 cells (Supplementary Figure 2 D-F) as measured by size and 
MTS assay. Additionally, the migratory and invasive capacity for both Hmeso and H2373 
cells was significantly reduced upon inhibition of exosome secretion (Supplementary 
Figure 3). 
Force-feeding MM Cancer Exosomes Back to MM Producer Cells attenuates 
tumorigenesis 
To validate our findings of retention of exosomes and decreased tumor characteristics, we 
ventured to assess if force-feeding the MM cancer exosomes back to the producer MM 
cells had a similar effect of reduced tumorigenesis via delivering back their secreted miR-
16-5p. As a first step, we validated that MM exosomes interacted with, and were taken up 
by their own cells by addition of PKH67-labeled exosomes (Figure 4A). All cell lines and 
their exosomes produced the same results of interaction and staining.  
Next, we isolated exosomes from conditioned media after 72 hours in culture for MM 
exosomes to accumulate. The pelleted exosomes were suspended in 0.5% FBS (exosome-
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free) media at three different concentrations: low, medium, and high, based on the amount 
of media from which the exosomes were pelleted, 5mL, 10mL, and 20mL, respectively. 
Suspended exosome pellets were added to 3,000 MM cells/well in 96-well plates and 
incubated overnight. The following day, cells were imaged and assayed for viability by 
MTS. The MM cells force-fed with their own concentrated exosomes endured significant 
amounts of cell death as observed by phase-contrast imaging and MTS assay (Figure 4B-
G). This was the case for both epithelioid MM subtypes (Hmeso and H2595) and the 
sarcomatoid subtype (H2373). As an additional control, we added a “mock” group of cells 
that were exposed to a mixture of exosome-free suspension media and ExoQuick-TC 
precipitation media after spinning alongside our true exosome isolates to verify that the 
ExoQuick-TC reagent was not having any effect on the cells. We found that the 
reagent/media mixture had no significant effect on target cells (Figure 4B, C). Furthermore, 
we also confirmed that miR-16-5p target protein CCND1 was reduced in abundance. 
(Figure 4H, I). 
To check for the selectivity of exosome force feeding response, we conducted force-
feeding of cancer exosomes to non-cancer mesothelial cells (LP9) and also of non-cancer 
LP9 exosomes to themselves and to the Hmeso MM cancer cells. We found that MM cancer 
exosomes only killed the MM cancer cells from which they were produced and had no 
effect on LP9 mesothelial cells. LP9 exosomes had no effect on the proliferation of their 
producer cells and had a somewhat promotive growth effect on Hmeso cancer cells as 
analyzed by MTS proliferation assay (Supplementary Figure 4). 
miR-16-5p overexpression in MM tumor cells inhibits MM tumorigenesis 
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To ensure that the above effects seen with exosome secretion inhibition and force-feeding 
cancer exosomes was in fact due, at least in part, to miR-16-5p levels within the cancer 
cells we employed direct transfection of miR-16-5p mimics to Hmeso cells. Initial analysis 
determined that as expected miR-16-5p transfection led to significantly higher levels of 
intracellular miR-16-5p (Figure 5A). We observed decreased levels of miR-16-5p in 
exosomes from transfected cells (Figure 5B), suggesting two possibilities; either secretion 
of exosomes is inhibited in response to transfection or loading of miR-16-5p into exosomes 
is decreased. Therefore, we conducted NTA from transfected experiments and found that 
the cells with over-expressed miR-16 upon transfection had no significant change in 
exosome secretion compared to control cells (Figure 5I). 
Further, overexpression of miR-16-5p within the cells resulted in significant reduction in 
miR-16-5p target proteins CCND1 and BCL2 as analyzed by Western blot (Figure 5C-E). 
This result also coincided with significantly reduced viable Hmeso cells after miR-16 
transfection alone as well as with cisplatin (Figure 5F). To establish that transfection was 
not specific to only one particular set of miR-16-5p mimics, we transfected cancer cells 
with two separate miR-16-5p mimics from different lots and observed comparable results. 
The migratory and invasive capacity of Hmeso cells was also significantly abrogated upon 
miR-16-5p transfection (Figure 5G, H). 
HuR is possibly involved in loading miR-16 into exosomes of MM cells 
Based on previous work done by other groups, it has been decisively implicated that the 
RNA binding protein HuR interacts with miR-16-5p (21). Therefore, a further investigation 
into exosomal miR-16-5p was to uncover if the RNA binding protein HuR was involved 
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in loading the miRNA into the vesicles. Immunostaining indicated that HuR was indeed 
present in the cytoplasm and nucleus of Hmeso MM cells (data not shown). Western blot 
analysis showed that no measurable amount of HuR was present in MM exosomes (data 
not shown). 
Transfection of siHuR to Hmeso MM cells resulted in significant reduction in HuR protein 
levels (Figure 6A). Additionally, HuR inhibition caused significantly higher levels of 
intracellular miR-16-5p and significantly lower levels of exosomal miR-16-5p (Figure 
6B,C) suggesting a possible role of HuR in exosomal miRNA chemistry. Interestingly, it 
has been shown that miR-16 may target the expression of HuR (22), and our data also 
provides the same evidence by Western blot analysis of Hmeso cells transfected with miR-
16-5p (Figure 6D).  
 
Discussion 
Malignant mesothelioma is a cancer of mesothelial cells caused by asbestos exposure, with 
dismal prognosis, and virtually no effective methods of early diagnosis or successful 
therapeutic approaches.  Our hypothesis was to attack these knowledge gaps by embarking 
to uncover potential miRNA biomarkers and therapeutic targets with the focus on MM 
tumor exosomes. To date, exosomes have been a trending theme in cancer research and 
there have been wonderful advancements in understanding cancer through the lens of 
tumor exosomal miRNAs as possible biomarkers and therapies in many cancers (23-25), 
however, not much is known about their role(s) in MM. 
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Our initial findings were surprising in that we observed MM tumor cells secreting 
significantly higher levels of tumor suppressor miRNAs, particularly miR-16-5p, 
compared to non-cancer mesothelial cells in exosomes. Previous studies of MM have well-
characterized miR-16-5p as both a tumor suppressor by targeting oncogenes BCL2 and 
CCND1 (26-28), and as a remarkably under-expressed miRNA in MM tumor cells and 
tissues (10,29). Moreover, miR-16-5p has been reported as a potential therapeutic molecule 
by restoring its expression in MM (30-32). Based on these previously reported pieces of 
evidence on the role of miR-16-5p in MM, and our new findings of presence of miR-16-
5p in exosomes led us to the innovative hypothesis that MM tumor cells preferentially 
secrete miR-16-5p, among other tumor suppressors, via exosomes to rid their cancer-killing 
effects. Similar results have been stated previously in ovarian cancer that may behave 
similarly in secreting high levels of tumor suppressor miRNAs (33).  
The other over-expressed tumor associated exosomal miRNAs also have interesting 
biological relevance in MM: miR-222-3p is downregulated in MM and is a negative 
regulator of CDK1 (p27) and is a PTEN suppressor (34); miR-30a-5p (along with miR-
222-3p and miR-31-5p), in the same family as miR-30e, is associated with good prognosis 
when in higher abundance in MM tumors (35); and miR-320 family members are suggested 
as potential biomarkers for malignant pleural mesothelioma (36). 
This set of miRNAs along with miR-16-5p were under-expressed in the MM cells from 
which they were being secreted. Our findings are supported by literature that MM cells and 
tumors have low levels of tumor suppressor miRNAs including miR-16-5p (10) as 
compared to mesothelial cells. This leads us to the possibility that miR-16-5p is not simply 
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randomly packaged into cancer exosomes due to inherently high abundance in the exosome 
producer cells, but that it must be systematically sequestered into exosomes by a 
biologically preferential loading process. The low miR-16-5p in MM tumor cells observed 
by us and others could be attributed to its increased secretion via exosomes, as opposed to 
common loss of tumor suppressors via mutation and deletion. 
Because of miR-16-5p’s tumor suppressive effect and our hypothesis of its preferential 
secretion from MM tumor cells by exosomes, we aimed to inhibit MM cell tumorigenesis 
by inhibiting exosome secretion. The idea being that if exosome secretion were 
significantly down-regulated, that miR-16-5p stores would rebuild in the tumor cells and 
lead to oncogenic targeting and subsequent cell death. 
Based on successful outcomes in the literature we chose to use two separate exosome 
secretion inhibitory approaches. The neutral sphingolmyelinase-2 inhibitor GW4869, 
which blocks ceramide production that is needed to bud exosomes inward at the endosomal 
surface, has been indicated as a useful avenue for blocking exosome secretion as well as 
increasing the efficacy/reducing chemotherapeutic drug resistance to cisplatin (19,37,38). 
Further, a combination of two small molecules bisindolylmaleimide-I and chloramidine 
have also been shown to reduce exosome secretion from cells and increase 
chemotherapeutic retention (18). 
Using GW or B&C treatment of Hmeso cells, led directly to significant reductions in 
exosomal miR-16-5p along with other miRNA secretions and significantly increased stores 
of cell cytoplasmic miR-16-5p. The inhibition of exosome release coupled with miR-16-
5p retention in cells provided direct evidence that the miRNAs we were investigating were 
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indeed being released in exosomes, and that we could prevent their preferential release and 
achieve the goal of miR-16-5p tumor suppressor retention. Also, we see that both inhibitors 
used, did not appear to negatively regulate the expression of miR-16-5p in the cells, as seen 
by the increased cellular miR-16-5p, so we can conclude that the drugs work by inhibiting 
exosomal miR-16-5p secretion and not the levels within the cell. Further confirmation of 
miR-16-5p retention was assessed by significantly reduced protein abundance of the miR-
16-5p targets CCND1 and BCL2 and substantial inhibition in tumorigenesis as measured 
by loss of cell number, 3D tumor spheroid growth, transformation/colony growth, 
migratory and invasive capacity of MM tumor cells.  
Additionally, we indicate that exosome secretion may play an important role in 
chemotherapeutic resistance of MM to cisplatin, given that exosome inhibition leads to 
increased cisplatin-induced cell death in our in vitro studies. In support to our findings, it 
has been reported before that chemotherapeutic drugs can be lost via exosomes (39,40).  
The logical next step for our studies was to show if we can feed back these exosomes to 
tumor cells and see the similar effects on tumorigenesis and confirm the findings of 
exosome secretion inhibition. All studies to date on the effect of tumor exosomes has 
indicated that they are pro-tumorigenic by multiple means (immunosuppression, drug 
resistance, enhanced tumor growth/proliferation, metastasis, angiogenesis, 
mesenchymal/fibroblastic transitions etc.) (25,41-47). However, our hypothesis was 
different because of our intriguing findings that MM tumor exosomes have high volumes 
of tumor suppressor miRNAs, especially miR-16-5p, and may have a tumor killing effect.  
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Remarkably, addition of MM exosomes back to the producer MM cells, led to incredible 
levels of cell death in a dose dependent manner as compared to controls. Further, upon 
force-feeding of MM cancer exosomes to cancer cells, we see significant decreases in miR-
16-5p target oncogenic protein CCND1. This is a vital result in that it shows that we can 
demonstrate the same result as exosome inhibition but in a separate route. Importantly, 
MM cancer exosome force-feeding, even more notably, was only seen to kill MM cancer 
cells and had no effect on normal mesothelial cells. Also, normal mesothelial cell exosomes 
had no effect on cancer cells or on themselves when force-fed back.  
These findings are the first of their kind, to show that not only can a certain cancer’s 
exosomes lead to the death of their producer cells, but they do so in a specific manner that 
does not affect non-cancer cells. The implications of this are exciting in that they may 
suggest a very new therapeutic option in MM by targeting tumor cells with their own 
exosomes. This is especially noteworthy given that the effect of MM exosomes on the 
cancer cells is implicated in the effect of the tumor suppressor miR-16-5p that is 
functioning in the exosome inhibition experiments.  
We do understand that we are drawing our discussion of force-feeding exosomes based 
only on one component of what is being redelivered to the tumor cells. In reality, the 
exosomes will be delivering back a vast array of molecules in combination to the miR-16-
5p and other tumor suppressors, and those effects should be considered. Essentially, we 
know that miR-16-5p plays a role in this complicated biology, but there is likely a lot of 
interplay with everything else within the MM tumor exosomes that needs to be studied. 
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Moreover, we recapitulated the same findings from exosome inhibition and force-feeding 
via direct transfection of miR-16-5p, providing firm evidence that not only is exosome 
secretion a pro-tumorigenic mechanism of MM by preferential secretion of miR-16-5p but 
that exosomal miR-16-5p is of potential therapeutic importance as reported before 
(10,32,48). As a counterintuitive piece of evidence, we did see that although miR-16-5p 
levels increased intracellularly in MM cancer cells after transfection of miR-16-5p mimic, 
the levels in their exosomes significantly plummeted. This may suggest that miR-16-5p 
levels may also play a role in the loading or secretion of exosomes with miR-16-5p within. 
As NTA analysis showed no significant differences in the number of particles in response 
to miR-16-5p transfection, there is a further possibility of miR-16-5p exhibiting an effect 
on packaging/loading system of exosomes. 
Here we also intended to unlock the potential mechanism for miR-16 loading into 
exosomes within MM cancer cells.  Based on previous reports of RNA binding protein 
HuR  interaction with miR-16-5p (21) and evident role in exosome secretion of other 
miRNAs (49), we explored its role in our experimental settings. Significant reduction in 
HuR expression via siRNA lead to increased amount of miR-16-5p in cells, and 
significantly reduced the amount secreted in exosomes. This result is evidence that HuR is 
at least partly involved in the packaging of miR-16-5p into MM cancer exosomes. 
Furthermore, previous research has also shown that miR-16 targets the expression of HuR 
(22), we also provide this same evidence as measured by Western blot analysis, telling us 
something very interesting about the mechanistics of miR-16-5p exosomal loading and the 
interplay of HuR. Based on our results thus far, we have drawn together a proposed 
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mechanism that may be involved where HuR promotes miR-16-5p loading into exosomes, 
meaning that siHuR knockdown of HuR protein levels leads to reduced exosomal miR-16-
5p, and hence increased miR-16-5p in the cell. It is then implicated that miR-16-5p targets 
HuR expression at the protein level, meaning that high miR-16-5p levels lead to low HuR 
and therefore, reduced exosomal miR-16-5p, which is exactly what our data represents. 
Because miR-16-5p upregulation by transfection does not affect exosome secretion by 
particle number, we know that this effect is limited to the packaging process of exosome 
cargo. Along this logic, we theorize that MM cancer cells not only have the evolutionary 
advantage for uncontrolled cell growth because of low intracellular stores of miR-16-5p 
based on high exosomal removal, but that miR-16-5p itself negatively regulates its own 
packaging into exosomes by targeting HuR (Supplemental Figure 5). 
Taken together, our findings strongly indicate that miR-16-5p is preferentially secreted by 
MM tumor cells via exosomes in vitro, and by inhibiting exosome secretion, miR-16-5p 
levels increase thereby reducing oncogenic protein levels and lead to significant loss of 
tumorigenic capacity of the MM cancer cells. We also indicate that the mechanism of 
exosomal miR-16-5p secretion is at least somewhat regulated by HuR, and that there is a 
negative feedback loop involved in this packaging when miR-16-5p levels are increased 
within the cell. 
Altogether, this novel research study provided unprecedented indications that MM tumor 
exosomes can be used to inhibit tumorigenesis, and this is related to the fact that the MM 
tumor cells preferentially secrete miR-16-5p through their exosomes to rid themselves of 
its tumor suppressor function. A recent study published by Guo et al. (50) supports our 
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concept that autologous tumor cell-derived particles (eg. exosomes) can be a promising 
therapeutic target for treating malignancies. As discussed above there are limitations to this 
study as exosomes contain lot more than just tumor suppressor miRNA. Our future 
endeavors include a series of in vivo experiments such as using exosome inhibition and 
exosome force-feeding in mice allografted with MM tumors to see if any effect can be seen 
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Figure 1. miRNA Array and validation of exosomal miRNAs from mesothelial and 
mesothelioma cells. A) GeneChip miRNA 4.0 array heat map of miRNA abundances from 
human mesothelioma cell (Hmeso, H2373) exosomes as compared to normal primary 
human mesothelial cell (HMP3) exosomes. B) qPCR validation of exosomal miR-16-5p, 
miR-30a-5p, miR-222-3p, and miR-31-5p in 4 MM cell lines compared to HPM3 cells. C) 
Cellular miRNA expression of validated exosomal miRNAs in MM cell lines as compared 
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to HPM3 cells by relative log decrease in expression, with control HPM3 expression levels 
set to 1.0. Number of replicates are 2 (n=2), data is presented as mean+ SEM, and *p ≤ 
0.05, by 1-way ANOVA as compared to HPM3 cells. 
  
Figure 2. Inhibition of exosome secretion from Hmeso MM cancer cells attenuates 
exosomal miRNA secretion. A) Nanoparticle tracking analysis plots of control (bold gray) 
exosomes overlaid with either GW4869 (GW) treated cell exosomes or 
Bisindolylmaleimide-I with Chloramidine (B&C) treated cell exosomes (light gray). B) 
Particles/mL of control exosomes compared to both exosome inhibitor treatment groups, 
n=3/group. C) miR-16 expression in cells and exosomes after exosome secretion inhibition, 
n=3. D) qPCR validation of other miRNAs being reduced in MM exosomes after exosome 
inhibition. All miRNA qPCR data is normalized to synthetic spike-in control cel-miR-39-
3p, which was added to all exosome or cell isolates prior to RNA isolation. N=2, mean+ 
SEM, and *p ≤ 0.05, by 1-way ANOVA or two-tailed Student’s t-test as compared to 




Figure 3. Inhibition of exosome secretion from MM cancer cells reduces proliferation 
and cellular abundance of oncogenic proteins targeted by miR-16.  A) MTS 
proliferation assay on Hmeso cells after cisplatin treatment, exosome inhibition, or 
combination of both treatments after 72hr, n=6.  B) and C) MTS proliferation assay on 
H2595 and H2373 cells, respectively, after cisplatin treatment, exosome inhibition, or 
combination of both treatments after 72hr, n=6  D) Immunoblot of Hmeso cellular proteins 
and miR-16 targets CCND1 and BCL2, normalized to β-actin. n=2. E) Immunoblot of 
175 
 
H2595 cellular protein and miR-16 target CCND1, normalized to β-actin content. n=2. 
qPCR of miR-16-5p oncogenes F) CCND1 and G) BCL2 after exosome inhibition, as 
normalized to HPRT endogenous control. *p ≤ 0.05 as compared to control, † p ≤ 0.05 as 
compared to cisplatin treated group by 1-way ANOVA. 
 
Figure 4. Force-feeding MM cancer cell exosomes back to MM cells leads to cancer 
cell death. A) PKH67 labeled exosomes from Hmeso cells added to Hmeso cells show 
uptake/interaction of exosomes with target cancer cells. B) Phase contrast images of Hmeso 
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cells after addition of three different concentrations of Hmeso exosomes (concentrations 
based on volume of cell media collected from) or Mock (ExoQuick-TC), and C) MTS 
proliferation assay of force feeding MM cancer exosomes, n=6. Similar experiments with 
H2373 cells by D) phase imaging and E) MTS proliferation assay, as well as with H2595 
MM cells by F) phase imaging and G) MTS proliferation assay, n=6. Force feeding Hmeso 
exosomes to Hmeso MM cells H) significantly reduced protein levels of CCND1 as 
analyzed by Western blot analysis. Western blot images shown are representative images 
and quantitation graphs of I) CCND1 are combined quantitation of 3 repeated experiments. 
N=3, Phase contrast images were taken with 40× objective lens, scale bar = 100µm, mean 





Figure 5. miR-16 overexpression in Hmeso cells leads to decreased MM cancer cell 
proliferation and protein abundance of CCND1 and BCL2. A) Cellular levels of miR-
16 increased after transfection, whereas, contradictorily, B) miR-16 levels in exosomes 
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significantly decreased upon transfection of miR-16 into Hmeso cells. n=3. The target 
proteins of miR-16 C) (immunoblot), D) CCND1 and E) BCL2 were reduced after miR-16 
transfection. Transfection of miR-16 also resulted in F) significantly reduced proliferation 
of MM cells by MTS, and increased cell death by cisplatin (n=6), along with attenuated 
capabilities of G) migration (n=3) and H) invasion (n=3). I) miR-16 transfection had no 
effect on secreted exosome numbers as assessed by NTA. All miRNA qPCR data is 
normalized to synthetic spike-in control cel-miR-39-3p, which was added to all exosome 
or cell isolates prior to RNA isolation.  Mean + SEM, *p ≤ 0.05 as compared to control and 




Figure 6. HuR is involved in the exosomal secretion of miR-16 from MM cells. A) 
Transfection of siHuR significantly reduced the protein abundance of HuR as analyzed by 
Western blot analysis B), and led to significantly increased cellular expression of miR-16 
and C) significantly decreased expression of miR-16 in exosomes. D) Transfection of miR-
16 mimic similarly induced significant reductions in HuR protein levels as analyzed by 
Western blot analysis (using the same immunoblot as Figure 5, therefore B-actin is the 




Supplementary Figure 1. Hmeso cell exosome characterization. A) TEM showing 
exosome membrane-bound structures and size range; indicated by arrow in middle of field. 
Scale bars, 100 nm. B) Nanoparticle Tracking Analysis (NTA) indicating exosome size 
distribution and concentration of particles. C) Western blot analysis for presence of 
exosome marker CD81 from two replicate (R1 and R2) exosome preparations from Hmeso 
conditioned cell culture supernatant, normalized by equal volume of exosomal input from 




Supplementary Figure 2. Exosome secretion inhibition from MM cancer cells inhibits 
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tumor 3D spheroid growth. A) Hmeso cells were grown as 3D spheroids as described in 
materials and methods section and treated with cisplatin (Cis, 20µM), GW4869 (GW, 
40µM), combination of Bisindolylmaleimide-I 10µM with Chloramidine 50µM (B&C), or 
combinations. Phase contrast images were taken after 6 days of growth with 20× objective 
lens, scale bar, 500µM B) 3D spheroid sizes were measured in ImageJ, and C) solubilized 
and measured for proliferation using MTS assay. D-F) Similar experiments with H2373 
cells n=3, mean+ SEM, *p ≤ 0.05 as compared to vehicle control and † p ≤ 0.05 as 
compared to Cis alone by 1-way ANOVA 
 
 
Supplementary Figure 3. Exosome secretion inhibition from MM cancer cells 
attenuated migration and invasion. MM cells were treated with exosome secretion 
inhibitors and then put on tranwells to assess migration /invasion after 72 h as described in 
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the materials and method section. Inhibition of exosome secretion attenuated migration (A, 
B) and invasion (C, D) of Hmeso and H2373 MM cells. n=3, mean+ SEM, *p ≤ 0.05 as 
compared to vehicle control by 1-way ANOVA. 
 
 
Supplementary Figure 4. Exosome force-feeding leads to cancer cell specific effects. 
A) Phase contrast images of control and force-fed mesothelial (LP9) or mesothelioma 
(Hmeso) cells in various combinations and B) MTS proliferation assay of force-feeding 
MM cancer exosomes and LP9 mesothelial cell exosomes to either target Hmeso MM cells 
or target LP9 cells. n=6, Phase contrast images were taken with 40× objective lens, scale 





Supplementary Figure 5. Schematic representation of hypothesized mechanism of 
exosomal miR-16-5p secretion in MM cancer cells. According to our results, along with 
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published literature, we concluded that in malignant mesothelioma (MM) cancer cells A) 
miR-16-5p is loaded into exosomes, with the help of the RNA binding protein HuR, and is 
secreted at high levels in those exosomes. Further, we know that miR-16-5p, a potent tumor 
suppressor, acts to block gene expression of oncogenic BCL2 and CCND1, and that miR-
16-5p negatively regulates HuR, leading to the circumstance that MM cancer cells have 
low intracellular miR-16-5p and high exosomal miR-16-5p. Our further experiments 
indicated that: B) force-feeding of MM cancer exosomes to MM cancer cells leads to cell 
death by blocking oncogenic protein abundances of BCL2 and CCND1; miR-16-5p 
transfection leads to low HuR levels therefore low miR-16-5p secretion and replenished 
miR-16-5p intracellular stores, also leading to cell death by BCL2 and CCND1 regulation; 
and that direct regulation of HuR by siHuR can recapitulate this same cycle of potential 
therapeutic targeting to increase miR-16-5p expression in cancer cells. Exosome inhibition 
was omitted from the schematic for clarity and because the role of inhibiting exosome 











Supplementary Table 1. List of differentially expressed miRNAs in MM cancer 







(log2) Fold Change P-val 
hsa-miR-30a-5p 6.12 2.79 10.05 4.58E-06 
hsa-miR-16-5p 6.89 4.18 6.52 0.0015 
hsa-miR-92b-3p 4.78 2.4 5.2 0.0257 
hsa-miR-1268a 5.76 3.66 4.31 0.0433 
hsa-miR-25-3p 4.57 2.52 4.14 0.0361 
hsa-miR-320e 5.54 3.57 3.92 4.30E-06 
hsa-miR-222-3p 7.37 5.49 3.7 0.0036 
hsa-miR-15b-5p 4.26 2.41 3.62 0.0063 
hsa-miR-92a-3p 9.96 8.13 3.56 0.0185 
hsa-miR-320d 7.71 5.96 3.36 0.0009 
hsa-miR-320c 9.46 7.8 3.17 0.0095 
hsa-miR-20a-5p 5 3.47 2.88 0.0191 
hsa-miR-320a 9.5 8.02 2.79 0.0035 
hsa-miR-320b 9.45 8 2.72 0.0049 
hsa-miR-4445-3p 4.06 2.65 2.66 0.0231 




3p 3.36 2.17 2.28 0.0206 
hsa-mir-7515 4.36 3.31 2.08 0.0447 
hsa-miR-744-5p 3.55 2.54 2.02 0.0365 
hsa-miR-3910 2.2 1.2 2.01 0.0018 
hsa-miR-885-3p 2.63 3.67 -2.05 0.0165 
hsa-miR-4655-5p 1.93 2.97 -2.05 0.0203 
hsa-miR-6124 1.35 2.4 -2.07 0.0123 
hsa-miR-4681 1.67 2.73 -2.09 0.0029 
hsa-miR-6820-5p 2.35 3.45 -2.14 0.0178 
hsa-miR-5196-5p 1.48 2.6 -2.17 0.004 
hsa-miR-6875-5p 1.15 2.27 -2.17 0.0065 
hsa-miR-3162-5p 1.47 2.6 -2.18 0.0011 
hsa-miR-3619-5p 1.97 3.1 -2.19 0.0314 
hsa-miR-6775-5p 4.05 5.2 -2.21 0.0185 
hsa-miR-6127 1.69 2.84 -2.23 0.0054 
hsa-miR-4707-5p 3.93 5.12 -2.29 0.0027 
hsa-miR-6125 5.39 6.61 -2.32 0.0341 
hsa-miR-1233-5p 3.35 4.57 -2.32 0.0156 
hsa-miR-6729-5p 6.31 7.53 -2.33 0.0026 
hsa-miR-1207-5p 3.64 4.86 -2.33 0.0352 
hsa-miR-498 3.25 4.48 -2.33 0.0298 
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hsa-miR-6077 1.69 2.94 -2.38 0.0015 
hsa-mir-4281 2.36 3.62 -2.39 8.84E-05 
hsa-miR-4787-5p 6.9 8.18 -2.44 0.0014 
hsa-miR-135a-3p 1.06 2.35 -2.46 0.0017 
hsa-miR-7109-5p 1.56 2.86 -2.47 0.0038 
hsa-miR-5787 7.89 9.23 -2.54 0.0054 
hsa-miR-210-3p 3.87 5.21 -2.54 0.042 
hsa-miR-6724-5p 3.95 5.37 -2.66 0.0123 
hsa-mir-6800 3.31 4.73 -2.68 5.50E-05 
hsa-miR-6848-5p 2.59 4.02 -2.69 0.0304 
hsa-miR-6787-5p 2.95 4.38 -2.7 0.0116 
hsa-miR-6782-5p 3.33 4.79 -2.75 0.0049 
hsa-miR-4665-5p 1.5 2.95 -2.75 0.006 
hsa-miR-6850-5p 3.37 4.84 -2.76 0.0012 
hsa-miR-5100 1.56 3.08 -2.87 0.0156 
hsa-miR-6791-5p 3.72 5.25 -2.89 0.0026 
hsa-miR-204-3p 1.59 3.16 -2.97 0.0181 
hsa-miR-4749-5p 2.69 4.33 -3.13 0.0001 
hsa-miR-4417 0.83 2.48 -3.14 0.0002 
hsa-miR-4758-5p 2.39 4.04 -3.14 0.0138 
hsa-miR-6727-5p 5.4 7.11 -3.28 0.0014 
hsa-miR-6858-5p 3.49 5.21 -3.28 0.0005 
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hsa-mir-6800 3.25 4.98 -3.33 4.85E-05 
hsa-miR-1227-5p 3.16 4.92 -3.4 0.0026 
hsa-miR-4674 1.86 3.63 -3.41 0.0051 
hsa-miR-6824-5p 1.57 3.37 -3.48 0.008 
hsa-miR-8069 4.97 6.77 -3.49 0.0251 
hsa-miR-7108-5p 3.58 5.39 -3.5 0.0116 
hsa-miR-1915-3p 4.95 6.76 -3.51 0.0014 
hsa-miR-4689 1.3 3.13 -3.55 0.0325 
hsa-miR-149-3p 4.62 6.46 -3.59 0.0056 
hsa-miR-6786-5p 5.73 7.6 -3.64 0.0018 
hsa-miR-1909-3p 1.2 3.07 -3.66 0.0048 
hsa-let-7e-5p 2.04 3.96 -3.79 5.73E-05 
hsa-miR-4492 2.44 4.37 -3.82 0.0005 
hsa-mir-4466 1.92 3.89 -3.93 0.0022 
hsa-miR-6891-5p 1.87 3.85 -3.94 0.0126 
hsa-miR-3665 6 8 -4 0.0099 
hsa-miR-3196 4.67 6.68 -4.01 0.0128 
hsa-miR-6743-5p 3.05 5.06 -4.02 0.023 
hsa-miR-3960 7.34 9.36 -4.06 0.0025 
hsa-miR-6716-5p 1.38 3.41 -4.07 0.0093 
hsa-miR-3180-3p 1.91 3.95 -4.1 0.0182 
hsa-miR-6805-5p 3.42 5.46 -4.13 0.0285 
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hsa-miR-6771-5p 1.86 3.91 -4.13 0.0016 
hsa-miR-6722-3p 2.14 4.25 -4.33 0.0021 
hsa-miR-7110-5p 2.2 4.32 -4.37 0.002 
hsa-miR-8072 5.39 7.6 -4.61 0.0036 
hsa-miR-3656 4.76 7.04 -4.84 0.0013 
hsa-miR-6802-5p 1.21 3.49 -4.84 0.0171 
hsa-miR-4651 3.41 5.7 -4.9 0.0007 
hsa-miR-6798-5p 3.16 5.51 -5.1 0.0052 
hsa-miR-1273g-
3p 3.74 6.11 -5.19 0.0105 
hsa-miR-4649-5p 2.3 4.68 -5.19 0.001 
hsa-miR-6803-5p 5.16 7.57 -5.31 3.29E-05 
hsa-miR-1225-5p 1.6 4.01 -5.32 0.0334 
hsa-miR-4488 4.71 7.19 -5.54 0.0111 
hsa-miR-6869-5p 4.81 7.28 -5.56 0.0025 
hsa-miR-3648 1.55 4.08 -5.76 4.26E-05 
hsa-miR-3663-3p 1.46 4.04 -5.99 1.64E-05 
hsa-miR-4466 5.7 8.33 -6.18 0.0003 
hsa-miR-6752-5p 3.61 6.24 -6.19 0.0015 
hsa-miR-6088 4.96 7.6 -6.23 0.0001 
hsa-miR-4433b-
3p 2.4 5.09 -6.44 0.0049 
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hsa-miR-4508 4.51 7.22 -6.56 6.58E-05 
hsa-miR-6087 6.18 8.9 -6.58 5.78E-05 
hsa-miR-1228-5p 3.89 6.67 -6.84 0.0003 
hsa-miR-6789-5p 1.99 4.77 -6.87 0.0005 
hsa-miR-3940-5p 3.09 5.9 -7.03 0.0088 
hsa-miR-6749-5p 1.84 4.71 -7.3 0.0036 
hsa-miR-4463 2.47 5.4 -7.61 0.0009 
hsa-miR-4687-3p 3.02 6.04 -8.13 0.002 
hsa-miR-4497 7.03 10.11 -8.45 0.0012 
hsa-miR-6765-5p 2.96 6.1 -8.82 0.0003 
hsa-miR-6090 6.32 9.5 -9.06 0.0003 
hsa-miR-6089 6.5 9.77 -9.63 0.0002 
hsa-mir-6089-1 2.4 5.73 -10.1 0.0002 
hsa-mir-6089-2 2.4 5.73 -10.1 0.0002 
hsa-miR-1343-5p 1.72 5.07 -10.14 3.07E-06 
hsa-miR-31-5p 1.32 4.83 -11.4 0.0002 
hsa-miR-328-5p 2.98 6.54 -11.81 0.0003 
hsa-miR-3197 3.95 7.8 -14.5 0.0285 
hsa-miR-1237-5p 4.63 8.53 -14.86 1.97E-05 
hsa-miR-762 4.39 8.37 -15.73 4.18E-05 
hsa-miR-4745-5p 2.59 6.61 -16.25 0.001 
hsa-miR-4516 3.26 7.34 -16.88 0.0003 
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hsa-miR-6816-5p 3.01 7.58 -23.72 0.0001 
hsa-miR-6780b-
5p 2.38 7.17 -27.84 2.72E-06 
hsa-miR-3178 4.72 9.54 -28.29 0.0012 
hsa-miR-4281 1.8 6.94 -35.37 4.75E-06 
hsa-miR-4532 1.83 7.14 -39.78 9.00E-07 
hsa-miR-6126 4.73 10.36 -49.59 8.07E-05 
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CHAPTER FIVE: DISCUSSION AND FUTURE DIRECTIONS 
 
The work conducted within this thesis was the culmination of nearly five years of work 
based upon the novel ideas generated within the Shukla lab. The genesis of these research 
studies, which thus far have resulted in three research publications, were an effort to fill 
parts of the enormous knowledge gap in the field of asbestos induced mesothelioma. 
Specifically, the projects and data enumerated upon above were works to uncover the 
layers of two dominant themes of cellular secretion and communication: how does asbestos 
inhalation in the lung lead to disease on distant mesothelial cells, and how mesothelioma 
cancer cells’ biology is regulated by secreted factors in exosomes. These two concepts (or 
questions) were coupled with the hopes of potentially finding biomarkers of asbestos 
exposure or MM, and to identify possible therapeutic targets. The focal plane of this 
exciting work was homed in on the secretory vesicles known as exosomes, and we proudly 
made multiple first-of-their-kind discoveries regarding exosomes and MM. 
Our initial investigations were to assay the proteomic content of exosomes secreted from 
asbestos exposed cells, and assess if these exosomes could potentiate changes to 
mesothelial cells that might mimic tumor-like transitions. Within this context, we 
employed both in vitro and in vivo experiments.  
The in vivo study resulted in a descriptive set of evidence on serum exosomes’ proteomic 
signature in mice after asbestos exposure. We exposed mice to asbestos via oropharyngeal 
aspiration and after 56 days harvested the serum exosomes for proteomic analysis. Tandem 
mass tag labeling and subsequent mass spectrometry provided data that differential 
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abundances of certain proteins were measurable in asbestos exposed mice serum exosomes 
as compared to controls. We focused on those proteins increased in abundance as our 
research is looking for potential biomarker identification. The increased exosomal proteins 
which were validated by Western blot analysis were ceruloplasmin, haptoglobin, and 
fibulin-1. In support of our findings these proteins have been identified before by other 
groups in response to asbestos exposure or mesothelioma, however, not in exosomes. 
Additionally, we identified 376 total exosomal proteins between both groups. The main 
finding here was that we were capable of identifying a proteomic signature based on 
abundance differences in serum exosomes between control and asbestos exposed mice. 
This demonstrates that asbestos exposure, at an organismal wide level, can lead to systemic 
changes in circulating exosomal protein content. The fact that we can measure these 
differences is an important step forward in the exosome field of asbestos exposure. 
One of our core concepts about this work was to explore if exosomes secreted from 
asbestos exposed lung epithelial cells and macrophages can affect mesothelial cells. Our in 
vitro work on asbestos exposure attempted to answer this question. First, we identified 
protein dissimilarities in exosomes from asbestos exposed cells, and then studied target cell 
effects on mesothelial cells. Using two experimental set-ups, both epithelial cells and 
macrophages, as these are the first cells in the lung to encounter asbestos fibers; we exposed 
each cell type to asbestos and collected their exosomes.  
Proteomic analysis of epithelial cells indicated significant differential abundances of 145 
proteins, including increased abundance in the asbestos group: plasminogen activator 
inhibitor 1, vimentin, 14-3-3 protein sigma, thrombospondin, transitional endoplasmic 
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reticulum ATPase, and glypican-1. Western blot validation was performed for glypican-1, 
notable for its role as an exosomal biomarker for pancreatic cancer, and thrombospondin 
which is overexpressed in MM tumors. Furthermore, exosomes from these asbestos 
exposed epithelial cells altered the gene expression of EMT related genes E-cadherin, 
desmoplakin, and IL1 Receptor Antagonist (IL1RN) in target mesothelial cells, 
potentiating the cells to becoming more mesenchymal, a hallmark of tumorigenesis.  
The same experimental setup was then performed on macrophages (with the exception of 
the means of gene expression analysis, microarray instead of PCR array, and the 
incorporation of an asbestos fiber exposed positive control group of mesothelial cells). 
Asbestos exposed macrophages secreted exosomes with 32 differentially abundant proteins 
compared to control cells’ exosomes. Two were validated by Western blot, superoxide 
dismutase, elevated in asbestos exposure models described elsewhere and in mesothelioma 
studies elsewhere, and vimentin, a key regulator in the response to asbestos exposure by 
regulating the NLRP3 inflammasome. 
Targeting mesothelial cells with exosomes from asbestos exposed macrophages led to gene 
expression modulation in 498 genes , 241 up and 257 down, and importantly, 206 of these 
genes were changed when mesothelial cells were exposed to asbestos fibers alone. This 
told us very plainly that exosomes from asbestos exposed cells can alter mesothelial cells 
in some of the same ways that asbestos fibers alone do. Especially because, after validation 
of six of these genes (upregulated hCCNB2, hEGR1 and hFANCD2, and downregulated 
hCRELD2, hERO1B and hJAG1), we connected the expression differences to be of 
potential significance in mesothelial cells becoming more tumorigenic in capacity.  
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The two studies mentioned above have a few major takeaways: Firstly, asbestos exposure 
leads to measurable protein differences in exosomes both from cells in vitro and in serum 
of whole mice and after further validation can be used as biomarkers of asbestos exposure 
for the early diagnosis of mesothelioma. Secondly, we were able to prove that exosomes 
from lung epithelial cells and macrophages can alter the gene expression of target 
mesothelial cells in ways that may be inducing the necessary changes that beget MM tumor 
development. 
We also unsuccessfully performed some in vivo experiments where mice were inoculated 
with MM tumors and 24 h later were injected with exosomes from the same tumor cell line. 
The intent was to show the effect of exosomes on tumor growth and metastasis. We did not 
observe any effect of tumor exosomes on tumor weight/volume or metastasis in this 
preliminary 4-week experiment. 
Our next steps for these studies are to perform our in vivo work with larger groups of mice 
to increase statistical power, and study the exosomal proteomic signature of human serum 
of healthy patients, asbestos exposed patients and patients with MM after asbestos 
exposure. In addition, we want to recapitulate the targeting effects of asbestos-induced lung 
exosomes on mesothelial cells in vivo. 
Shifting gears to the final study of this thesis, we indulged in the focus of exosome-
contained miRNAs from MM tumor cells themselves. This study provided insight into the 
miRNA composition of MM tumor exosomes, shedding light on biological information 
that may be used as possible biomarkers for MM in the future. The initial hypothesis, along 
with the intent of characterization of MM exosomal miRNAs, went along the common 
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dogma of tumor exosomes that MM tumor cells secrete high volumes of exosomes with 
pro-tumorigenic miRNAs that allow signaling in the tumor microenvironment to aid MM 
growth and invasion. It turns out we were completely mistaken. 
The MM tumor cells we cultured all secreted exosomes with upregulated levels of tumor 
suppressor miRNAs, particularly one that is of known importance in MM, miR-16-5p. This 
miRNA is well known to be underexpressed in MM tumor cells and tumor specimens. The 
function of miR-16-5p is that it prevents expression of oncogenic proteins, particularly 
BCL2 and CCND1. Because we saw increased secretion of tumor suppressor miRNAs 
such as miR-16-5p, we altered the hypothesis to state that MM tumor cells secrete high 
levels of tumor suppressor miRNAs via exosomes to rid themselves of the anti-tumorigenic 
effects.  
We first employed small molecule inhibitors to inhibit exosomes secretion and found that 
upon reducing secretion of exosomes, we saw concomitant reductions in miR-16-5p 
secretion. This reduced secretion correlated with two major findings: miR-16-5p was 
indeed being secreted from MM tumor cells through the exosome pathway, and blocking 
secretion led to direct increases in the intracellular stores of miR-16-5p.  
Exosome secretion inhibition led to a variety of anti-tumorigenic effects also: reduced 
proliferation, increased efficacy of cisplatin chemotherapeutics, reduced 3D spheroid 
growth, reduced colony formation, increased apoptosis, and reduced migration and 
invasion. This showed that exosome secretion may be a potential target in MM therapy, 
and that chemotherapeutic resistance may be in part related to exosome secretion. 
Furthermore, exosome inhibition led to significantly reduced amounts of miR-16-5p target 
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oncoproteins BCL2 and CCND1, telling us that the effects seen were at least in part 
dependent on miR-16-5p being restored. 
The following experiment was to force-feed concentrated MM tumor exosomes back to the 
producer tumor cells. Upon this force-feeding, we witnessed significant levels of cell death 
in multiple MM subtypes. This was also correlated with BCL2 and CCND1 being reduced 
in the force-fed tumor cells indicating that the exosomal miR-16-5p was playing a role. 
Additionally, MM tumor exosomes did not kill healthy mesothelial cells, nor did healthy 
mesothelial cell exosomes have any killing effect on either cancer or non-cancer cells. This 
indicates that force-feeding may also be a new approach to MM therapeutics and its effects 
appear to be tumor cell specific. 
To verify that these results were miR-16 specific, we directly transfected tumor cells with 
miR-16-5p mimic. The results from exosome inhibition and force-feeding were 
recapitulated, providing further evidence of the role miR-16-5p is playing in this approach. 
However, we did see something contradicting in our results; miR-16-5p transfection led to 
increased miR-16-5p intracellularly, as expected, but led to significantly less miR-16-5p in 
the exosomes. 
Moreover, we were given a lead on to an RNA binding protein, known as HuR, that may 
also be involved in the mechanism of miR-16-5p going into exosomes. HuR has been 
shown to interact directly with miR-16-5p in the cytoplasm, so we though it may be a 
player in putting miR-16-5p into exosomes. Upon siRNA knockdown of HuR, we saw 
significant reduction in exosomal miR-16-5p and increased intracellular miR-16-5p, 
proving a role for HuR in miR-16-5p packaging. Further, we also found that HuR is directly 
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targeted by miR-16-5p, allowing for an interpretation to the contradictive evidence 
indicated in the previous paragraph.  
This evidence allowed for the development of a schemed mechanism of action where HuR 
promotes miR-16-5p loading into exosomes, so siRNA knockdown of HuR leads to 
reduced exosomal miR-16-5p, and hence increased miR-16-5p in the cell. It is then clear 
that miR-16-5p targets HuR expression at the protein level, meaning that high miR-16-5p 
levels lead to low HuR and therefore, reduced exosomal miR-16-5p, which is exactly what 
our data represents. Because we also showed that miR-16-5p upregulation by transfection 
does not affect exosome secretion by particle number, we know that this effect is limited 
to the packaging process of exosome cargo. Along this logic, we theorize that MM cancer 
cells not only have the evolutionary advantage for uncontrolled cell growth because of low 
intracellular stores of miR-16-5p based on high exosomal removal, but that miR-16-5p 
itself negatively regulates its own packaging into exosomes by targeting HuR. 
The next steps forward are to perform the exosome inhibition and force-feeding concepts 
in mouse models of MM to understand if they function similarly in in vivo settings. We 
also aim to conduct miRNA analysis of human serum exosomes from MM patients and 
asbestos exposed individuals compared to healthy people. Additionally, we find that 
because exosome targeting may be of use in cancer treatment, there may be a role of cancer 
prevention if exosome targeting can be employed specifically to cells that are contributing 
to the development of MM (as in asbestos exposed epithelial cells or macrophages in the 
lung). These future experiments will undoubtedly add to the already innovative and 
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important work described within this thesis, and it will be very exciting to see what results 
are yielded. 
Altogether, this evidence provides novel insight into tumorigenic mechanisms that may be 
targeted in potential therapeutic advancements in MM. We have shown proteomic evidence 
of differentially abundant proteins in exosomes from asbestos exposure, both in vitro and 
in vivo. We have implicated asbestos exposed cells’ exosomes as being messengers to 
mesothelial cells and thereby modulating them to having more tumorigenic gene 
expression. MM exosomes, based on this work, appear to be conduits of tumorigenic 
growth by means of removing the tumor suppressor miR-16-5p. This mode of ridding miR-
16-5p can be targeted by exosome inhibition and force-feeding MM exosomes to MM cells 
resulting in tumor cell death and reduced tumorigenic capacities. Based on all this, there is 
reason to expect that future experiments will add to this promising outlook for potential 
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